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INTRODUCTION TO ACCESS, 
COST, AND QUALITY 
 
The United States healthcare system is complex and sometimes controversial.  Despite 
attempts to improve quality of healthcare and access to it, costs in the United States (US) are 
high and continuing to rise. Projections suggest US health expenditures could exceed $4 
trillion by the year 2020, or approximately 20% of the US gross domestic product.1 
Conservative models have estimated that waste accounted for nearly 20% of total US 
expenditures in 2011, or approximately $500 billion.2 Despite spending more than other 
countries on healthcare, the US falls short on improving overall health and wellbeing as a 
nation.  
A 2017 study by the Commonwealth Fund ranked the US last (11th out of 11) in overall health 
care among other industrialized countries. Despite spending the most per capita, the US 
ranked 5th in care process, 10th in administrative equity and last 11th in access, equity, and 
health care outcomes.3  A 2016 report by the Centers for Medicare and Medicaid Services 
(CMS) showed that the annual National Healthcare Expenditures (NHE) for the year reached 
$3.3 trillion dollars, an average of over $10,300 per person.4 The CMS report also shows that 
the US had spent 17.9% of its gross domestic product (GDP) on healthcare in 2016, which far 
exceeds the amount spent by any other country in the world.4  The following chapters will 
discuss how cost, access, and quality are impacted in interactions between patients, payers, 
and providers.  
Access, cost, and quality are three major factors used to evaluate healthcare systems.5 
Countries maintaining a good balance between these components have more effective 
healthcare systems. Optimizing the balance can be difficult because changes or 
improvements to one may come at the expense of the others. 
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SECTION 1 
ACCESS 
Access to care is fundamental in allowing patients to achieve successful outcomes. Access 
may be defined as reaching necessary providers and being able to pay for the care needed. 
Patient-centered medical homes (PCMH) and neighborhoods focus on the needs of patients 
as a central component to delivery of care. This may include multidisciplinary team-based 
care, email communication directly with providers, and flexibility through extended hours or 
seven-days a week appointment options. PCMH provide key components for coordination of 
patient care and are usually a component of Accountable Care Organizations (ACOs) 
discussed in Section 2. 
Providers must be prepared for patient-centered collaborative care. Successful patient 
outcomes must be achieved regardless of the patient’s health literacy, health status, and 
socioeconomic considerations. Studies have shown that a positive relationship exists 
between health literacy levels and an individual’s knowledge of available health services and 
payment, and results in improved overall health outcomes.1 Individuals who understand their 
payer coverage are more likely to successfully navigate their financial benefits. Providers, 
including pharmacists, can help bridge the literacy gaps that may exist between patients and 
payers.  
Pharmacists can clinically and financially assist patients with low health literacy. 
Community pharmacists are an easily accessible source of clinical knowledge. They may 
assist patients transition home after an inpatient stay, including navigating new providers 
and understanding the care necessary for a new diagnosis. The ability to consider the 
economic, social and cultural issues of the patient population they serve will likely increase 
pharmacists’ success and satisfaction with their profession.   
Ultimately, pharmacists have the clinical knowledge to meet heightened demands for 
patient-centered care and contribute to the growing need for access, cost, and quality-minded 
health care providers. They will have interactions with different types of providers. These 
interactions range from providing education, recommending drug therapy, or answering 
questions.  In general, interactions are for the ultimate benefit of the patients and are aimed 
at improving patient care.   
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CHAPTER 1 
WHO PROVIDES THE CARE? 
Author: Trish Devine PharmD 
 
A multitude of healthcare professionals provide patient care. With nearly 18 million workers, 
healthcare providers/professionals are considered among the largest groups of employees in 
the US and they comprise the fastest growing sector of the US economy.1 Furthermore, they 
constitute one of the most gifted, well-educated, highly-compensated, and diverse groups of 
employees in the nation.2 In this section, the similarities and differences between the most 
frequently encountered healthcare professionals will be covered. While many of these 
providers have traditionally been considered providers of either inpatient or outpatient care; 
however, many provide direct patient care in both settings.   
PHYSICIANS 
Physicians are at the center of the healthcare setting and play one of the biggest roles in 
providing care to patients.1 Physicians diagnose conditions, examine patients, order and 
evaluate diagnostic tests, and prescribe medications.3 Physicians must complete many steps 
in their training in order to practice. First, they must graduate from an accredited medical 
school with either a Doctor of Medicine (MD) or Doctor of Osteopathic Medicine (DO) degree. 
Most complete at least four years of undergraduate study then complete four additional years 
of medical school to earn this degree. After completing their degree, prospective physicians 
complete a residency where they gain on-the-job training and may become specialized in 
certain areas. These residencies typically take between three and eight years.1 After they 
complete the residency, physicians then take an examination to become licensed to provide 
direct patient care in a particular state.1   
There are many different types of physicians. Generally, physicians are categorized as MDs 
or DOs. MDs practice allopathic medicine, which focuses on using medical treatment as 
active intervention to treat and counter an illness or disease.2 Most MDs are specialists in one 
particular area, such as cardiology, emergency medicine, oncology, surgery, or urology. DOs 
practice osteopathic medicine, which focuses on preventative measures and treating the 
whole patient with a special emphasis on the musculoskeletal system of the body.4 Most DOs 
are primary care providers (also known as “generalists”), which means they practice family 
medicine, general medicine, general internal medicine, or general pediatric medicine.2   
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Psychiatrists and ophthalmologists are medical doctors (MD or DO) who are sometimes 
confused with psychologist and optometrist respectively.  Psychiatrists specialize in mental 
health, including substance use disorders, are qualified to assess both the mental and physical 
aspects of psychological problems and can prescribe medication for treatment.  Clinical 
psychologist have a masters or doctorate degree in psychology and specialize in emotional 
and behavior mental health diseases.  In most states, they are only allowed to use talk therapy 
as treatment.  A few states allow psychologists to prescribe some psychiatric medications if 
they have met the required training.5  Patients must be seen by a psychiatrist or other medical 
doctor to receive medication treatment.  Ophthalmologists are medical doctors who 
specialize in eye and vision care whereas optometrist complete an undergraduate degree and  
four years at a college of optometry  obtaining a doctor of optometry (OD) degree.  The scope 
of practice varies by state but in general an optometrist are licensed to provide primary vision 
care, nonsurgical management of eye diseases including medication treatment.6   
DENTISTS 
Dentistry is a branch of medicine that is involved with the study, diagnosis, prevention, and 
treatment of diseases, disorders, and conditions of the oral cavity and structures in the jaw 
area. Dentists are doctors specializing in oral health who have earned either a Doctor of 
Dental Medicine (DMD) degree or a Doctor of Dental Surgery (DDS) degree. Dentists 
primarily work in private outpatient practice but some work in the inpatient setting.7 
PHYSICIAN ASSISTANTS 
Another important component of the inpatient care team is the physician assistant (PA). PAs 
must be associated with and practice under the direction of a physician. The supervision does 
not need to be direct and the physician may either be on or off site.1,8 They may examine 
patients, diagnose illnesses and injuries, and prescribe medications according to the laws of 
the state where they practice.  Most PAs complete two to three years of training and receive a 
master’s degree.2 After completing a PA program, a PA must become licensed in order to 
practice. PAs become certified (PA-C) by passing a national certifying examination and are 
licensed in the state which they practice.3,9 
NURSES 
Often considered the front line of inpatient care, nurses are the largest group of healthcare 
professionals.9 There are many different types of nurses and the level of care they can deliver 
depends on their degree. The first type of nurse is a Licensed Practical Nurse (LPN). These 
nurses provide for the basic needs of patients and are asked to take vital signs (such as blood 
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pressure, heart rate, pulse, etc.), assist with activities of daily living (ADLs), make 
observations, and keep records. They typically have a high school diploma, followed by 
completion of a one year nursing program and passage of a state licensing exam.1   
Another type of nurse is a registered nurse (RN). RNs must also be licensed in the state in 
which they provide care and obtain their level in one of three ways: a 2-3 year hospital diploma 
program, a 2-3 year associate’s degree in nursing (ADN) from a community college, or a 4 year 
Bachelor of Science degree in nursing (BSN) from a college or university. After becoming 
licensed and depending on their level of practice and expertise, nurses may do all or any of the 
following: administer medications, record progression of a patient’s condition, provide 
patient education, perform medical procedures, and assist physicians.9   
Nurses can specialize in specific fields of nursing.  It may take more schooling or training 
depending on the speciality.  Some of the areas of speciality include but not limited to: 
neonatal, critical care, dialysis, pain management and pediatric nursing.10 
ADVANCED PRACTICE NURSES 
If a registered nurse decides to receive advanced training and education beyond the level of 
an RN, they may become an advanced practice nurse (APN).1 There are four different types of 
APNs: nurse practitioner (NP), clinical nurse specialist (CNS), certified nurse midwife 
(CNM), and certified nurse anesthetist (CNA). APNs, as outlined by state laws, are typically 
allowed to provide direct patient care and often serve as an intermediary between doctors and 
RNs.8   
Comprising the largest group of the APNs, nurse practitioners (NPs) are registered nurses 
who obtain a master of science in nursing (MSN) degree.1 Working closely with physicians 
under collaborative practice agreements but not necessarily always under their direct 
supervision, NPs can do many things that a physician can do.8  These duties include 
evaluating patients, diagnosing and treating common conditions, providing patient education 
and resources, and prescribing most types of medications depending on the laws in their 
respective states.2,8 Along with becoming certified (NP-C), nurse practitioners can also 
specialize in certain areas, including geriatrics, pediatrics, or family care. NPs and PAs are 
often favorably viewed by patients due to their increased accessibility and amount of time 
they spend with their patients. Both NPs and PAs are cost-effective alternatives to physicians 
in regards to treating common conditions and educating patients about different disease 
states.1 
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MEDICAL ASSISTANTS 
Some of the fastest growing healthcare-related occupations are the medical assistant (MA), 
certified medical assistant (CMA) and registered medical assistant (RMA).11 MAs are 
normally found on the “front lines” of physicians’ offices and routinely perform 
administrative tasks including scheduling appointments, greeting patients, answering phone 
calls, ordering supplies, and filing medical records. Some may also assist the healthcare 
professional with clinical duties, such as preparing patients for surgery/examination, 
recording vital signs, taking medication histories, collecting and preparing lab specimens, 
and calling prescriptions into pharmacies. MAs may receive formal training by attending 
vocational-technical high schools or community colleges. Others may attend colleges or 
universities where they receive either a one-year certificate or a two-year associate’s degree. 
Still others may have a high school degree or equivalent and receive on-the-job training.  
A medical assistant may become certified by passing a national exam. Medical assistants have 
quickly become crucial members of healthcare teams and their roles are expected to expand 
with the proliferation of physician’s offices.11 
PHARMACISTS 
Pharmacists are the health professional most accessible to the public.  They have been 
traditionally perceived as engaged only in the community setting, dispensing medications, 
counseling patients, and providing medical advice and expertise. However, pharmacists have 
also been working in hospitals, nursing homes, medical industries and other settings for many 
years. Roles of the pharmacists have evolved over the years to provide high quality care for 
patients and the general public.   Pharmacists work closely with other members of medical 
teams to enhance patient care, making drug recommendations based on evidence-based 
medicine and therapeutic guidelines, monitoring lab results and patient-specific responses 
to therapies, and educating patients and their families on disease states and their 
medications.12 Pharmacists also participate in health promotion through health-related 
campaigns, community group education, and health fairs.12   
All pharmacists, regardless of setting, must receive a doctor of pharmacy (PharmD) degree 
from an accredited institution and licensed in their state to practice pharmacy.13 After 
graduation, a prospective pharmacist gains licensure by successfully completing the North 
American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy 
Jurisprudence Exam (MPJE) or an equivalent state-level law exam.8  
After receiving licensure, pharmacists may pursue residency programs. Residents are 
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exposed to different facets of practice and learn about the many career paths available to 
pharmacists today. During a one-year residency (Post-Graduate Year 1 or PGY1), pharmacy 
residents are generally trained in a variety of areas within the residency setting. Most 
pharmacy residency programs are hospital based; however, there is an increasing number of 
residency opportunities in community and managed care areas.  Usually a second year of a 
residency program (Post-Graduate Year 2 or PGY2) is specialized in a certain area, such as 
pediatrics, ambulatory care, critical care, infectious diseases, cardiology, and many others.8   
In addition to residencies, pharmacists can obtain disease-specific multidisciplinary 
certification. Pharmacists can voluntarily become certified in certain disease states, such as 
diabetes, asthma, anticoagulation, and dyslipidemia.12 For example, a pharmacist can become 
a “Certified Diabetes Educator” in order to help diabetic patients learn about and understand 
their condition, as well as help them to manage the condition and their medications.  
Certifications can be obtained through national programs that involves didactic, professional 
diabetes patient experience and exams.  This type of certification is also available to other 
healthcare professionals. 
More specifically, pharmacists can become board-certified in a specialty practice area of 
pharmacy through The Board of Pharmacy Specialties’ (BPS) post-licensure certification 
program. BPS board certification is considered the gold standard when it comes to 
determining a pharmacist’s qualifications and capabilities within a specialty area. The BPS 
currently offers eight distinct specialty areas, including: Ambulatory Care, Critical Care, 
Nuclear, Nutrition Support, Oncology, Pediatric, Pharmacotherapy, and Psychiatric 
pharmacy.14 Pharmacists must practice at least three to four years in the speciality area and 
pass a speciality certification examination to become a board-certified pharmacy specialist 
(BCPS) and must be recertified every seven years.15 Becoming BPS board certified enables 
pharmacists affirm their knowledge and skills to provide more comprehensive patient care in 
a specific area, be recognized for their expertise by other healthcare professional, employers, 
patients and insurers. With more opportunities to provide direct patient care in inpatient and 
outpatient settings, pharmacists are seeing their roles expanding and are moving closer to 
being recognized as providers rather than just “drug experts.” 
ALLIED HEALTH PROFESSIONALS 
An allied health professional is someone who has received special training and earned a 
certification or degree in a science related to healthcare and has responsibility for the delivery 
of health or related services. This does not include anyone who has received a degree in 
medicine, dentistry, veterinary medicine, optometry, podiatry, chiropractic, pharmacy, 
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psychology, or equivalent. Allied health professionals can be divided into two categories: 
technicians/assistants and therapists/technologists. Technicians and assistants generally 
receive less than two years of postsecondary education and require supervision. Examples are 
physical therapy assistants, medical laboratory technicians and respiratory therapy 
technicians. Therapists and technologists receive more advanced training and education and 
are responsible for evaluation, diagnosis and development of treatment plans and can 
practice independently from a physician in some states.16 
Therapists & Technologists 
Occupational therapists (OTs) work with individuals who have conditions that are mentally, 
physically, emotionally or developmentally disabling. A master’s degree is the typical 
minimum requirement for entry into this field.17   
Physical therapists (PTs) help injured or ill people improve their movement and manage their 
pain. These therapists are often an important part of the rehabilitation and treatment of 
patients with chronic conditions, illnesses, or injuries. A Doctor of Physical Therapy (DPT) 
degree and license is required to practice. 17 
Respiratory therapists (RTs) care for patients who have trouble breathing, from a chronic 
respiratory disease, such as asthma or emphysema, or emergency care, such as heart attack or 
drowning. Patients range from premature infants with undeveloped lungs to elderly patients 
with diseased lungs. Respiratory therapists typically need an associate’s degree, though some 
have bachelor’s degrees, and a state license is required in all states except Alaska. 17 
Speech therapists or pathologists assess, diagnose, treat, and help to prevent communication 
and swallowing disorders in patients. Speech, language, and swallowing disorders result from 
a variety of causes, such as a stroke, brain injury, hearing loss, developmental delay, 
Parkinson’s disease, cleft palate, or autism.  Speech-language pathologists typically need at 
least a master’s degree and must be licensed in most states. 17   
Audiologists diagnose, manage, and treat a patient’s hearing, balance, or ear problems.  
Audiologists need a doctoral degree and all states require a license. 17 
Dietitians and nutritionists are experts in the use of food and nutrition to promote health and 
manage disease. They advise people on what to eat to lead a healthy lifestyle or achieve a 
specific health-related goal. Most dietitians and nutritionists have a bachelor’s degree and 
have completed supervised training through an internship. Many states require dietitians 
and nutritionists to be licensed. 17 
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Social workers help people solve and cope with problems in their everyday lives. Social 
workers may work with children, people with disabilities, and people with serious illnesses. 
Their work varies based on the type of client. There are child and family, clinical, school, 
healthcare, and mental health social workers. Social workers assess clients’ situations, and 
support networks to determine their needs.  They help clients adjust to changes and 
challenges in their lives, such as illness, divorce, or unemployment by providing  community 
resources, such as food stamps, child care, and healthcare to assist and improve a client’s 
well-being.   Most social workers need a bachelor’s degree in social work, while clinical social 
workers must have a master’s degree and 2 years of post-master’s experience in a supervised 
clinical setting. Clinical social workers must also be licensed in the state in which they 
practice.18 
Counselors provide support and advice to people. There are many different kinds of 
counselors, including substance abuse and behavioral disorder counselors who advise people 
suffering from alcoholism, drug addiction, eating disorders, or other behavioral problems. 
Genetic counselors assess individual or family risk for a variety of inherited conditions. They 
provide information and support to other healthcare providers or to individuals and families 
concerned with the risk of genetic disorder and birth defects. Most positions require a 
bachelor’s degree, though educational requirements can vary from a certification to a 
master’s degree depending on the employer. 17    
ADVANCED PRACTITIONERS 
Centers for Medicare and Medicaid Services (CMS) and the US Department of Justice’s Drug 
Enforcement Administration (DEA) use different terminology to identify non-physician 
healthcare providers such as nurse practitioners, clinical nurse specialists, and physician 
assistants who are authorized to dispense controlled substances by the state in which they 
practice. The term “mid-level practitioner” is used by the DEA, while CMS uses “non-
physician practitioner.” There is a movement to change this nomenclature, as the descriptor 
“mid-level” does not represent the advanced degrees earned by these health care providers. 
Patients may feel they will not receive high quality care if they are seen by a “mid-level or non-
physician practitioner” instead of by an advanced practitioner or their actual degree title.19,20 
HOSPITALISTS 
Society of Hospital Medicine defines a hospitalist as a physician, nurse practitioner or 
physician assistant who is engaged in clinical care, teaching, research, and/or leadership in 
the field of hospital medicine. Hospitalists coordinate the care of patients' in hospital. They 
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organize the communication between different providers caring for a patient, and serve as the 
point of contact for other doctors and nurses for questions, updates, and provides safe 
transitions of care within the hospital and from the hospital to the community. Hospitalist 
are the main point person for patients and family members to contact for patient care 
questions. 22 
CREDENTIALING AND PRIVILEGES 
Each medical staff member who provides medical services in a hospital setting and for health 
insurance holders must meet the credentialing and privileging standards of a nationally 
recognized accrediting/certifying body such as the Joint Commission, the American 
Association for Ambulatory Health Care, or the Centers for Medicare and Medicaid 
Services. Medical staff includes physicians (MDs and DOs), dentists, physician assistants 
and nurse practitioners, and those defined by the hospital’s policies and procedures manual 
and bylaws.23 
Credentialing is the primary source verification of a healthcare practitioner’s education, 
training, work experience, and license. A variety of resources are used to verify this 
information, including but not limited to direct communication with educational and 
training institutions, past and current hospital affiliations and employers, peer reference 
letters, certification boards and licensing agencies.23 
Privileging is granting approval for an individual to provide specific aspects of patient care 
within a specific institution. Examples of privileges include admitting, prescribing, and 
performing procedures. In some instances, healthcare providers may be credentialed, 
trained, and licensed to provide certain care but may have their practice limited by the 
privileges granted within a hospital.23 For example, a physician assistant specializing in 
pediatrics may only be granted privileges to the pediatric unit and would not be able to admit 
a patient to other areas of the hospital. Healthcare providers go through similar processes at 
all hospitals where they want to practice and each hospital makes an independent decision 
regarding privileges.6, 24   
INTERPROFESSIONAL EDUCATION AND HEALTH CARE TEAMS 
According to the World Health Organization (WHO), “inter-professional education occurs 
when students from two or more professions learn about, from, and with each other to enable 
effective collaboration and improve health outcomes. Once students understand how to work 
inter-professionally, they are ready to enter the workplace as members of the collaborative 
practice team. This key step moves health systems from fragmentation to a position of 
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unity.”25 
Interprofessional healthcare teams are composed of an array of healthcare professionals who 
bring their specialized knowledge, experience and skills to work together to provide optimal 
care for patients. Many organizations interprofessional healthcare teams consist of a nurse, 
pharmacist, physician, social worker and therapist. Members of an Interprofessional team 
communicate and work together, as colleagues, to provide quality, individualized care for 
patients.26   
In the United States, an Inter-Professional Education Collaborative (IPEC) was formed in 
2009, with five health professional associations represented allopathic and osteopathic 
medicine, dentistry, nursing, pharmacy, and public health to promote a more consistent 
approach to inter-professional education (IPE) and improve population health outcomes. By 
2017, fourteen additional health care professional associations became members 
representing over 20 professions including podiatry, physical therapy, occupational therapy, 
psychological medicine, veterinary medicine, physician assistant, optometry, allied health 
and social work.27 IPEC developed four interprofessional collaborative practice  competency 
domains for future health professionals in training.   The four domains with their general 
competency statement are:   
Values/Ethics for interprofessional Practice- Work with individuals of other professions to 
maintain a climate of mutual respect and shared value. 
Roles/Responsibilities- Use the knowledge of one’s own role and those of other professions to 
appropriately assess and address the healthcare needs of the patients and populations served.  
Interprofessional Communication- Communicate with patients, families, communities, and 
other health professionals in a responsive and responsible manner that supports a team 
approach to the maintenance of health and the treatment of disease. 
Teams and Teamwork- Apply relationship-building values and the principles of team 
dynamics to perform effectively in different team roles to plan and deliver patient-centered 
care that is safe, timely, efficient, effective, and equitable.27 
The accreditation council for pharmacy education has included Interprofessional Education 
in its Standards. Schools of pharmacy must include IPE in their curriculum for 
accreditation.28 In an effort to enhance quality and meet the evolving needs of patients, 
interprofessional team based delivery of health care is used.   
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Interprofessional teams’ goal is to provide patient-centered care. There is evidence that 
shows including patient preferences into patient care improves outcomes.29 
Interprofessional or multi-disciplinary teams have been a part of health care delivery in 
hospitals for a long time.  Accountable Care Organizations and Patient-Centered Medical 
Homes are beginning to utilize interprofessional teams to improve patient care and decrease 
health care costs.6  Interprofessional team practice arrangements vary from inpatient to 
outpatient teams as well as from patient to patient depending on individual needs. The central 
goal of an integrated health care practice is to provide the most effective, accessible, and 
efficient care to the patient, based upon clinical and patient-focused outcome measures or 
assessments.30  
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GLOSSARY 
Medical Provider Credentialing 
A detailed process that reviews doctors’ qualifications and career history including their 
education, training, residency and licenses, as well as any specialty certificates. 
Medical Provider Privileges 
Defines a physician's scope of practice and the clinical services he or she may provide. 
Patient-Centered Care 
Identify, respect, and care about patients’ differences, values, preferences, and expressed 
needs; relieve pain and suffering; coordinate continuous care; listen to, clearly inform, 
communicate with, and educate patients; share decision-making and management; and 
continuously advocate disease prevention, wellness and promotion of healthy lifestyles, 
including a focus on population health. 
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CHAPTER 2 
HEALTHCARE SETTINGS 
Author: Carriann Smith, BS, PharmD 
 
Healthcare is provided in a variety of settings usually categorized as inpatient or outpatient. 
Table 2-1 displays examples of inpatient and outpatient facilities and more details are 
provided in this chapter. Examples of facilities that provide inpatient services include 
hospitals and nursing homes. Various facilities that provide outpatient care include 
physician offices and urgent care centers.  
 
Healthcare Settings 
Inpatient Outpatient 
● Hospitals 
● Mental institutions 
● Nursing homes 
● Long-term acute care facilities 
● Long-term skilled nursing 
facilities 
● Inpatient rehabilitation centers 
● Physicians' offices 
● Urgent care centers 
● Emergency departments 
● Home health agencies 
● Outpatient surgery centers 
● Rehabilitation centers 
● Dialysis centers 
● Sports medicine clinics 
● Chemotherapy centers 
 
Table 2-1. Examples of inpatient and outpatient facilities 
 
While these general distinctions exists, a facility may function as an inpatient or outpatient 
setting depending on the type of treatment being given and admission status of an individual 
patient. For example, inpatient facilities, such as hospitals, may have outpatient offices and 
provide outpatient services, such as surgeries, rehabilitation, and ambulatory clinics, without 
admittance to the hospital.1 Determining whether someone is admitted as an “inpatient” or 
seen at the facility as an “outpatient” impacts how bills will be submitted and paid.  
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INPATIENT CARE 
Not everyone who goes to the hospital is considered an inpatient. Based on various factors, 
such as the prescriber’s judgement of the situation, seriousness of the condition, and medical 
necessity for hospital services, the physician will choose whether or not to order admission 
for a patient.1 The decision to admit may not be immediate. A patient in a hospital bed may be 
considered an observational outpatient (sometimes termed “obs”) to allow physicians time to 
run tests and/or make further evaluations before they decide whether to fully admit as an 
inpatient or discharge to home or another facility. Patients can only be considered 
observational (i.e., outpatient) for less than 24 hours before a decision must be made on 
whether they will be admitted. This observation may or may not include an overnight stay and 
the observation can occur anywhere in the hospital, including the ED.1  
A patient will typically be admitted if the patient is expected to need at least two days of 
hospital care that can be provided by the facility.1 If the physician determines that the patient 
does not need to be admitted, they will discharge the patient from their care. However, if the 
physician has ordered admission, the hospital must then formally accept the order and admit 
the patient as an inpatient. Hospitals may only allow physicians to have admitting privileges 
excluding other practitioners.2    
Types of Institutions 
Hospitals 
Hospitals are commonly recognized as the provider for acute care services.  Hospitals can be 
classified in a number of different ways, including type of service provided, ownership, and 
average length of stay.3 Type of service includes two main types of hospitals: general and 
specialty.3 General hospitals, such as Massachusetts General Hospital, provide a wide range 
of services with few limits. These services include surgeries, labor and delivery, and 
treatment of most of acute disorders or illnesses. Specialty hospitals, such as Peyton Manning 
Children’s Hospital or MD Anderson Cancer Center, focus on specific types of patients or 
specific illnesses or diseases.3 
There are two primary types of hospital ownership: public and private. Public hospitals may 
be owned by the federal, state, or local government.4 The federal government owns and 
operates federal hospitals, such as the Veterans Administration (VA).5 The VA consists of 
hospitals, clinics, and nursing homes that provide care and services solely for retired United 
States armed forces veterans.5 Other examples of federal hospitals and networks include 
Indian Health Services, which provides healthcare for Native Americans.4 Facilities owned 
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and funded by state governments typically include long-term facilities for psychiatric 
patients and those with chemical dependency and addictions. Local governments, such as 
counties, also fund and operate hospitals. These hospitals are usually general hospitals that 
are open to anyone, regardless of insurance or their ability to pay for care.5 Often thought of 
as “safety-net” hospitals, these facilities often focus on providing services to underserved 
populations at reduced costs. 
Private hospitals typically only provide care to patients who are part of their private network, 
except for emergencies.5 Private hospitals are named because of their private source of 
funding. They are not government operated and may be either non-profit or for-profit.4,5 Non-
profit hospitals are frequently affiliated with charitable organizations or religious 
denominations.4 As a non-profit hospital, the government does not require them to pay taxes. 
Profits are reinvested in operating expenses, hospital improvement, or donated to the 
community rather than given to shareholders or private investors.3 For-profit hospitals are 
owned by private corporations. A portion of their profits are used for operations and making 
improvements and some of their profits are disbursed to owners and investors via dividends.3 
Hospitals may also be classified by how long patients are expected to stay in the facility. 
Short-term hospitals, also known as acute care hospitals, care for their patients for an average 
of less than thirty days.6 Patients are admitted for short-term needs, such as routine surgery 
or an acute illness like pneumonia, receive the care they need, and are discharged home. Long 
term acute care hospitals provide care for patients who need to stay for an average of thirty or 
more days.3 
Long Term Acute Care Facilities (LTAC) 
In the past, patients would stay in a general hospital for their entire acute critical illness 
episode, including time needed for recovery.7 With the advent of LTAC facilities, patients 
who need additional care are transitioned to these facilities.8 Patients moved to LTAC 
facilities typically do not need as much intensive care as they previously received for their 
injury or condition from an acute care hospital, but they still have needs for ongoing care that 
they cannot receive outside of a facility.7 Some of the services typically offered at LTAC 
facilities include respiratory therapy, head trauma treatment, and intensive pain 
management.8 With the additional time and care, patients have been shown to have 
experienced improvement in their conditions and fewer re-admittances for similar or related 
conditions.8 LTAC hospitals have proven to be successful in reducing costs and improving 
patient outcomes. 
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RS was admitted to an inpatient facility following a serious motor vehicle accident. RS had 
damage to several internal organs and is still on a ventilator. He has been transferred to a 
LTAC facility until he can be weaned from the ventilator and begin rehabilitation. 
Nursing Facilities 
Nursing facilities, more commonly known as nursing homes, provides long term nursing care 
without the level of medical attention or specialty provided at LTAC facilities.8 This type of 
long term care may involve around-the-clock nursing, custodial care or both. Skilled care is 
care administered when direct medical attention is needed and provided by a licensed 
medical professional in a certified facility. Custodial care may be performed by someone 
without professional medical skills either at home or in a facility. Custodial care provides 
assistance with activities for daily living (ADLs), like eating and bathing, and not direct 
medical treatments.   
Inpatient Rehabilitation Centers 
Sometimes when patients are past their acute illness they still need functional assistance but 
not medical assistance. This functional therapy is provided by occupational therapists, 
physical therapists, or speech language pathologists. The goal of these therapies is to assist 
the patient in returning to as much of their normal functioning as quickly as possible. 
OUTPATIENT CARE 
Physician Offices and Integrated Care Models  
As often portrayed on TV, physician offices traditionally featured a physician, a nurse, and 
office staff. While some of these sole practitioner offices still exist today, integrated care 
offices are becoming more common. These primary care practice models have multiple 
physicians and other practitioners, such as pharmacists, physician assistants, nurse 
practitioners, and social workers to meet the needs of their patients.  
In the spirit of providing value based care, there has been increased interest in healthcare 
delivery models that are more patient-focused. These models include Patient-Centered 
Medical Homes (PCMHs). These practices represent a primary care delivery model focused 
on comprehensive, coordinated, and integrated management of all aspects of a patient’s 
health.9  
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Emergency Departments 
Emergency departments (EDs) and various outpatient clinics may be part of a hospital or 
health system. Many patients with limited resources use the ED for nonurgent care, resulting 
in around 10 million nonurgent visits per year.  
Urgent Care Centers 
Urgent care centers are walk-in clinics that offer a variety of services during convenient 
hours. Although they are not quite as equipped for emergencies as EDs, urgent care centers 
can be used when doctors’ offices are closed and are much cheaper than EDs.  
Retail Clinics 
Often seen in pharmacies and grocery stores, retail clinics are operated for patient 
convenience. Physicians are not required and they are staffed by nurse practitioners or 
physician assistants. 
Ambulatory Surgery Centers 
Some minor surgeries don’t require an overnight stay. Approximately two-thirds of surgeries 
performed in the last 10 years were outpatient surgeries.9  
Other Outpatient Models 
Other models of outpatient care include community health centers, charitable clinics, local 
government health departments, home health, hospice, telemedicine, and 
complementary/alternative medicine. 
Why are Patients Increasingly Seeking Outpatient Services? 
Since the 1980s, the volume of outpatient services delivered has grown considerably. 
Advances in medicine and technology have enabled us to provide more advanced treatments 
in outpatient settings. The introduction of the Medicare Prospective Payment System in 1983 
changed the way hospitals were reimbursed for inpatient hospitalizations and encouraged 
shorter lengths of stay.3 This provided incentive to continue treatment in outpatient settings 
without payment restrictions.10 
Increased use of outpatient services and fewer doctors pursuing primary care practice 
provides an opportunity for pharmacists to increase their involvement in the primary care 
setting. Residencies are now available and the Board of Pharmacy Specialties offers a 
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specialty certification in ambulatory care pharmacy practice. Similar to outpatient care, 
ambulatory care includes all health-related services in which patients walk to seek their 
care.11  
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CHAPTER 3 
ROLES OF AMBULATORY CARE PHARMACISTS 
Author: Jessica Wilhoite, PharmD, BCACP 
 
Ambulatory care pharmacists may practice in a variety of settings, but similar skill sets are 
utilized throughout different practices. This section will review general pharmacy services 
which will be helpful in learning how they are applied in specific ambulatory care settings. 
MEDICATION HISTORY AND RECONCILIATION 
Before managing a new patient, pharmacists should obtain a comprehensive list of 
medications the patient is currently taking, which is referred to as the patient’s medication 
history.1 A medication history should include both prescription and over-the-counter 
medications, such as herbal products and nutritional supplements. Vaccines and injectable 
drugs may also be added to the list. It is important to note the route, frequency, and time that 
the patient is taking the medications. Additionally, any drug allergies and adverse reactions 
to drugs should be recorded.1,2 
A medication history can be obtained in several ways. You may be able to consult a patient on 
what medications they are taking, particularly if they carry a list of their medications with 
them and are able to say what they are or are not taking.  However, speaking with the patient 
is not always possible or the patient may be confused about their medications.2 In these 
instances, there are several other options. The patient’s regular community pharmacy may 
have a list of prescriptions filled recently by the patient, which may indicate the patient is 
currently taking those medications. Prescribers may also be contacted to determine what the 
patient has been prescribed and should be currently taking. If the patient is coming from a 
hospital, it may be possible to obtain from the hospital the patient’s prescriptions at 
discharge.1,2 
After this information has been acquired and documented, the process of medication 
reconciliation may begin. The Joint Commission defines medication reconciliation as:  
“the process of comparing a patient's medication orders to all of the medications that 
the patient has been taking. This reconciliation is done to avoid medication errors 
such as omissions, duplications, dosing errors, or drug interactions. It should be done 
at every transition of care in which new medications are ordered or existing orders are 
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rewritten. Transitions in care include changes in setting, service, practitioner, or level 
of care.”2   
In medication reconciliation, a pharmacist looks for discrepancies in the patient’s drug list. 
During this exercise, the pharmacist may find several possible errors: inappropriate drug 
therapy, duplicate therapy, drug-drug interactions, drug-disease state interactions, or 
incorrect doses.1,2   
Medication reconciliation is an important process in patient care. Table 3-1 includes 
medication history discrepancies that may lead to issues in patient care. 
 
Discrepancy Result 
A medication is listed in the 
patient’s history that the patient 
is no longer taking 
This medication may continue to be dispensed to the 
patient 
● Could lead to duplicate therapy or drug 
interactions 
The incorrect strength of a drug 
is listed 
The patient may be getting too high or too low of a 
dose 
● Could lead to adverse side effects (dose too 
high) or inadequate therapy (dose too low) 
The patient’s medication list may 
be incomplete and does not 
include all the medications the 
patient is taking 
The pharmacist may not be able to identify all 
possible drug interactions 
● Meds not listed may interact with other meds 
Medications may be added that interact with 
medications not listed 
● Could cause drug adverse effects or decrease 
the effectiveness of drug therapy 
How the patient is taking the 
medication may be incorrectly 
listed 
If the patient is taking the medication more or less 
than listed, the patient may be getting too much or 
too little of the drug 
● Could lead to adverse side effects or 
inadequate therapy 
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Discrepancy Result 
If the patient is taking the medication at a different 
time of day than listed, the pharmacist may be 
unable to identify inadequate therapy or side effects 
related to the time of day 
● Could decrease effectiveness of drug therapy 
or side effects (e.g. if a sedating drug were 
given in the morning) 
The pharmacist may not be able to identify if the 
medication interacts with other medications the 
patient is taking 
● Certain drugs need to be separated from one  
● another and taken at different times 
The incorrect dosage form of a 
medication is listed 
The patient may be getting inadequate drug therapy 
● Example: If an immediate release formulation 
is given instead of an extended release 
formulation, patient may not be getting 
enough drug 
 
Table 3-1. Medication history discrepancies  
 
 
By obtaining a thorough medication history and carefully checking through it, pharmacists 
can help to reconcile these and other errors that may have gone unnoticed. 
MEDICATION THERAPY MANAGEMENT 
Medication therapy management (MTM) involves a scope of activities with the goal of 
optimizing health outcomes for patients and helping patients manage their medications. 
Pharmacists and other healthcare professionals providing patient care are included in this 
process (Figure 3-1). Many patients may be eligible for MTM; however, patients who benefit 
most from MTM services include elderly patients, patients taking multiple medications, and 
patients with multiple or complex disease states.4 These patients may have more difficulty 
managing their medications and pharmacists can help with this task. 
In ambulatory care, MTM services are generally provided via one-on-one patient 
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appointments.4 Patients may be referred to an ambulatory care pharmacist by their health 
plan, physician, or other healthcare providers. Medication therapy management services are 
generally done in person but may also be provided over the phone. Although both in-person 
and phone appointments are possible, face-to-face interactions allow the pharmacist to 
visually observe the patient for potential health problems. Regardless of the type of visit, an 
MTM appointment typically includes a medication therapy review, developing an action 
plan, and referral to other health care providers.3,4  
 
 
 
Figure 3-1. The MTM process3 
 
 
Medication Therapy Review  
Pharmacists review patient information and drug therapies to identify any medication-
related problems.4 After obtaining an accurate medication history, the pharmacist can 
identify if problems or side effects experienced by the patient are related to their drug 
therapy.5 During this time, the pharmacist may also address patient adherence and identify 
barriers that may be preventing patients from taking medications as they should. Any issues 
the patient is experiencing could stem from incorrect use of the medications rather than the 
drug therapy itself; therefore, it is the pharmacist’s responsibility to identify the source of 
medication-related problems. 
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Developing a Plan 
After the pharmacist has identified drug-related problems, a plan for resolving the issues 
is then developed.4 During this process, the pharmacist works with the patient and the 
physician/healthcare provider to determine possible options for fixing the drug-related 
problems. These options may include discontinuing therapy that is ineffective for the patient 
or is causing side effects the patient cannot tolerate, adding drugs onto inadequate drug 
therapy, or adjusting doses. Medications that are discontinued may also be replaced with 
medications that can provide the same type of therapy. In other cases, drugs may be added 
onto current drug therapy if the patient has a health concern not being managed. The drug 
dose may also be adjusted according to the needs of the patient. Any type of drug therapy 
changes should be discussed and explained to the patient.4 
Referral 
Medication therapy management services include referral to other healthcare providers as 
deemed appropriate.4 These providers should be consulted if a patient’s care goes beyond the 
extent of the pharmacist’s scope of practice.  In these instances, the patient should be referred 
to the appropriate provider.4 
 
 
Situations that may require referral to another health care provider 
The patient is experiencing a medical problem outside of the pharmacist’s scope of 
practice 
The patient is experiencing any type of medical emergency 
The patient needs medication adjustments unable to be made by the pharmacist 
 
Table 3-2. Situations requiring referral. 
 
DRUG INFORMATION SERVICES 
Another service commonly provided by ambulatory care pharmacists is providing drug 
information.6 As experts in medication knowledge, pharmacists are able to provide accurate 
drug information to both patients and healthcare providers. Pharmacists utilize primary 
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literature and medication databases to provide accurate drug information.  Educating 
patients on their disease states and medications enables patients to better manage their 
health, and providing drug information to healthcare providers can help them to care for 
patients more effectively.6 
DISEASE STATE MANAGEMENT 
Many medications are used to treat chronic disease states. Pharmacist responsibilities 
include managing patient medications which translates into managing chronic disease. 
Disease state management may be accomplished through patient visits with a pharmacist and 
can occur in a variety of settings including, but not limited to: physician offices, pharmacist-
managed disease state clinics, or community pharmacies.  In pharmacist-managed clinics, 
the pharmacist is independently responsible for providing primary care via protocol with a 
physician, which includes ordering lab tests, modifying drug therapy, and following up with 
patients.14 Helping patients with their medication regimens can help to optimize disease state 
outcomes, such as: 
● In one smoking cessation group clinic, pharmacists were able to assist patients in 
quitting smoking, with 47.6% of patients smoke-free at 3 months and 52.4% of patients 
smoke-free at 6 months.19 
● A pharmacist-managed spirometry clinic resulted in pulmonary drug regimen 
changes in 80% of patients, with referral to physicians or further diagnostic testing in 
27.4% of patients.18 
● A study on pharmacist-managed hypertension clinics resulted in 81% of patients 
reaching their blood pressure goals versus only 12% of patients who did not meet with 
a pharmacist.21 
Pharmacy services in ambulatory clinics may focus on a single disease state, such as diabetes, 
or may be focused around multiple conditions related to a high risk medication, such as 
warfarin.7 Medication management services can be expanded further when pharmacists 
work in collaboration with other healthcare professionals.   
Collaborative Drug Therapy Management 
Collaborative drug therapy management (CDTM) has been defined as a formal partnership 
between a pharmacist and physician or group of pharmacists and physicians to allow 
pharmacists to manage a patient’s drug therapy.8 CDTM agreements allow pharmacists to 
expand their scope of practice by allowing them to perform services they would not be allowed 
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to perform without a CDTM agreement. CDTM can help improve patient outcomes, increase 
patient satisfaction, and lower costs.   
 
Potential Problem Pharmacist Intervention 
Medication adverse events Pharmacists may identify drug interactions, 
resolve side effects, identify inappropriate 
medications or doses 
Limited patient access to healthcare 
practitioners 
Pharmacists may help provide care to 
patients, lessening patient load for 
physicians 
High healthcare costs Pharmacists can reduce costs by optimizing 
medication use 
● Can identify unnecessary or 
inappropriate medications 
● Ensuring patient adherence to 
medications can help prevent 
hospital admissions 
 
Table 3-3. CDTM Benefits9 
 
 
Ambulatory care pharmacists utilize CDTM agreements to work collaboratively with 
physicians to enhance patient care. Based on the pharmacist’s scope of practice in their state, 
responsibilities of a pharmacist under CDTM agreements may include implementing or 
modifying drug therapy, ordering and evaluating drug-therapy related laboratory tests, and 
administering medications such as immunizations.  However, these responsibilities may 
vary depending on the legal agreement and scope of practice.8,9 
ADMINISTRATION 
In some clinics, particularly those providing services to underserved populations, ambulatory 
care pharmacists may be asked to assist with developing drug formularies and monitoring 
prescribing habits. A formulary is a list of medications and related drug information that is 
continually updated and reviewed by physicians, pharmacists, and other healthcare 
professionals.10,11 For health plans, a formulary includes all the prescription medications 
covered by the plan. Hospitals also have drug formularies, which include drugs that the 
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hospital carries. Formularies are developed by identifying the most medically appropriate 
and cost-effective drug therapy options. Pharmacists play a key role in this process by 
continually reviewing primary literature and guidelines on medications to determine the 
most appropriate drug therapies to include in formularies and relaying findings to physicians 
and other healthcare professionals.10,11  
PREVENTATIVE CARE / WELLNESS SCREENINGS 
In addition to helping patients manage existing chronic disease, pharmacists may also help to 
prevent disease. For example, an annual wellness visit (AWV) may serve as an annual health 
screening for patients. Medicare Part B covers the patient’s cost and provides reimbursement 
for the practitioner providing this service. AWV occur in a physician office and during these 
visits, patients are assessed to determine if they have risk factors for certain disease states 
and may be referred to health education or other preventive services.12, 13  
 
 
 
 
Figure 3-3. Elements of an AWV12 
 
 
DIRECT PATIENT CARE 
Direct patient care is one of the primary services performed by ambulatory care pharmacists. 
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CDTM agreements facilitate pharmacist-independent and team-based patient care 
services.14 Table 3-4 outlines the pharmacist’s role in various clinic types, which can be 
provided by pharmacist-independent or team-based care. 
Pharmacist-Independent Care 
Ambulatory care pharmacists may be independently responsible for providing patient care, 
generally when working collaboratively under a physician.14 This is most commonly seen in 
disease state management with CDTM in place. When a pharmacist is working 
independently to care for a patient, responsibilities may include completing medication 
histories, physically assessing the patient, ordering lab tests, adjusting medications, and 
following up with the patient.15 Additionally, based on the collaborative agreement in place, 
pharmacists may also authorize refills of certain medications and provide immunizations.15 
Team-Based Care  
Ambulatory pharmacists may also work as a member of a team with other healthcare 
professionals to provide care for a patient.14 In this setting, pharmacists may meet with the 
patient at the same time as other healthcare providers.  During shared appointments, 
pharmacists are able to address medication questions and concerns brought up by the patient 
or the other healthcare providers.15 Pharmacists may still have independent responsibilities 
in this setting, such as obtaining medication histories and performing medication reviews.14 
 
 
Clinic Type Pharmacist Role 
Diabetes9,16 ● Help patients set self-management goals 
o Blood pressure and A1C targets 
o Investigate barriers to achieving these goals 
● Adjust medications to help achieve these goals 
● Provide diet and exercise education 
Anticoagulation17 
(primarily warfarin) 
● Adjust warfarin doses 
● Assess for drug interactions or diet changes that may affect 
warfarin therapy 
● Interpret INR results to see if dose adjustments need to be 
made to keep patients in therapeutic range 
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Clinic Type Pharmacist Role 
Pulmonary18  ● Provide spirometry tests to evaluate patient pulmonary 
functions 
● Identify respiratory problems related to inadequate 
medication therapy 
● Counsel on proper inhaler and nebulizer use 
Smoking 
Cessation19 
● Instruct on both prescription and over-the-counter 
medications to help quit smoking 
● Provide strategies and tips in quitting 
● Follow up with patient to ensure no relapse 
Heart Failure20 ● Ensure patient is not taking medications that may worsen 
heart failure 
● Inform patient’s primary care provider of any inappropriately 
prescribed drugs 
Hypertension21 
 
● Take patient’s blood pressure 
● Suggest adjustments to patient’s medications based on blood 
pressure results 
● Diet and lifestyle counseling 
Behavioral Health9 ● Help to adjust or initiate psychiatric medications  
o Disease states include depression, schizophrenia, and 
bipolar disorder 
o Consider special populations such as geriatrics and 
pediatrics 
HIV22 ● Help to optimize treatment regimens 
o Analyze patterns of resistance to the HIV virus 
● Ensure patients have access to medications 
Hepatitis C23 ● Manage drug interactions 
● Assess appropriateness of treatment regimens based on 
patient genotypes 
 
Table 3-4. Pharmacist’s role based on clinic type 
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CARE COORDINATION 
Transitions of Care 
Transitions of care refers to the movement of a patient from one setting of care (hospital, 
ambulatory care practice, long-term care, home health, rehabilitation facility) to another.24 
Transitions of care may also apply to patients who are leaving a healthcare setting to go 
home. When patients leave one healthcare setting and move to another, it is important that 
they are receiving continuous care. Care should be coordinated between all healthcare 
professionals providing care to the patient. When patients are transferred from one setting to 
another, adverse events may occur, often caused by medication errors. Recent studies have 
shown that 54% of patients experienced medication errors upon hospital admission; a 
significant percentage of these errors (39%-45%) were found to be potentially harmful to the 
patient.25 Patients who are admitted to a care facility, such as a hospital, may leave with a 
different prescribed medication regimen than what they had previously. If these changes are 
not adequately communicated between healthcare providers, the patient may end up 
receiving inappropriate and/or duplicate drug therapy. This is why it is important for 
healthcare providers to effectively communicate any changes in drug therapy.24,25  
Pharmacists may play a significant role in facilitating a patient’s transition of care in 
collaboration with other health care providers such as, physicians, nurse practitioners, 
clinical nurse specialists, or physician assistants.24,26 Obtaining a patient’s complete 
medication history in order to accurately perform medication reconciliation is important in 
reducing medication errors.27 The patient’s medication list should be reconciled again upon 
discharge to another healthcare facility and should be available for the next healthcare 
providers taking care of the patient. Patient adherence to new drug regimens is also important 
and can be improved through disease state education and medication education. Educating 
the patient about their condition, medication, how to take the medication, and potential side 
effects can improve medication adherence rates. Disease state education can help a patient 
understand their new diagnosis and the risks involved can help motivate patients towards 
better adherence. Immediate patient follow-up is another task in which pharmacists can 
help.26 Care transition pharmacists make contact with the patient within a few days of 
discharge from the inpatient setting. This quick initial contact can help answer questions the 
patient may have and help them to better manage their new diagnosis effectively. In addition 
to these services, pharmacists can also integrate MTM services and medication counseling 
services. In some practices, pharmacists are able to continue following the patient if the 
patient’s chronic conditions match those in which the pharmacist manages at the clinic.  
Pharmacists provide a unique, medication-specific approach to transitions of care, which has 
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been shown to decrease hospital admissions, readmissions, and ED visits.24,27 
 
 
 
CASE 3-1 
 
Dr. Jones is a local physician whose patient population consists largely of 
diabetic and atrial fibrillation patients. Many of his patients appear not to be 
adequately managed in their disease states. Additionally, Dr. Jones has a 
high patient load which prevents him from seeing his patients as often as he 
should, resulting in poor outcomes, trouble managing appointments, and 
difficulty bringing in new patients.  Due to poor performance scores, Dr. 
Jones is at risk for facing penalties and/or not receiving full reimbursement 
amounts with his payers. 
What are opportunities for ambulatory care pharmacists in this 
scenario?  What services could be provided? 
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SECTION 2 
COST 
There are many reasons healthcare costs so much in the United States, but the answers 
usually fall into two categories: costs due to the healthcare system itself and costs due to the 
nature of disease and society.1 Costs caused by the healthcare system can be attributed to 
insurance used as insulation, lack of transparency, and lack of standardization and 
coordination.1 Insurance was originally designed to protect against high, catastrophic costs 
that could lead to medical bankruptcy or significant financial loss. Insurance as insulation 
attempts to assist consumers with even low cost expenses, increasing the cost of insurance 
because providers can no longer calculate costs based solely on the risk of catastrophic 
events. This more extensive coverage relies heavily on private negotiations and opaque 
contracts to control costs.  
The American healthcare system is a private, competitive, market-driven system with 
limited government regulation, price controls, and salary caps. Many other countries have 
centralized negotiation programs where companies compete for contracts by offering lower 
prices.2 In the United States, private and government payers may negotiate prices with 
healthcare administrators without involvement of the patient or healthcare provider. 
Therefore, price does not equal cost or reimbursement for a particular healthcare service or 
product. This lack of transparency allows for variable prices for similar services and further 
impacts competition. Prices for drugs, office visits, and procedures are typically higher in the 
United States than any other country. These costs support innovation, advanced technology, 
attractive facilities, and higher salaries of healthcare providers. A 2013 Gallup Poll suggests 
that Americans have more positive feelings about their personal healthcare than the 
country’s healthcare.3 Approximately 2/3 of Americans rate their personal healthcare 
coverage as excellent or good and about 1/3 give the country’s healthcare coverage a high 
rating.3 59% of respondents indicated they were satisfied with the cost of their own 
healthcare.3  
Costs related to the nature of disease and society include costs of chronic disease care, end of 
life care, unhealthy behaviors, and health literacy.1 According to the Agency for Healthcare 
Research and Quality (AHRQ), in 2013, 5% of the US population account for 48.7% of 
spending with an estimated annual mean expenditure of $43,253.4 The lack of incentive for 
preventive care and unhealthy lifestyles leads to an increase of chronic disease. The 
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expectation of insurance payment for chronic disease management is part of the systemic 
costs of increased perception of insurance as insulation. Attitudes toward prevention and 
healthy lifestyle are part of the costs related to the nature of disease and society. Societal 
views on extensive end of life care contributes significantly to healthcare spending, especially 
as the baby boomer population ages.  Other factors that impact the cost of care will be 
discussed later.  
Until the early twentieth century, insurance for routine healthcare did not exist. The first 
modern group health insurance plan was formed in 1929. A group of teachers in Dallas, Texas 
negotiated a contract with a local hospital for services in exchange for a fixed monthly fee.5 
This arrangement led to the startup of organizations such as Blue Cross and Blue Shield 
which offered similar insurance programs. Offered only by some employers, insurance was 
generally purchased by the patient consumer and having insurance was uncommon. This 
changed during World War II when the federal government imposed wage freezes. At the 
time, employers could not raise salaries but could offer benefits to employees and employers 
competed for workers by offering better benefits packages. A key component was new or 
improved health insurance plans. This led to major demand and growth for private employer-
based health insurance and by the late 1950s the majority of Americans had some amount of 
healthcare coverage. However, those who were unemployed, self-employed, or employed by 
small employers were unable to afford the care they needed.  In response, Medicare and 
Medicaid were created in 1965 providing public funding for healthcare coverage for the 
elderly and indigent.5 Each of these coverage options may use one or more payment 
structures, including fee for services, network negotiations, capitated payments, or salaried 
providers. 
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CHAPTER 4 
FROM INSURANCE BASICS TO PLAN 
SELECTION 
Author: Carriann Smith, BS, PharmD  
 
By purchasing insurance, plan members are buying protection from a large debt in the event 
of a catastrophic need for medical care. However current practice in using insurance to cover 
non-catastrophic expenses causes higher premiums and may decrease the amount available 
to pay for covered expenses.  
On average, a three day hospital stay can cost about $30,000 and a reasonable question might 
be how health insurance companies pay for the large bills.1 The insurance company’s job is to 
spend money to benefit the most members without having to raise premiums or deny 
additional services. This includes using profits to pay competitive salaries to employees. The 
business of health insurance in the United States relates as much to finance as it does to 
healthcare. Plan members pay for insurance through regular premiums and insurance 
companies invest that money to pay for illnesses that happen to anyone in the group.  Proper 
investing and money management provides the best coverage to cost ratio for beneficiaries.   
Insurance is paid via premiums, deductibles, co-payments, and co-insurance amounts. 
Premiums are a monthly payment to ensure the member stays covered under a plan (like a 
basic phone bill without usage charges). Many insurance plans require patients to pay a 
deductible at the beginning of each year of coverage, typically January 1. A deductible is the 
total amount a member must spend on their care per policy period (generally one year) before 
insurance will begin to cover their portion. Therefore, beneficiaries pay for coverage but the 
insurance doesn’t work right away. Depending on the plan, deductibles may only apply to 
certain types of care. For instance, if the deductible does not apply to prescriptions, the 
patient does not have to pay the deductible first for prescriptions. 
Once a patient has met their deductible, they may continue to have to pay a portion of their 
bills until they have reached their out-of-pocket maximum. Having beneficiaries paying some 
of their own costs, cost sharing has been shown to engage them in keeping costs low. It also 
helps to keep the costs of premiums down by decreasing insurance company spending. The 
patient will pay a portion of costs through co-pays, which are flat fees, and co-insurance, 
which is a percentage of total charges. Insurance will cover the remainder of the bill.  
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Health insurance plans negotiate prices and have out-of-pocket maximums to help prevent 
members from going bankrupt despite having insurance. Once the out-of-pocket maximum is 
reached, insurance will cover 100% of a member’s healthcare costs for the rest of the year.1  
PATIENT TO PAYER CONNECTIONS 
Fundamental knowledge of insurance terminology is necessary for navigating patient to 
payer interactions. The primary purpose of health insurance is to help protect an individual 
from financial risks of medical expenses, which can often be very high, and to help avoid 
significant financial loss.1 Health insurance in the United States usually includes both 
medical insurance (doctor and hospital coverage) as well as prescription coverage. A common 
misconception is the belief that insurance will pay for all health care expenses that occur.2 
Health insurance plans identify services or expenses that are covered or eligible for insurance 
payment.3 It may also list items that are excluded, where an individual will pay any expenses 
incurred without insurance help. When a health care provider or patient submits these 
expenses to the insurance company for processing (send in the bill), the expenses are referred 
to as claims. Additional vocabulary such as deductible, coinsurance, etc. is defined in the 
glossary.  
Types of Insurance Coverage 
Figure 4-1 below provides an overview of the primary types of health insurance coverage 
available in the US.3 Health insurance may be purchased privately, either individually or as 
part of a group, or publicly, through state or federal government. Employer coverage, a form 
of group coverage, is the most common type of private insurance.3   
Employers who offer health insurance plans to their employees generally offer better 
coverage at a cheaper rate than if the employee were to purchase it on their own as an 
individual policy. Employers may also choose to cover a portion of the premium for each 
employee. The employees then pay their portion of the premium through paycheck 
deductions.3  
Others are not able to obtain employer health insurance. These individuals may not work 
enough hours to qualify for employer coverage, are unemployed or work for a small employer 
who does not offer regular group coverage. These individuals can purchase private coverage 
through the health insurance marketplace (online) or from private agents.   
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Figure 4-1. An overview of the types of insurance coverage available to Americans 
 
 
IN-DEPTH LOOK AT THE MARKETPLACE 
Marketplace 
The Patient Protection and Affordable Care Act, PPACA, created a new, private insurance 
marketplace in all 50 states and the District of Columbia.4 Some states created their own 
marketplace and others utilize the federal health insurance marketplace. These marketplaces 
include a central online location, called the Small Business Health Options (SHOP) 
Exchange, that enable individuals and small groups to shop for private health insurance 
plans.4,5 Here, small businesses, currently defined by the federal government as 50 or fewer 
full time equivalent (FTEs) employees, can set up accounts to allow individuals to compare 
available plans specifically selected by the small employer.5 In the SHOP, individuals have 
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fewer options than on the individual marketplace, but the employer pays a portion of the 
premium.5   
People who select insurance plans through the individual health insurance marketplace may 
be eligible for tax credits to help cover their premium. These credits are based on the person’s 
income.6 Some individuals may also choose to self-pay for medical bills, rather than pay for 
insurance coverage. However, this choice will result in penalty taxes the individual will be 
required to pay, unless they qualify for a tax exemption.6   
Marketplace exchanges support individual access and comparison of health insurance 
coverage. Resources are available to help individuals navigate the exchanges.  HealthCare.gov 
offers a wide variety of information regarding navigation and utility of the federal health 
insurance marketplace. Individuals can apply online, by phone, via a paper application, or 
with in-person help using a tool on HealthCare.gov, which enables individuals to enter their 
location information, and select the type of coverage they are searching.6,7 
Function and Navigation 
Individuals can enroll in plans during yearly open enrollment periods (OEP) that is set by the 
federal government.6 During this timeframe, individuals may browse and enroll in a health 
insurance plan for the following year.  Enrollment outside of the OEP cannot occur unless the 
patient, also known as a beneficiary, qualifies for a special enrollment period.6 Special 
enrollment periods occur over a 60 day period following particular life events that result in a 
change of family status, such as marriage, childbirth, or after the loss of prior health coverage.6  
HealthCare.gov offers screening tools to help individuals determine if they are eligible for 
either Medicaid, Children’s Health Insurance Program (CHIP), or a special enrollment 
period.  Both Medicaid and CHIP are discussed later in this chapter.   
Marketplace Plans 
The federal health insurance marketplace categorizes insurance plans into four “metals” or 
“medals”: Bronze, Silver, Gold, and Platinum.  Although a common misconception, the 
“metals” do not reflect or categorize plans according to quality or amount of care provided by 
each plan.8 Each metal level reflects the cost of monthly plan premiums and the portion of 
costs for care or services, such as hospital visits or prescriptions, that the patient will be 
expected to pay.8 “Metal” categories are defined in Figure 4-2.9 
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“Metal” Federal Health Insurance Marketplace Categories 
Bronze 
• Health plan covers approximately 60% of total average costs 
• Beneficiary covers approximately 40% of total average costs 
Silver 
• Health plan covers approximately 70% of total average costs 
• Beneficiary covers approximately 30% of total average costs 
Gold 
• Health plan covers approximately 80% of total average costs 
• Beneficiary covers approximately 20% of total average costs 
Platinum 
• Health plan covers approximately 90% of total average costs 
• Beneficiary covers approximately 10% of total average costs 
 
Figure 4-2. “Metal” insurance plans for the federal health insurance marketplace 
 
 
Catastrophic health plans, often referred to as a ‘fifth category’ within the marketplace, exist 
for individuals under 30 years of age or those who have a hardship exemption.9 Hardship 
exemptions are a set of specific criteria, such as being homeless, experiencing domestic 
violence, or facing substantial medical debt, that enable an individual from having to obtain 
health insurance coverage for a particular period of time.9,10  Catastrophic plans focus their 
benefits on high medical costs such as serious injury or hospitalization rather than 
outpatient, chronic care.10 Under these Catastrophic plans, health insurance companies pay 
less than 60% of the total average costs of care, placing more payment responsibilities on the 
patient.9 These plans are an option for younger individuals who are healthier and do not 
utilize their insurance coverage on a regular basis.10 Individuals under hardship exemptions 
are eligible, regardless of age or income, to purchase a Catastrophic health plan, but are not 
required.10   
Public/Government Insurance Coverage Options 
Individuals who have a very limited income and significant medical need may obtain health 
insurance through the state government Medicaid program. Medicaid is a collection of 
programs available for different levels of need. Medicaid provides health insurance options 
for low-income families and children, pregnant women, the elderly, and people with 
disabilities. Low income in most states is defined as at or below 133 percent of the federal 
poverty level.11 Some states have expanded their Medicaid programs to cover all adults below 
138% (133%+/-5%) levels.11 Medicaid recipients typically don’t pay a premium and copays are 
low to nonexistent since coverage is funded by the state and federal government.  
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Although each state administers their own program, the federal government provides some 
financial support to assist with Medicaid funding. The federal government also sets 
minimum guidance standards, such as criteria for enrollment and evaluation of claims, 
Medicaid programs must follow to ensure some consistency of coverage between state 
programs.11 Therefore, though all states must meet minimum standards, Medicaid benefits 
vary between states based on individual state budgets and overall population need. 
Individuals who are over 65, disabled for 24 months or longer, have End Stage Renal Disease 
(ESRD), and/or ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease) qualify for 
another government program called Medicare.12 It is important to note that individuals may 
qualify for both Medicaid and Medicare. Table 4-3 describes the different types of Medicare 
programs available to patients.12   
 
Types of Medicare 
 
Medicare Part A & B 
(“Original Medicare”) 
 
Original Medicare is a fee-for-service health plan that has two 
parts: Part A (Hospital Insurance) and Part B (Medical Insurance). 
After the member pays a deductible, Medicare pays its share of the 
Medicare-approved amount, and the member pays their share 
(coinsurance and deductibles). 
 
 
Medicare Part C  
(“Medicare 
Advantage”) 
 
Medicare health plan that contracts with Medicare and uses 
managed care arrangements with providers to provide Part A and 
Part B benefits to Medicare patient.  Medicare Advantage Plans 
include Health Maintenance Organizations, Preferred Provider 
Organizations, Private Fee-for-Service Plans, Special Needs Plans, 
and Medicare Medical Savings Account Plans.  Patients choose 
either Medicare Advantage or Original Medicare.  Most Medicare 
Advantage Plans offer prescription drug coverage. 
 
 
Medicare Part D 
 
A separate program that helps pay for prescription medications for 
people with Medicare.  All Medicare Part D plans are offered 
through private insurance or prescription benefit companies, there 
48 
 
is no “original” Medicare Part D plans offered by the federal 
government.  There are two ways to get Medicare prescription 
drug coverage: through a stand alone Medicare Prescription Drug 
Plan or a Medicare Advantage Plan that includes medication 
coverage.  
 
 
Table 4-3. Types of Medicare 
 
 
Other examples of government-funded programs include federal coverage through the 
Department of Defense for military members and their families and coverage for veterans 
through the Veterans’ Administration (VA).12 Government-funded coverage may also be 
referred to as public health coverage. 
RELATIONSHIPS BETWEEN PAYERS AND PROVIDERS 
Fee-For-Service (FFS) 
Before the 1970s, Medicare and private insurance primarily offered insurance, called 
indemnity insurance, that used a fee-for-service model. Fee-for-service means that each item 
or expense would be itemized to one or more bills. Providers would be paid a specified amount 
for each service amount established by each insurer. In the fee-for-service model, the patient 
chooses their own providers and has no restrictions on the use of specialty services. Providers 
who receive reimbursement directly from payers may then charge the patient what the 
insurance did not cover. This is referred to as balanced billing because the patient is billed for 
the remaining balance.13 This is demonstrated in figure 4-4.   
Figure 4-4. Fee for service model 
Patient receives 
care
Provider bills the 
payor
Payor pays 
patient
Patient pays 
provider with 
money received
Payor pays 
provider
Patient pays 
differences or 
provider loses that 
portion
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In 1973, President Richard Nixon signed a law to help control the rising healthcare costs.14 
With this law, a model for a managed care organization (MCO) was initiated.15 An MCO is a 
private insurance company with agreements in place with selected healthcare administrators 
and providers. This agreement is settled before patient care is delivered and outlines 
negotiated prices and payment arrangements. MCOs lower costs for patients by limiting their 
healthcare provider options to only those with an agreement. There are several types of 
MCOs, including: Health Management Organizations (HMOs), Preferred Provider 
Organizations (PPOs), and Point of Service (POS) plans.14 The options described below 
outline the financial agreements between healthcare providers or administrators and payers 
in managed care coverage. This is important to help patients understand their coverage and 
to help providers understand how they will be reimbursed.  
HEALTH MAINTENANCE ORGANIZATION (HMO) 
Healthcare providers within an HMO network are usually paid by salary or a capitated (per 
person, per year) amount, allowing the HMO to exert more connection and possibly control 
over the providers and their healthcare decisions. Therefore, patients can only receive 
healthcare services from providers in the HMO network.14  If a patient uses a provider that is 
not an HMO provider, their insurance plan will not pay for any services from that provider 
and the patient is responsible for all associated costs.  
Under an HMO plan, a patient is usually required to choose a primary care provider (PCP) 
who serves as a gatekeeper for their care.13 As gatekeeper, the PCP provides primary care and 
is the only provider who can refer the patient to specialists for care beyond the PCP’s scope of 
practice.13 This is demonstrated in Figure 4-5. 
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Figure 4-5. Health maintenance organization model  
 
 
PREFERRED PROVIDER ORGANIZATION (PPO) 
In a PPO, a patient has a preferred in-network list of providers from which to choose. If a 
patient chooses to see a provider who is out-of-network, it is more expensive than seeing a 
provider that is in-network but there will be some coverage from the insurer. In-network 
providers offer services at discounted rates in exchange for increased business from that 
insurance company. High deductibles may be options within PPOs (Figures 4-6 and 4-7), 
which can be offset by putting money into a tax-free account referred to as a Health Savings 
Account (HSA).   
Patient 
identifies a 
primary care 
provider 
within the 
HMO network
Provider gets 
paid either a 
salary or a 
capitated 
amount 
because the 
patient is now 
identified as 
being under 
their care
Patient goes 
to provider 
and pays a 
copay if 
applicable
Provider cares 
for the patient
If patient 
needs to see a 
specialist they 
must be 
referred by the 
primary care 
provider
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Figure 4-6.  PPO plan without a high deductible 
 
 
Figure 4-7.  PPO plan with a high deductible 
 
 
POINT OF SERVICE (POS) 
A POS may be considered a combination of an HMO and PPO.14 In these plans, a patient is 
typically required to choose a primary care provider (PCP) similar to an HMO. The PCP 
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coordinates the patient’s care and can refer them for additional services. At this point, the 
patient can choose to receive point of service (POS) care from a less expensive in-network or 
more expensive out-of-network provider.14 The out-of-network providers are more 
expensive because they are reimbursed on a fee-for-service basis. 
In summary, managed care attempts to limit healthcare costs by steering patients toward 
specific providers and controlling the number and variety of paid for services. A lack of 
provider knowledge of costs, limited patient knowledge about the care they need, and third-
party negotiations have made it difficult for patients embrace manage care. A trend toward a 
new structure, called accountable care, integrates healthcare providers to consider cost 
versus benefit with a focus on outcomes and value to patients.  
ACCOUNTABLE CARE 
The intent of the Patient Protection and Affordable Care Act (PPACA) was to shift from 
paying providers for the amount of care, fee-for-service, to paying providers based on the 
quality and value of the care they provide. The goal of pay-for-performance is to improve 
patient outcomes, enhance the quality of patient care, and reduce overall system costs.13,16 
Instead of having payers lead the decisions, the PPACA directed health care providers to be 
accountable for their patient care. This was done through changes to reimbursement for 
providers. New payment structures are based on measures of improving clinical outcomes, 
increasing overall patient satisfaction with the provider, minimizing adverse events, or 
decreasing length of stay and treatment times.17  
Accountable Care Organizations 
The PPACA established a new model to encourage and support accountable care: the 
accountable care organization (ACO). ACOs consists of groups of physicians, hospitals, and 
other health care providers. The ultimate goals of ACOs are to increase the use of evidence-
based quality measures, actively engage patients in their care, and coordinate patient care 
between providers.16 Coordinated care is intended to provide patients with the right care, 
avoid unnecessary duplication, and improve patient outcomes.8 
Medicare provides coverage to individuals who are at least 65 years old or those of any age 
who are permanently disabled. A new payment model, the Medicare Shared Savings Program, 
offers financial incentives to certain ACOs. Providers must meet different criteria but if they 
are successful and improving outcomes while cutting costs, they received a portion of the 
money saved back. To help measure success and determine reimbursement, ACOs are 
required to submit information to the Centers for Medicare & Medicaid Services (CMS) on 
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quality measures which together comprise four domains: Patient/Caregiver Experience, 
Care Coordination/Patient Safety, Preventative Health, and At-Risk Populations.18 Looking 
at the domains, it is easy to see how the focus on both the patient experience and clinical care 
connects to providing value based care. 
Accountable Care and Pharmacists 
The sustainability of ACOs is dependent on how well they can control costs through 
coordinated care while improving healthcare quality. Pharmacists are in a position to help 
ACOs succeed. The pharmacist’s role in accountable care will continue to include optimizing 
treatment choices, considering cost, ensuring medications are being prescribed and used 
properly, reducing medication-related adverse events, and helping other providers manage 
chronic disease states.16.19 
For example, think about a patient who has high cholesterol. The outcome of treatment is to 
lower the cholesterol. Lowering cholesterol may be done by changes in diet and exercise and 
by medications. This patient in self-employed and has a fee-for-service plan. Each time the 
physician meets with the patient and orders a lab test, it will be paid for by the insurance 
company and the patient will pay a portion of the cost.  If the physician is concerned the 
patient is at risk of a heart attack, they may be very aggressive may order frequent tests, 
prescribe new medications, and schedule regular appointments because each item will be 
paid. The physician is free to make clinical judgment without any review.  
The patient changes jobs and now has employer coverage using a health maintenance 
organization (HMO). The physician the patient had been seeing is not in network, so he must 
go to a different provider. After making an appointment with the new physician, the patient 
learns this will be his primary care provider who will decide what additional care the patient 
needs.  This is the gatekeeper and the name appears on the patient’s insurance card.  This 
physician is focused on maintaining the patient’s health and limiting the use of expensive 
laboratory tests and medications to reduce cost for the HMO and the patient. This physician 
recommends more extensive exercise and nutrition.  The physician makes recommendations 
based on the guidelines and policies provided by the HMO. The physician’s payment and 
employment is based on following the HMO criteria and managing cost and risk to the HMO.  
The patient now retires and enrolls in Medicare.  The patient changes physicians to one that 
takes Medicare.  This physician is part of an accountable care organization (ACO).  This 
physician knows that his reimbursement is based on the patient achieving his cholesterol goal 
and staying out of the hospital.  He implements a diet, exercise and medication plan that fits 
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nationally recognized guidelines and the physician’s clinical experience.  The physician 
considers the costs of care and balances that with maximizing the benefits for the patient.  
The physician considers what quality measures exist for patients with high cholesterol and 
set goals for the patient that match this goal.  If this and other patients meet their quality 
measures for cholesterol management, the physician will receive the remainder of his 
reimbursement.   
This is a simplified approach to understanding the difference between payment structures to 
clearly delineate how healthcare providers may be impacted. It is not likely that a provider 
would change their treatment by the type of insurance coverage but different settings are 
likely to place different emphasis on treatment options. There is certainly overlap between 
what drives different providers and their use of quality measures, national guidelines, payer 
guidelines, and clinical experience. 
 
Figure 4-8. Transition from Fee for Service to Accountable Care. 
 
 
Fee for Services versus Managed Care Organizations 
As discussed, there are three primary forms or categories of health insurance plans:  
1. fee-for-service 
2. health maintenance organizations 
3. preferred provider organizations.2,3  
 
Traditional fee-for-service plans are often the most expensive coverage options but offer 
patients the most flexibility when choosing health care providers.3 Health maintenance 
organizations (HMOs) offer lower co-pays for patients than traditional fee-for-service plans 
and cover most costs for preventative care, but patients are only allowed to use a limited 
number of health care providers and facilities except in emergency situations.3,20 HMOs 
require their patients to select a primary care provider in order to receive coverage.3,20,21 
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Additionally, HMOs may require referrals from a single primary care provider, also known as 
a gatekeeper, to see providers outside of the plan’s network.20 Point-of-service options may 
also be offered by some HMOs and allow patients to receive care outside the preferred 
network, but at a higher, out-of-pocket cost through higher premiums.20 
Preferred provider organizations (PPOs) offer lower co-pays than traditional fee-for-service 
plans and provide more flexibility to patients when selecting health care providers or 
facilities.20  PPOs typically provide the most coverage for providers within network but allow 
patients to receive care out-of-network at higher costs and usually do not require referrals for 
such care.21,22  Unlike HMOs, PPOs do not require patients to choose a primary care 
provider.3,22  
Comparing and Selecting Health Insurance Plans 
Ultimately, selecting a health care insurance plan requires evaluation by the individual 
seeking coverage. They must first understand the types of coverage available to them, such as 
private or public. Based on the type of coverage, different forms of reimbursement (HMO, 
PPO, fee-for-service) may impact a patient’s choice.20,21,22 A patient’s current health status, 
health behaviors, and financial situation must also be considered when selecting insurance 
plans. Acceptance of risk should also be taken into consideration.21 Like a warranty plan for 
an appliance, paying for more insurance coverage decreases the risk that an individual would 
have to pay out of pocket for unplanned medical expenses. Alternatively, if patients do not 
wish to pay for coverage they may not need, they may want to reduce the amount of coverage 
they select.  Patients not expecting to go to the doctor may select a plan with lower monthly 
premiums but less coverage.6,9 However, a healthy patient wishing to avoid the expense of 
unexpected healthcare services may choose to pay higher premiums under a private 
insurance plan to ensure better coverage.  
Less coverage may be defined in different ways: it may mean the insurance plan covers fewer 
expenses or that the insurance company covers the same number of expenses but the patient 
must pay more out of pocket.6,9 Paying a higher cost share may mean a patient pays 30% 
instead of 20% of the medical cost, for example.6,9 Insurance plans may also have different 
coverage for different levels of care, referring to the location of where care was received.6 For 
instance, a patient with a fever and flu symptoms would likely pay much more for a visit to the 
ED than an urgent care. The same visit would cost even less at a physician’s office. 
In choosing a plan, the patient should be aware of how networks function. Based on the plan 
they choose, they may have little to no coverage at certain providers who are out of 
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network.20,21,22 If there is a certain provider or service needed, the patient should make sure it 
is covered under their intended plan. By limiting the number of providers that a patient can 
receive care from allows the insurance company to reduce expenses and pass that savings on 
to the patient.20,21,22 For example, seeing a primary care physician for a physical may be 
covered, whereas seeing a renal specialist for the same physical may not be covered. This 
helps direct patients to the most appropriate provider for their care need.   
Some plans may offer tax-exempt Health Savings Accounts (HSAs) or Flexible Spending 
Accounts (FSAs).23 These accounts enable patients to deposit and save money, tax-free, to 
help pay for future medical expenses. Typically, a percentage of a patient’s paycheck will be 
directly pulled and deposited into the accounts.23 This is a great way to save money and 
manage healthcare costs. Since the accounts are commonly used with high-deductible 
policies, patients typically pay higher costs upfront and track their expenses more carefully.23 
It is important to determine if the plan includes prescription drug coverage, especially if the 
patient is currently taking prescription medications. Patients should consider a health 
insurance company’s formulary when selecting plans to better determine their prescription 
coverage needs and/or costs.24,25,26 Medications or brands not on the formulary can be much 
more expensive or may not be covered at all. Sometimes the plan will place formulary 
restrictions on certain medications and only cover them after the patient has completed a 
step therapy or other type of prior authorization, discussed later in this chapter, to prove the 
medication is medically necessary.24,25,26   
Ultimately, premiums, deductibles, and benefits must be weighed and balanced. Patients who 
need high cost prescriptions may purchase a different plan than a person who primarily needs 
support for wellness and emergency care. 
Explanations of Benefits 
Explanations of benefits are sent to patients by the insurance company to explain their health 
insurance coverage. These explanations of benefits (EOBs) outline what claims were covered, 
the negotiated contracted price for the medication, the amount owed by the patient, the 
amount paid by the insurance company and the reason for any claim rejections, where the 
insurance company refuses to cover a particular medication and/or therapy.  
Fees for Not Having Health Insurance 
As set in the PPACA, individuals may be subject to penalties should they not have health 
insurance coverage. Individuals who can afford health insurance but choose not to purchase 
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coverage are required to pay a fee called the Individual Shared Responsibility Payment, also 
known as a penalty, fine, or individual mandate.25,28 Individuals without coverage are 
required to pay the fee for any month they, their spouse, or their tax dependents do not have 
health insurance coverage that qualifies as minimum essential coverage.28 Payments are 
required upon filing for federal tax returns for the year coverage was not held.28 Fees are 
calculated per person as a percentage of an individual’s household income. HealthCare.gov 
provides resources to estimate mandated fees. 
Exemptions for the Individual Shared Responsibility payment may be available for qualifying 
individuals. An individual must meet one of the following criteria, (see Figure 4-9), to be 
exempt, which prevents them from holding minimum health insurance coverage:26 
 
Have no affordable coverage options due to the fact that the minimum required costs for 
the annual premium rises more than 8% above the household income10 
Have gap in health coverage lasting less than 3 consecutive months10 
Qualify for an exemption for at least one various reason, such as having a hardship that 
prevents an individual from obtaining coverage or belonging to a group explicitly exempt 
from the health insurance coverage requirement10 
 
Figure 4-9. Criteria for exemptions for Individual Shared Responsibility payment 
 
 
Simply holding insurance coverage may not enable an individual to avoid penalties.  Under 
the PPACA, health insurance coverage must meet minimum comprehensive benefit 
standards.5  Figure 4-10 outlines these essential health benefit standards.29 
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Essential Health Benefits 
Ambulatory Patient Services  
(outpatient care, non-hospital admittance) 
Mental Health/Substance Use  
Disorder Services 
(counseling, psychotherapy, etc.) 
Emergency Services Laboratory Services 
Hospitalizations 
(surgery, overnight stays, etc.) 
Pregnancy, Maternity, and  
Newborn Care 
Prescription Drugs Rehabilitative/Habilitative Services/Devices 
(help gain or recover mental/physical skills) 
Pediatric Services 
(oral, vision, etc.) 
Preventative/Wellness Services and 
Chronic Disease Management  
 
Figure 4-10. Essential Health Benefits 
 
 
All marketplace plans meet minimum standards.4,28,29 Most plans obtained through 
employer,  government, or state programs also meet minimum standards.28 Providers should 
advise patients who wish to purchase insurance outside of these programs to ensure all 
coverage requirements are being met. HealthCare.gov can be used to help identify whether a 
plan meets minimum standards. 
Pharmacists in different practice settings may assist patients and providers in making the 
most of their insurance benefits including plan and benefit selection. While this chapter has 
focused on medical (hospital and office visit) benefits. The next chapter will focus on 
pharmacy benefits (outpatient prescription) benefit.  
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GLOSSARY 
Annual Limit 
The maximum amount a member’s insurance company will pay for healthcare in a year. 
These caps may be placed on particular services such as hospitalizations as dollar limits or 
number of services such as number of therapy appointments. After the annual limit is 
reached, the member must pay all associated healthcare costs for the rest of the year. 
Beneficiary 
A patient who is insured under a specific insurance policy. This could be the primary 
cardholder or any dependents. 
Benefits 
The health care items or services covered by a health insurance plan. Covered benefits are 
defined in the health insurance plan's coverage documents such as the policy or certificate. 
Claim 
A request for payment (bill) that the member or their healthcare provider submits to the 
health insurer for healthcare products or services. 
Coinsurance 
The percent the patient pays (for example, 20%) of the allowed amount for a covered 
healthcare service or product.  
Copayment 
A fixed amount (for example, $15) paid for a covered healthcare service, usually when the 
service is provided.  
Covered Expense 
A healthcare service or product that is covered as part of the specific insurance plan.  A 
covered expense does not mean it is covered at 100%, but instead that some amount of 
coverage will be provided.  
Deductible 
The amount the patient must pay towards a covered health care product or service before the 
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health insurance plan begins to pay. For example, if the deductible is $1,000, the plan won’t 
pay anything until the member has paid $1,000 for covered services. If a covered expense is 
NOT subject to deductible, then the patient will not have to pay the deductible first.  
Dependent 
A child or other patient that benefits from the insurance policy but is not the cardholder. One 
type of beneficiary. 
Excluded Services 
Health care services that the health insurance or plan doesn’t pay for or cover. This may also 
be referred to as non-covered. 
Flexible Spending Account (FSA) 
An arrangement set up through the employer to allow employees to designate money from 
their paycheck to be used for healthcare before taxes are taken out. This makes the use of 
these funds tax free. The member decides how much of their pre-tax wages are taken out of 
their paycheck and put into an FSA. Unlike an HAS, there is no carry-over of FSA funds at the 
end of the plan year.  
Formulary 
A list of prescription drugs covered by a prescription drug plan or another insurance plan 
offering prescription drug benefits.  
Health Savings Account (HSA) 
A savings account that can be set up at a bank for patients enrolled in a High Deductible 
Health Plan. The funds contributed to the account aren't subject to federal income tax at the 
time of deposit. Funds must be used to pay for qualified medical expenses. Unlike a Flexible 
Spending Account (FSA), funds roll over year to year if they are not spent. 
Lifetime Limit 
The maximum amount that an insurance company will pay during a person’s lifetime. After a 
lifetime limit is reached, the insurance plan will no longer pay for covered services. The 
PPACA eliminated lifetime limits from most insurance plans.  
Member 
A member is a patient who benefits from an insurance plan. Member is another word for 
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beneficiary. Member is more likely to be used with managed care plans. 
Network 
The list of all facilities, providers and suppliers the health insurer or plan has contracted with 
to provide health care services. 
Out-of-Pocket Maximum 
The most the member will have to pay for covered services in a policy period (usually one 
year). After reaching this amount, the health plan will pay 100% for covered essential health 
benefits until the annual or lifetime limit is reached. The calculation towards out-of-pocket 
maximum includes the yearly deductible and may also include any cost sharing after the 
deductible. It doesn’t have to count premiums, out-of-network cost-sharing, or non-covered 
expenses. 
Preauthorization 
A decision by the health insurer or plan that a health care service, treatment plan, 
prescription drug or durable medical equipment is medically necessary. Sometimes called 
prior authorization, prior approval or precertification. Your health insurance or plan may 
require preauthorization for certain services before the member receives them, except in an 
emergency. Preauthorization is not a guarantee that the health insurance or plan will cover 
the cost. 
Premium 
The amount that must be paid to keep coverage under a health insurance or plan. The member 
and/or employer usually pay it monthly, quarterly or yearly. 
Readmission 
When a patient returns to the hospital shortly after being discharged this is considered a 
readmission. This is usually counted if it is within 30 days of the discharge.  It may count if it 
is for the same condition or another condition.  
Reimbursement 
Reimbursement is the amount a payer provides to the health care provider in response to a 
claim.  For managed care plans, reimbursement amount may be based on the terms of the 
contract.  Usual, customary and reasonable amounts may apply to fee for service plans.  
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Referral 
A written order from a primary care doctor for the member to see a specialist or get certain 
medical services. In many Health Maintenance Organizations (HMOs), a referral is 
necessary receiving medical care from anyone except the primary care doctor. Without 
getting a referral first, the plan may not pay for the services. 
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CHAPTER 5 
PRESCRIPTION INSURANCE 
Author: Carriann Smith, BS, PharmD 
 
When patients are choosing health insurance, pharmacy or outpatient prescription benefits 
are usually part of the health insurance package. Medicare Part D is the exception that focuses 
only on outpatient pharmacy benefits. In this chapter, more detail will be provided on 
prescription benefits. While prescription benefits are only part of a health insurance package, 
they may be the most used component of a person’s plan and careful consideration should be 
given to what they cover.  
PHARMACY BENEFIT MANAGERS 
Functioning as a third-party administrator of prescription drug programs, pharmacy benefit 
managers (PBMs) are companies (not individuals) often hired to help design, manage, and 
maintain formularies for insurance companies.1,2 However, PBMs may also be utilized to 
form contracts with pharmacies, negotiate discounts and rebates with medication 
manufacturers, and process payment for prescription medication claims. PBMs can help 
maintain or reduce pharmacy costs of insurance plans, while providing value and flexibility 
to patients. Some PBMs may offer additional resources that provide patients with 
information, such as lower-cost therapeutic alternatives, medication therapy management, 
and mail order services.1,2   
Pharmacists are often employed by PBMs to provide high quality medication therapy 
management for members within an insurance plan while considering the 
pharmacoeconomic implications as well.1,2 Managed care pharmacists perform a variety of 
roles including medication distribution and dispensing, patient safety monitoring, clinical 
program development, business operations, analysis of therapeutic outcomes,  and formulary 
management.1,2 
FORMULARIES 
Most health insurance plans utilize a formulary, which is a list of particular medications that 
ensures drug products are used in a rational, safe, and cost-effective manner. Formularies can 
be either open or closed.3 Insurance plans with open formularies pay for all medications, even 
those not on the formulary. Closed formularies only provide coverage for medications that are 
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listed on the health insurance plan’s formulary.3 The medication listed on a formulary is often 
organized into tiers. These tiers will represent different levels of payment by the insurance 
company and the patient. Generally preferred medications will be cheaper than non-
preferred agents as well as generic medications cheaper than brand name. Preferred refers to 
products that are identified by the insurance company as those that may produce more value 
or cost savings.  
Formularies are typically developed by pharmacy and therapeutics (P&T) committees, which 
are made up of primary care and specialty physicians, pharmacists, nurses, legal experts, and 
other health care professionals.3 As mentioned previously, the goal of this committee is to 
provide a formulary that represents the optimal therapy for patients based on evidence-based 
efficacy and safety information. Additionally, elements such as cost and ease of delivery are 
considered when determining which medications should be on a formulary, which are 
discussed further in Chapter 6.4   
PRIOR AUTHORIZATIONS  
Health insurance plans have implemented prior authorizations (PAs) to ensure efficacious 
and safe medications are being covered, optimizing patient outcomes. A PA requires 
physicians to provide explanations and/or documentations to justify the use of specific 
medications for a patient.4 Insurances use this information to determine whether they will 
approve or deny coverage of the medication. This helps ensure medications are administered 
according to recommended therapeutic guidelines and provides better control over costs for 
health insurance plans.4 PAs may also be used to limit the use of high risk medications or 
institute other quality measures set by different quality organizations.4   
For example, a patient presents a prescription for Crestor® to their community pharmacy, 
which submits a claim to the patient’s health insurance plan. Unfortunately, the brand name 
medication is not covered by their insurance plan and the claim is rejected or unpaid. Since 
brand name medications are not on the formulary, the patient may choose to have their 
prescriber submit a PA to their insurance plan. The prescriber may then do one of two things:  
1. Deem the generic medication for Crestor® (rosuvastatin) equally effective for the 
patient’s condition 
2. Deem the generic medication to be non-equivalent and not effective for the patient’s 
condition 
Should the prescriber choose option 2, they must request pre-approval from the insurance 
plan to cover the brand medication. Thus, the provider submits the appropriate 
67 
 
documentation and/or explanation (to the insurance plan) that Crestor® is medically 
necessary and more beneficial/effective, than the generic medication, for their patient. The 
patient’s insurance will then review the prescriber’s request for pre-approval and will 
determine whether or not the medication will qualify for coverage under the patient’s health 
insurance plan.  
In this example, the brand name medication was deemed medically necessary by the patient’s 
insurance, and a PA for medication coverage was granted. It is important to note that had the 
patient’s insurance found no medical need for the brand name medication, the patient would 
then face several options:  
1. Try the generic medication under physician approval 
2. Try a different medication under physician approval 
3. Pay cash for the full cost of the brand name medication not covered by their insurance 
plan 
Other options may exist based upon the particular situation and patient factors. 
Guidelines and administrative policies for PA’s may vary between insurance plans and 
companies. Although prior authorizations may be time consuming and frustrating for 
consumers and health providers, they can help minimize overall health care costs by helping 
avoid inappropriate medication use and promote utilization of evidence-based medication 
therapy when used appropriately.4  
Prior authorizations can be implemented in a variety of ways. Some prior authorizations 
require additional clinical patient information, such as diagnosis and laboratory results, 
before a providers is allowed to prescribe that medication.4 Figure 5-1, identifies common 
types of prior authorizations that may be utilized.4,5 
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Types of Prior Authorization 
Indication • Off-label 
• One indication vs. another 
Prescriber Coverage for 
Particular Medication • Specialist vs. Primary Care Physican 
Quantities outside FDA-
Approval 
• Duration of therapy 
• Days supply 
• Maximum daily dose limits 
Non-step Therapy • Utilizing second-line, more complex, and/or more expensive options/alternatives before first line options 
Medications outside of patient’s health insurance plan’s formulary 
High misuse or abuse potential medications 
 
Figure 5-1. Types of prior authorizations 
 
In another example, a patient presents a prescription to their community pharmacist for a 
migraine medication, which they have been prescribed to take four times daily.  However, 
their insurance company rejects the submitted claim. According to their formulary, the 
insurance plan will only cover (or pay) for the migraine medication to be taken three times 
daily. The patient may then choose to have their prescriber submit a PA to their insurance 
plan. Should the prescriber provide appropriate documentation and/or explanation that 
proves taking the migraine medication four times daily is medically necessary, the insurance 
plan may issue a PA for coverage of medication costs. 
EXCEPTION AND APPEALS PROCESS  
Prior authorizations may also be referred to as exceptions. Insurance plans can evaluate 
coverage based on individual patient cases to determine whether or not coverage exceptions 
will be made.4 Patients may also request an exception when an insurance plan executes a 
change to their formulary and their medication is no longer covered.16  
Insurance plans differ on the amount of time it takes them to review an exception.  Some 
plans, such as Medicare Part D, offer expedited requests based on prescriber 
recommendations for the patient’s overall health.5 In the event that coverage exceptions or 
PAs are denied, patients may complete an appeal to request further evaluation or re-
evaluation of their original exception.5 Because certain exceptions must be initiated by the 
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payer, completed by the prescriber, and reviewed by the payer, the response time can vary. If 
possible, pharmacists can assist patients by suggesting an alternative medication to avoid this 
lengthy process.  
HOW TO READ AN INSURANCE CARD 
Although insurance cards may look different, they often contain similar information needed 
to complete claim submissions for payment. In order to submit a claim to an insurance plan, 
a patient’s member identification, BIN, Group, and PCN number are necessary. Should a 
member’s coverage be expired or not active until a later date, submitted claims will not be 
reviewed for coverage. Help phone numbers are typically found on the back of an insurance 
card and may be utilized for various issues, such as when insurance card components are 
missing or claims are rejected. Figure 5-2 defines common components of an insurance card, 
whereas Figures 5-3 and 5-4 are examples of what an insurance card may look like.6,7 
 
Components of an Insurance Card 
Member 
Identification 
Number 
• Used to identify the individual covered or “holding” the 
insurance 
• Numbers may be similar for other covered under the original 
card holder 
Group Number 
• Used to track specific benefits of the insurance plan 
• Helps identify the individual covered under the insurance 
plan 
BIN Number 
• Unique six digit number that identifies the third party 
processor 
• Third party processors may contract with multiple companies, 
which utilize the same BIN number 
PCN Number • Help identify different plans via utilization of numbers or letters 
Plan Type 
• May have either HMO, PPO, HAS, Open, or other 
words/labels to describe the type of network the insurance 
plan maintains 
Phone Numbers • Help lines, information, questions, etc. 
Effective Date • Date the coverage became active 
Figure 5-2. Components of an insurance card 
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Figure 5-3. Sample insurance card6 
 
 
 
 
Figure 5-4. Sample insurance card7 
 
 
SUBMITTING CLAIMS 
Pharmacy claims are most often transmitted at the point of sale. Usually, when a patient 
brings a prescription to the pharmacy, a pharmacist, technician, or intern will either access 
their insurance information stored within their pharmacy computer (entered from prior 
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transactions) or enter/update their insurance card information.  The pharmacy’s computer 
system will transmit the patient’s claim electronically to the insurance company or pharmacy 
benefit manager. This digital information will be processed electronically and information 
will be sent back to the pharmacy to determine whether or not the patient is currently 
enrolled under the entered insurance plan, if the prescription is covered under the plan, what 
amount the patient owes for the prescription, and what amount of reimbursement the 
pharmacy can expect to receive for the prescription. Although the information can be viewed 
within the pharmacy’s computer system, the amount owed by the patient and saved by the 
insurance is typically printed along with the patient prescription label, which are packaged 
with the medication and distributed to the patient.  
If a prescription is not covered, the pharmacy staff can communicate with the patient and 
prescriber to help determine what steps should be taken. Patients may decide to pay cash or a 
discount price (using eligible discount cards or coupons), but most often patients will choose 
to work with the physician and/or pharmacist to determine alternative therapies which may 
be covered through the insurance or available at cheaper costs for the patient. If a prior 
authorization process is required, the pharmacy staff will communicate that to the 
prescriber’s office and/or staff electronically. At this point, the prescriber will need to 
complete the prior authorization process with the patient’s insurance company before the 
pharmacy can re-submit a claim. Most prior authorizations are completed within 72 hours.  
LOWER COST SUPPORT/ASSISTANCE  
Inability to afford medications is a major cause of non-adherence.8 Uninsured patients 
lacking prescription and/or health insurance entirely and in need of assistance paying for 
their medications have several options. Many pharmacies offer free or discounted 
prescriptions for products such as vitamins, antidiabetic agents, antihypertensive 
medications, and antibiotics. Underserved medical clinics may also provide limited 
medications at no cost.  
Patient assistance programs are available for certain medications. Individuals who qualify 
can receive free or discounted medications for a particular period of time.  Websites such as 
NeedyMeds.org, RxAssist.org, and PPARX.org can be used to determine if an assistance 
program is available for a given medication and what that programs’ eligibility criteria might 
be. Patients who qualify may even apply for a program using these websites.   
Patients can also lower costs with discount cards. Although most discount cards have similar 
formatting and claims information, discount cards are not insurance cards.  Offered by a 
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number of companies, discount cards offer savings on a variety of medications. 
Unfortunately, most discount cards cannot be combined with insurance coverage. Discount 
cards may hold the most utility for consumers when a particular medication is not covered by 
their insurance.  In this situation, a discount card may be used in place of the insurance card. 
Most online medication coupons work the same way as a discount card and hold the same 
limitations, but resemble a regular merchandise coupon. Medication coupons are often 
specific to one medication, whereas discount cards can be applied to a variety of medications. 
Advertising claims for discount cards and medication coupons can be misleading, as most 
consumers do not understand the implications regarding their use. 
Manufacturer assistance cards, also known as co-pay assistance cards, can be found on 
manufacturer websites. Unlike discount cards or coupons, most manufacturer assistance 
cards can be used with an individual’s health insurance coverage. Although benefits vary 
between medication manufacturers, most manufacturer assistance cards offer a one time or 
twelve-month savings program. However, manufacturers will often set a maximum annual 
savings limit and most manufacturer assistance cards must be pre-ordered or downloaded, 
printed, and brought into community pharmacies by the patient. This may create some 
barriers for individuals lacking access to online resources. Unfortunately, most pharmacies 
do not have access to manufacturer assistance cards, but some physicians’ offices may 
provide them or are willing to help patients locate them. 
Uninsured patients are not the only patients who may need assistance. Underinsured 
patients, who have minimal health and/or prescription insurance coverage, also may have 
just as much difficulty affording medications.9,10 There are various resources available for 
such patients. Families with children can go to InsureKidsNow.org to check if their child is 
eligible for Children’s Health Insurance Program (CHIP).11 CHIP is jointly funded by the state 
and federal government and provides health and prescription coverage to low-income 
children and, in some states, pregnant women who do not qualify for Medicaid.11   
Patients with Medicare Part D may qualify for low-income subsidy or “Extra Help” and can 
apply online at Socialsecurity.gov/extrahelp.17 Both full and partial help is available through 
the federal government, but states often offer additional programs as well.  State based 
programs are usually referred to as State Pharmaceutical Assistance Programs (SPAPs).5,9,10 
Finally, patients can also be referred to a local State Health Insurance Assistance Program 
(SHIP) office when they are in need of advice about prescription and/or health insurance or 
extra assistance. 
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CONCLUSION 
In order to compare medical and prescription insurance coverage it is helpful to first consider 
the type of coverage that are available options and then the payer-provider relationship. 
Ultimately,  understanding the details of the coverage can allow beneficiaries to select the 
best coverage for them. Pharmacists can help patients and caregivers compare prescription 
drug coverage and educate them about the different insurance terms. 
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GLOSSARY 
Benefits 
Items, services, or payments covered in full or part by the insurance company for the 
beneficiary  
Co-insurance 
A percentage fee paid by an individual for health care services  
Co-payment/Co-pay 
Flat fees that must be paid by an individual for particular services, like a visit to a primary care 
physician 
Deductibles  
A set amount that one must pay each year before the insurance company will begin to pay on 
healthcare costs for an individual 
Formulary 
List of particular medications available for coverage by insurance companies that have been 
demonstrated as safe, effective, and providing the highest cost-benefits for patients 
Health Literacy  
The degree to which individuals have the capacity to obtain, process, and understand basic 
health information and services needed to make appropriate health decisions 
Member  
Individual enrolled under a particular health insurance plan  
Network  
Group of healthcare providers who provide services that are eligible for coverage under an 
insurance plan 
Out-of-Pocket Limits/Maximum 
Maximum amounts a patient, also known as a beneficiary, has to pay out of their own pocket 
for covered health care expenses  
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Pharmacoeconomic 
A branch of economics that compares pharmaceutical products and treatment strategies 
through analysis of cost-benefit, cost-effectiveness, cost-of-illness, cost-minimization, and 
cost-utility 
Premium  
What one must pay in order to have insurance coverage  
Prior Authorization 
Insurance requirement that physicians provide explanation and/or documentations to 
support the use of a specific medication therapy in order to determine medical necessity and 
appropriate therapy 
Step Therapy  
A treatment approach that utilizes the most cost-effective medication therapy and then 
progresses to alternative therapies, which may be more expensive or lack comprehensive 
research evaluating efficacy, to better control costs for insurance providers 
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CHAPTER 6 
PHARMACY AND THERAPEUTICS COMMITTEE 
Author: Joe Jordan, PharmD, BCPS 
 
Chapter 5 discusses access issues for patients including affordability and limits on access 
such as prior authorization. This chapter explains how and why access to different 
medications may be restricted on a formulary developed by a Pharmacy and Therapeutics 
Committee. 
While drug formularies have reportedly existed in the United States for over 200 years, their 
roles and purposes have changed, reflecting the increased complexity of the medications 
themselves, the healthcare systems within practice settings, and the roles and 
responsibilities of stewards of these lists.1 A common name given to a group responsible for 
oversight of a formulary is the Pharmacy and Therapeutics (P&T) committee. As the name 
implies, this committee involves pharmacists and those involved in the therapeutic 
application of these products. A typical committee is comprised of those who prescribe drugs 
(e.g. physicians), those who purchase and prepare drugs (e.g. pharmacists) and those who 
administer drugs (e.g. nurses), in addition to other personnel depending on setting (e.g. 
finance or risk management). Membership will vary based on practice setting but is usually 
representative of the primary medical services provided within that health care system. In 
addition to determining formulary selection criteria, P&T committees also oversee how 
products are purchased, stored, ordered, prepared/dispensed, administered, and monitored. 
Any policies or protocols addressing medication use, such as adverse drug event monitoring 
and reporting and approval of guidelines or care pathways, also fall under the P&T committee 
oversight. In the outpatient setting, prescription drug plans have their own P&T committees 
that use specific formulary management tools, such as prior authorization, step therapy, and 
copayment tiers.2-3 
A formulary, by definition, is a “continually updated list of medications and related 
information, representing the clinical judgment of physicians, pharmacists, and other experts 
in the diagnosis, prophylaxis, or treatment of disease and promotion of health”.2 The term 
medication has been interpreted broadly in some settings to include all products delivered in 
the context of care for diagnosis, prevention, and treatment. Given this definition, agents such 
as alternative remedies (herbals and supplements), nonprescription products, blood 
derivatives, and contrast media would also be included in some settings.3 While formularies 
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previously operated more as inventory control, now they are intended to function as systems 
to insure that drug products are used in a rational, safe, and cost-effective manner to support 
affordable and sustainable drug benefits.4,5 These systems are used in hospitals, home care, 
and long-term care settings, in addition to payer settings such as Medicare, Medicaid, 
insurance companies, and managed care organizations. 
DRUG FORMULARY EVALUATION 
In order for a formulary to have the best available medications available for use, it must be 
confident in the process of review of the medications.6-7 The first step for inclusion of a given 
drug on a drug formulary is through evaluation of evidence. Common elements of a drug 
review note the FDA approved indications and potential areas of off-label use, a review of the 
differences with similar agents on formulary with respect to pharmacokinetics and 
pharmacodynamics, a critique of individual trials used to support a therapeutic benefit, 
analysis of potential for harm incorporating both drug and formulation characteristics, and 
ultimately cost.3 Table 5-1 expands on common elements within a new drug review. A P&T 
committee could simply decide to add or not add to a formulary, but more commonly will offer 
recommendations for additional criteria, such as strategies for ensuring appropriate use.   
Questions to consider when determining whether to add drugs to a formulary should be based 
on quality of evidence and comparisons to therapeutic alternatives. One model cited in the 
literature is the Formulary Leveraged Improved Prescribing (FLIP) Project.7 In this model, 
five areas are addressed when reviewing a drug. 
Evidence of Need – Is this Drug Truly Needed? 5 
Depending on your setting of practice and the prevalence of conditions commonly treated by 
your practitioners, some indications of drugs may not be relevant. For example, glucarpidase, 
an antidote to methotrexate toxicity, is probably not needed in a community hospital that 
mostly sees patients in need of orthopedic and cardiovascular procedures. However, 
tranexamic acid, an agent used off-label to reduce postoperative blood loss, may be of interest 
to this setting. It is always worthwhile to reflect on what is available on your formulary and to 
describe the shortcomings of existing therapy with respect to safety, tolerability, or 
effectiveness. Framing your search based on shortcomings of existing therapy will help with 
discerning value, if any, of the drug you are considering.   
Efficacy – What is the Evidence to Support Claims for Drug? 5 
This is where being able to read, appraise, and apply clinical studies becomes particularly 
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important. Depending on sources of information, claims of efficacy will be considered 
differently if coming from high- or low-quality studies or those with high versus marginal 
differences. For example, a single-center, uncontrolled trial showing improvement in pain 
scores and decreased hospital length of stay is less generalizable than a multi-center, 
randomized, active-controlled trial demonstrating these same endpoints. Similar to the 
question of evidence of need, individual evidence should be assessed for relevance to the 
population you treat. There may be potential for off-label use of a product and it is important 
to note what evidence, if any, is available to support this since it may factor into decisions to 
restrict or regulate use. 
Safety – What are the Safety Issues that Should be Weighed? 5 
In addition to the safety information present in the labeling of a drug (e.g. contraindications, 
warnings, adverse effects), the potential for medication errors once it becomes available on 
formulary should be taken into consideration. The potential for look-alike/sound-alike errors 
or complicated administration or preparation requirements are a few examples of potential 
safety concerns beyond the package insert. As drugs are studied in relatively small sample 
sizes in relation to the size of the population they will be used, it is worth noting any safety 
signals or areas under review that may become more apparent once a drug is used in a larger 
population. Lastly, it is worth comparing the safety composite of the drug under review with 
existing therapeutic options on formulary. 
Misuse Impact Potential – What is the Potential for Misuse or Overuse? 5 
This question begins to address the issues of pharmaceutical advertisements and detailing. If 
a drug is heavily marketed to consumers or prescribers, there may be unrealistic expectations 
leading to demand for use in areas where the product may or may not be needed. Off-label use 
of drugs is very common and this is an area that a P&T committee should periodically review 
to ensure that products are being used optimally based on evidence of safety and effectiveness 
rather than on unrealistic expectations. 
Cost Issues – Is the Drug Worth the Costs? 
A common theme that arises with approval of new drugs is that while they must demonstrate 
that they can have an effect in a carefully controlled trial setting, these effects may or may not 
be seen in the uncontrolled real world when they are used in general practice. While a cost 
may be appropriate based on perceived utility in a controlled study, these costs may be 
considered excessive if a drug fails to demonstrate effect in a variety of patients in the general 
population with a given disease. Additional cost factors to consider include preparation and 
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storage costs, monitoring costs, and labor costs with administering product.     
After preparing a review, the information gathered is commonly shared among other 
healthcare professionals who would be impacted because they prescribe or would administer 
the product. From a cost standpoint, it is not unusual to have a financial party assess the 
relative cost-benefit of the potential impact on use of resources outside of pharmacy. 
Decisions about a drug are often driven based on the final composite analysis of benefit, risk, 
and cost in relation to agents on formulary. If it provides an improvement in benefit, risk, or 
cost and the other variables are not impacted (or improved) then a drug will likely be added to 
formulary. Similarly, if it worsens benefit, risk, or cost and other variables are not impacted 
(or worsen), then a drug likely won’t be added to formulary. However, it is rare that final 
analyses are this clean and there is usually some trade-off amongst these variables. When 
drugs are added to formulary with potential increased risk of safety and/or cost, it is not 
uncommon to have additional criteria to ensure they are used in a safe and cost-effective 
manner. 
STRATEGIES FOR MANAGING THE FORMULARY 
Ensuring medications are used in an optimal manner often involves educational, managerial, 
or regulatory strategies.3 Multi-disciplinary development of these strategies will increase the 
likelihood of success instead of creating them from one practitioner’s perspective.3,7-9 
Educational strategies are intended to inform or persuade healthcare practitioners to use a 
medication in a particular manner. Examples of this approach could be provision of a 
newsletter, preparation of consultative review documents, or one-on-one clinical 
supervision or consultation. This approach is often received well by clinicians who don’t 
perceive it as restrictive. A practical application of this could be providing an algorithm of 
how to treat a patient with blood pressure or high cholesterol. However, this approach is one 
of the least effective when trying to change behavior or practice. If a medication is not being 
used optimally from a benefit versus risk or cost standpoint, this approach will likely not 
result in changes in how that medication is used. For example, if a given clinician is adamant 
about using a PCSK9 inhibitor (~$14,000 per year) first line in their hyperlipidemia patients, 
providing an algorithm that has this class used after statin therapy won’t force them to 
change. 
Another approach is to use managerial strategies to guide or structure decisions. Guided 
strategies allow the product to be used, but with hardwire processes so they are used in 
particular way. Examples of this approach include clinical protocols or order sets, use of 
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tiered or step-wise approach, procurement selection based on cost, therapeutic interchanges, 
protocols converting intravenous to oral administration, and patient cost-sharing. Some 
examples could include converting all ACE inhibitors to lisinopril at an equivalent blood 
pressure dose (i.e. therapeutic interchange) or using an oral proton pump inhibitor instead of 
an IV proton pump inhibitor (i.e. IV to PO interchange) when patients can absorb oral 
therapies. This approach is less well-received by clinicians than educational strategies 
because it involves barriers or requiring them to “follow the rules” if they wish to use a 
particular medication or class of medications. The managerial strategy is commonly, but not 
always, employed because of cost or safety concerns. If multiple medications are available to 
treat a given condition and differences, if any, are considered marginal, then steering therapy 
to least costly agents first is an example of a tiered approach. Another simple approach that 
pharmacy can take is to procure a generic instead of a branded medication. In order to limit 
formulary options or possibly save on costs, therapeutic interchanges may allow for one 
medication to be used in place of another either within its therapeutic class or even out of the 
same class. This is commonly seen in hospital settings and requires approval by a P&T 
committee.   
Lastly, a less-accepted approach, but very effective, is to introduce restrictions or limitations. 
Examples of this regulatory approach could include banning certain drugs from an 
institution, requiring prior authorization before use of medications, or restricting use of 
medications to a certain provider. Limiting providers from writing for more than five 
continuous days of ketorolac therapy or restricting daily doses of acetaminophen to <3 or 4 
grams is an effective way to ensure safe use of these medications. Restricting use of an 
antimicrobial to an infectious disease physician or requiring that certain criteria be met 
before certain medications can be used (i.e. prior authorization) are often disliked by 
clinicians but can help ensure appropriate use. 
SUMMARY 
A P&T committee is a multidisciplinary group of professionals within an organization that 
oversee the selection and use of medications. The goal of this committee is to provide a 
formulary that represents the optimal therapy for patients based on relative efficacy and 
safety. As medications and healthcare systems become more complex and costly, P&T 
committees are focusing efforts to ensure medications on formulary are used efficiently by 
providing strategies for appropriate use.2,3 
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Uses/indications FDA approved indications, other potential uses based on clinical trials or agents with similar mechanisms of action 
Pharmacology 
Summary of drug and/or drug class noting similarities or 
differences within a class or versus other agents with similar 
indications 
Pharmacokinetics 
Depth varies depending on disease state.  For example, infectious 
disease drugs may have more coverage in this area than a blood 
pressure drug.  Highlight absorption, distribution, metabolism, 
elimination (ADME) of drug and note information on specific 
subsets of patients (e.g. renal & hepatic dysfunction, male vs 
female, pediatric vs adult vs elderly, bariatric vs normal weight) 
Guidelines and/or 
systematic 
reviews 
Review indications of drug noting prevalence of disease, current 
approaches to therapy, and areas of need.  Note role of current 
therapy in the disease approaches, if known. 
Comparative 
efficacy 
Review clinical trials of drug noting quality of study methods, 
relevance of populations studied, applicability of outcomes 
evaluated and magnitude and precision of results.  Contrast 
findings with other therapies available for indication 
Comparative 
safety 
Highlight contraindications, warnings/precautions, drug interactions 
and adverse reactions that a practitioner needs to be aware of to 
effectively manage a patient on this drug.  Note actions that a 
clinician can take to mitigate risks as well as similarities and 
differences with other drugs within class or drugs approved for 
same indication.  Contrast findings with other therapies available for 
indication 
Monitoring Recommended laboratory or other types of monitoring necessary for patients to be effectively and safety managed 
Dosing and 
administration 
Recommended dosing regimens both for FDA indicated and 
potential off-label use.  Special populations such as pediatrics, 
organ impairment (i.e. renal, hepatic), or obesity may have different 
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dosing strategies available from the literature.  Compatibility 
information for parenteral products and splitting or compounding 
information for oral products would go here. 
Availability 
How product is supplied noting specialty distribution programs, 
when applicable.  Some products are not orderable through normal 
supply chains and are shipped directly to patients. 
Pharmaco-
economic analysis 
In addition to the acquisition cost of drug, presenting cost as a 
function of per unit dose, per day, or per duration of therapy in 
relation to other therapies.  If available, note potential economic 
impact on other areas such as consumption of additional 
labs/supplies or ED/hospital visits. 
Potential misuse 
impact 
If approved, is there significant education required to ensure 
product is used optimally (i.e. safely and efficaciously).  Are there 
medication errors associated with this drug or this class and can 
policies or procedures be put into place to mitigate these.  Is 
product likely to be used in off-label areas 
 
Table 5-1. Common elements of drug monograph 
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CHAPTER 7 
BILLING AND REIMBURSEMENT FOR THE 
AMBULATORY CARE PHARMACIST 
Author: Jessica Wilhoite, PharmD, BCACP 
 
Chapter 6 discusses the variety of contractual arrangements that managed care companies 
make with healthcare providers such as networks, capitation fees, and salaried payment. That 
chapter also introduced the concept of coordinated providers under Accountable Care 
Organizations (ACOs). Medical insurers contract with physicians and hospitals through 
networks, capitation and bundled payment models of reimbursement. This section will 
outline how pharmacists are impacted by these payment arrangements.    
Pharmacists are usually paid as hourly or salaried employees of the pharmacy chain or 
independent pharmacy that employs them. It is almost always the pharmacy, hospital, or 
clinic, not the pharmacist, who negotiates with third party payers such as private insurers and 
pharmacy benefit managers. In the retail/community setting, claims are transmitted 
electronically when the patient fills a prescription and payment for each prescription is 
calculated at the point of sale. The pharmacist is removed from the contractual process but 
the bottom line is impacted by each prescription rejection.    
In the hospital setting, the charges for all services are added together for the patient’s stay. 
This list is often referred to as the charge master, which is then billed to the insurance 
company or government payer based on the contractual arrangement between that hospital 
and payer. This is usually done after the patient is discharged, although a pre-authorization 
may be requested to verify the patient has coverage and payment is likely. As discussed in 
Chapter 6, the charges may be fee-for-service or  may be submitted each day as a daily total 
(per diem) or one total for the whole hospital stay (per episode).1 
Hospitals and physician practices may be owned by the payer, as with a Health Maintenance 
Organization (HMO). The healthcare providers in the physician practice, including the 
ambulatory care pharmacist, are likely paid salary by the payer itself. In this case, a global 
budget is created for hospital and administrators who are responsible for charging against a 
budget and for appropriate use of funds.1 Hospital administrators who are unable to manage 
budgets appropriately will likely lose their jobs. With the movement towards accountable 
care and value-based payments, new contractual arrangements linking patient outcomes and 
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quality measures to payment are changing reimbursement structures.  
Ambulatory care pharmacy practice is one of the fastest evolving pharmacy sectors as the 
profession is continuously changing to include delivery of comprehensive clinical, 
consultative, and educational patient care services.2 Challenges in providing such services 
still remain; pharmacists lack provider status, as they are not recognized under Title XVIII of 
the Social Security Act, resulting in reimbursement ineligibility under Medicare Part B.3 One 
way health care professionals generate income is through billing for their services. Because 
pharmacists are not recognized as providers by many payers, including Medicare Part B, 
billing for clinical pharmacy services in the outpatient setting can be complex. Billing is the 
process of documenting services rendered to patients, and sending a bill for the eligible 
service to the third party payer for reimbursement. Services are separated into numerical 
codes, which correlate to the varying complexity of the services. Providers report these 
numerical codes to third-party payers in order to receive reimbursement for their services.  
Reimbursement is a dollar amount which is returned to the organization for properly 
performing, documenting, and billing for services. Reimbursement amounts for the same 
services can differ between payers. This means that a health care provider can be paid 
different amounts for performing the same service, depending on the third party payer. 
Medicare reevaluates and recalculates reimbursement amounts for outpatient services 
annually and makes that data publicly available. In general, Medicaid reimburses about half 
that of Medicare and private payers reimburse 20% more.4 Billing also includes cost-sharing, 
which represents the patient’s copay. The next section will focus on both direct and indirect 
billing methods utilized to receive reimbursement for ambulatory care pharmacy clinical 
services.  
PROVIDER STATUS 
Provider status is granted to healthcare providers who provide patient assessments, bill for 
their services, and receive reimbursement. The diversity of healthcare professionals included 
in a provider network can vary between private third party payers and the Centers for 
Medicare and Medicaid Services (CMS). Third party payers define a provider network to 
ensure quality healthcare is delivered to patients by qualified health care professionals. A 
summary of third party payer types, and pharmacist billing opportunities for each type can be 
found in Table 7-1. 
Medicare  
Title XVIII of the social security act recognizes health care providers eligible to receive 
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reimbursement from Medicare Part B. Such providers are listed in Figure 7-1. As mentioned 
previously, pharmacists are not recognized as providers under Title XVIII; therefore, lack 
ability to receive reimbursement for their services in the outpatient setting.3  
 
 
 
 
Figure 7-1. Non-physician providers eligible for reimbursement from Medicare Part B 
 
 
Additionally, Medicare Part D, which provides prescription benefits, gives variable options 
for patients to choose a prescription drug benefit plan to best suit their needs. Regardless of 
which plan is chosen, it is required that all plans offer medication therapy management 
(MTM) services to their beneficiaries.  MTM services can be provided by pharmacists or 
other qualified providers and is reimbursable by Medicare Part D when the service is 
provided in the community pharmacy setting.2 
State Programs 
Individual states have the ability to enact legislation to allow pharmacists to bill for services 
and receive reimbursement. A state legislature can trump the federal social security act and 
allow pharmacists to have provider status in that state. In May 2015, Washington became the 
first state to sign legislation requiring pharmacists be included in health insurance provider 
networks.5 At the time of this writing, 38 states designate pharmacists as providers in at least 
one statute or Medicare provision.6 
Private Third-Party Payers 
Generally, most private third-party payers follow CMS rules and regulations; however, 
pharmacists have worked directly with commercial third-party payers to create contracts for 
 
 Physician Assistants  Nurse Practitioners  Clinical Nurse Specialists  Certified Nurse Midwives 
 Clinical Psychologists  Clinical Social Workers  Physical Therapists  Occupational Therapists 
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payment of their services. There is no obligation for a commercial payer to recognize 
pharmacists as providers and it is up to their discretion whether they include or exclude 
pharmacists from their provider network.  
Self-insured employers are another third-party payer in which pharmacists may directly bill. 
Self-insured employers are businesses where the employer pays out-of-pocket for their 
employee’s healthcare expenses, handling all paperwork and payment for health claims. Self-
insured employers have the ability to recognize pharmacists as providers; however, like 
private third-party payers there is no obligation to include or exclude pharmacists within 
their provider network.  
Self-Pay Patients 
Cash paying patients always reserve the right to pay cash for services. Pharmacists may bill 
dependent on the market demand of patients willing to pay pharmacists cash for their 
services.  
 
Payer Types Can a pharmacist bill directly? 
Medicaid / State 
Programs 
Only if an individual state passes legislature.  
Medicare Part B – No. Pharmacists are not recognized as providers. 
Part D - Yes, Medication therapy management is a required 
element can be provided by pharmacists or other qualified 
providers.   
Commercial Third Party 
Payers 
Only if the commercial payer includes pharmacists in their 
network 
Self-Insured Employers Only if the Self-Insured Employer includes the pharmacists in 
their network 
Cash Paying Patients Yes, if the patient is willing to pay  
 
Table 7-1. Payer types24 
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BILLING FOR CLINICAL PHARMACY SERVICES IN AN AMBULATORY SETTING 
If a healthcare professional is not included in the provider network of a third-party payer, they 
will receive no reimbursement for their services from that payer; however, there are ways in 
which they can generate revenue by indirectly billing for services. Each health care 
professional carries their own unique National Provider Identifier (NPI) number. An NPI 
number identifies specific healthcare professionals or healthcare entities (e.g. hospitals, 
nursing homes, etc.) on HIPAA standard transactions such as bills.7 Although pharmacists 
are not eligible to bill Medicare Part B under their own NPI number, they can collaborate with 
a physician or other recognized provider to bill indirectly under the collaborating provider’s 
NPI number. To bill under another healthcare professional’s NPI number using any of the 
billing methods outlined below, a collaborative practice agreement is often written and 
signed by all parties. A collaborative practice agreement is a signed document granting 
authority to a pharmacist (or other healthcare professional) to bill for services under a 
supervising practitioner's NPI number.3 A collaborative practice agreement includes specific 
practice protocols which the pharmacist must follow.  
“Incident To” Billing Methods for Pharmacists  
Indirect or “incident to” billing is the framework under which a non-physician practitioner 
may bill under a supervising physician's NPI number, given certain criteria are met. CMS 
defines “incident to” as those services that are furnished “incident to” physician professional 
services in the physician’s office, separate office suite, in an institution, or a patient’s home.8 
In the outpatient setting, health care professionals utilize Current Procedural Terminology 
(CPT) codes to identify services rendered and International Classification of Diseases-10 
(ICD-10) codes to detail the indication for those services.  The indirect billing method is 
utilized by ambulatory care pharmacists and other mid-level practitioners who work in 
conjunction with a physician to see patients and bill for services. There are several conditions 
which CMS requires in order for a non-physician provider (NPP) to be eligible to bill for 
services “incident to” (Table 7-2).8 
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Establish with 
Physician 
Physician or Medicare Part B-approved provider must perform an 
evaluation or service for the same problem that is being evaluated by 
the pharmacist’s service 
 
Physician must establish a plan of care which includes future incidental 
services. 
Active 
Involvement 
Physician or Medicare Part B-approved provider must be actively 
involved in the patient’s course of treatment and provide subsequent 
services at a frequency that reflects their active involvement 
Common 
Services 
Services rendered must be of a type that are commonly furnished in 
the physician’s office or clinic.  
Services Order 
The physician or Medicare Part B-approved provider must have 
provided authorization for the service and authorization must be 
documented in the medical record.  
Employee 
Relationship 
The pharmacist providing the service must be an employee, leased, or 
contracted to the physician or Medicare Part B-approved provider.  
Scope Of 
Practice 
All services rendered must be within the scope of practice for that 
specific healthcare professional and medically appropriate to be given 
in the provider’s office.  
Direct 
Supervision 
A physician or Medicare Part B-approved provider must be on the 
premises, but not necessarily in the same room, when services are 
being performed.   
 
Direct Physician Supervision also requires the physician must be 
clinically appropriate to supervise any situation or emergency that 
may arise.  
 
Table 7-2. “Incident to” rules2 
 
“Incident to” Billing in an Institutional Ambulatory Setting 
Hospital based “incident to” billing refers to physician outpatient clinics that are financially 
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tied to a hospital. To determine if a physician clinic is financially tied to a hospital, check to 
see if they have similar tax identification numbers or ask the billing department for that clinic 
or hospital. When a patient is seen by a Medicare Part B recognized provider, they may bill 
two fees:  a professional fee for the services they perform and a facility fee for the hospital to 
cover facility expenses. Because pharmacists are not recognized providers under Medicare 
Part B, pharmacists can only bill via a facility fee and cannot bill a professional fee. The 
disadvantage of facility fee billing is the extra financial burden on the patient. For example, if 
a patient sees the physician and pharmacist in the same day, they will receive two bills: a bill 
for the professional fee for the physician and their facility bill, and a separate facility fee bill 
that includes the services provided by the pharmacist.2 
“Incident to” Billing in a Non-Institutional Ambulatory Setting  
Physician clinic based “incident to” billing refers to a physician outpatient clinic that is not 
financially tied to a hospital. The physician, or physician group, owns the entity in its entirety 
and the clinic practices under their own business tax identification number. Unlike hospital 
based “incident to” physician billing which can bill a facility fee, physician based clinics 
cannot bill a facility fee and only have the option to bill professional fees. Again, because 
pharmacists are not recognized providers under Medicare Part B, they must indirectly bill 
“incident to” physician for their professional fees. The same CMS “incident to” rules apply 
(Table 7-2). When billing “incident to” in physician based clinics, pharmacists may be 
reimbursed at 100% of the physician rate, or 85% of the physician rate if a non-physician 
provider (NPP) is serving as the supervising provider.9 
Billing Levels 
Billing for services in both hospital and physician based clinics are executed via five CPT 
codes 99211-99215. CPT code 99211, or level 1 billing, is the lowest level of billing and yields 
the lowest reimbursement. CPT code 99215, or level 5 billing, is the highest level of billing and 
yields the highest reimbursement amount. When billing at the lowest level, 99211, there are 
no documentation requirements; however, when documenting a patient visit to support a 
higher level of billing, there are three main areas required: number of body systems reviewed, 
number of disease states assessed, and the level of complexity of decision making.10 The level 
of billing is then determined by the complexity of the visit based on the components included 
in the note documentation (Table 7-3). For most regional carriers of CMS, pharmacists are 
limited to the lowest billing level, 99211, when billing “incident to” because they are not 
recognized Medicare Part B providers.2 For non-Medicare “incident to” billing, state 
Medicaid programs and commercial third party payers may allow pharmacists to bill at 
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higher levels as long as documentation supports the higher level of billing.2 
 
Patient 
History 
Patient history is comprised of several components such as family history, 
social history, history of present illness, chief complaint, and review of 
systems. Review of systems analyzes each organ system (genitourinary, 
respiratory, etc) pertinent to the patient’s chief complaint. The more systems 
reviewed, the more complex the visit and the higher the billing level able to 
be billed.  
Physical 
Exam 
The physical exam is a required component of the visit. Physical exam can 
range from a multi-system physical exam, to a single-organ exam. CPT code 
99211 may be billed without a physical exam. The more elements involved in 
the physical exam, the higher the billing level able to be billed.  
Medical 
Decision 
Making 
Medical decision making complexity is based on the three main components 
of the number of diagnostic options, amount of complexity, and the risk of 
decision making. A points system is utilized to categorize the level of medical 
decision making and the appropriate corresponding billing level. 
 
Table 7-3. Billing components2 
 
 
MEDICATION THERAPY MANAGEMENT 
Medication Therapy Management (MTM) is a medical service provided to optimize drug 
therapy and improve therapeutic outcomes. Medication therapy management services are 
patient-centered services, rather than product-centered services.11 In 2003, The Medicare 
Prescription Drug, Improvement, and Modernization Act (MMA) created Medicare Part D 
but also required insurers to cover MTM services for their beneficiaries.12 The MMA 
identifies three MTM parts: education to improve patient’s medication understanding, 
programs to increase medication adherence, and detection and prevention of adverse drug 
reactions.13 MMA does not require that MTM services be provided by a pharmacist, but as 
drug experts, pharmacists can play a vital role in improving patient’s health care quality and 
reducing exacerbations.13 MTM services can be billed via CPT codes which are chosen based 
on the visit length of time (Table7- 4). These CPT codes are not recognized by Medicare Part 
B, because MTM is not a covered service under Part B, only Part D; therefore, these CPT codes 
cannot be utilized in the physician clinic setting as Medicare Part B is the entity that covers 
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services provided in the physician office (hospital-based or physician-based). These CPT 
codes; however, can be utilized via contracts with prescription drug benefits plans under Part 
D in a licensed dispensing pharmacy setting. MTM services can still be provided by a 
pharmacist or other practitioner in the institutional or non-institutional outpatient settings; 
however, billing codes utilized are those that are covered by Medicare Part B and pharmacist 
billing methods are similar to other pharmacy services in these settings, as outlined 
previously.  
 
 
CPT Code 
99605 
Billed for a new patient visit for the initial 15 minutes of face-to-face MTM. 
CPT Code 
99606 
Billed for an established patient for the initial 15 minutes of face-to-face 
MTM. 
CPT Code 
99607 
Billed for each additional 15 minutes of MTM. This code can only be used 
after billing either 99605, or 99606. 
 
Table 7-4. MTM CPT Codes25 
 
 
TRANSITIONAL CARE MANAGEMENT 
Transitional care management (TCM) refers to services offered during a period where a 
patient is transitioning from an inpatient to an outpatient setting. This transition represents 
a vulnerable time for the patient who is now required to manage changes in diagnosis, 
medications, and/or lifestyle habits.14 These rapid and sometimes drastic changes can 
increase the patient’s risk of exacerbation and hospital readmission if not properly 
managed.14 The Centers for Medicare and Medicaid puts a strong emphasis on quality of 
healthcare, and in October 2012 introduced the Hospital Readmissions Reduction Program. 
Through this program hospital reimbursement rates are reduced if patients are readmitted to 
the hospital within 30 days.15 In addition, effective January 1, 2013, Medicare created a new 
method for reimbursement of transition-related activities. These CPT codes for TCM 
services may be used to bill physician and qualified non-physician providers care 
management following patient discharge. Qualified non-physician providers who may 
provide TCM services include: certified nurse-midwives, clinical nurse specialists, nurse 
practitioners, and physician assistants.14 TCM appointments aim to reduce hospital 
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readmissions by minimizing patient risk of new or changed medication regimens and 
ensuring proper education of lifestyle habits and self-management of chronic disease. The 
TCM CPT codes provide higher rates of reimbursement and combine face-to-face and non-
face-to-face TCM components into one billing code (Table 7-5). The required components 
for TCM billing are outlined in Table 7-6. Additional components, not required, may include: 
caregiver education, managing medications, obtaining and reviewing discharge information, 
reviewing pending diagnostic tests and treatments, communicating with other health care 
providers, establishing referrals, arranging community resources, and assisting with follow 
up with other providers or services.16-18 
 
 
Visit Type 
Timing 
(Calendar 
days) 
CPT Code Complexity Claim Deadline 
TCM Within 7 days 
of discharge 
99496 High 30 days from 
discharge 
TCM Within 14 days 
of discharge 
99495 Moderate 30 days from 
discharge 
 
Table 7-5. Billing Codes for Transitional Care Management (TCM) Billing16-18 
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Interactive 
Contact 
Interactive contact must be made with the patient via e-mail, telephone 
call or face-to-face appointment within 2 days of the date of care 
transition.  
Non-Face-To-
Face Services 
The practitioner must provide non-face-to-face services to the 
beneficiary. These services may be conducted by licensed clinical staff 
under the physician or NPP’s direction.  
 
If the physician or NPP determines that non-face-to-face services are 
not indicated, then they are not a required element.  
Face-To-Face 
Visit 
A moderately complex patient must have a face-to-face visit within 14 
days of the date of transition of care. 
 
A highly complex patient must have a face-to-face visit within 7 days of 
the date of transition of care.  
 
Medication reconciliation and management must be furnished before 
or on the date of the face-to-face visit. 
 
Table 7-6. Required components for transitional care management billing19 
 
While pharmacists are not included in the list of qualified non-physician providers able to bill 
for TCM services, these codes present an opportunity for pharmacist’s services to be 
reimbursed as a part of a multidisciplinary team. The billing claim itself must be submitted 
under a Medicare recognized provider and can only be billed once per beneficiary during the 
TCM period (30 days post-discharge); however, the high reimbursement rates reflect the 
need for involvement of multiple providers. As medication experts, the required medication 
reconciliation component offers pharmacists a unique niche to become a more incorporated 
part of the TCM team. 
ANNUAL WELLNESS VISITS 
Annual Wellness Visits (AWV) aim to provide a personalized prevention plan to reduce 
patient risk of morbidity or mortality. The components of a Medicare AWV include: a health 
risk assessment, establishing current providers, family history, past medical history, risk 
factors for depression or other mood disorders, and functional ability.19 AWVs also include a 
general checkup of height, weight, body mass index, blood pressure and any other 
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measurements deemed necessary based on the medical diagnoses the patient has received.19 
The health risk assessment component of an AWV addresses demographic data, self-
assessment of health status, psychosocial risks, behavioral risks, activities of daily living 
(dressing, bathing, and walking etc.), and instrumental activities of daily living (shopping, 
housekeeping, and managing finances etc.) at a minimum.19 Unlike TCM services, Medicare 
Part B will reimburse for AWVs performed by a pharmacist. Additional providers recognized 
by Medicare to provide AWV include: physicians, qualified non-physician practitioners 
(physician assistant, nurse practitioner, or certified clinical nurse specialist), or medical 
professionals (health educators, registered dieticians, nutrition professionals, or other 
licensed practitioner) under the direct supervision of a physician. Pharmacists fall under the 
category of other licensed practitioner; therefore, require direct supervision (as defined in 
“incident to” rules) by a physician.19 
Billing for Medicare AWVs can be multifaceted, because there are time frames and 
requirements to consider when billing. Optimally, AWV would be conducted on an annual 
basis for each patient. The initial AWV is billed with one code (G0438) and subsequent AWVs 
are billed with a separate code (G0439). An Initial Preventive Physician Examination (IPPE) 
is a “Welcome to Medicare” physical and can only be performed by a physician or NPP. 
Medicare will cover the initial AWV if it is 1) at least 12 months following an IPPE or 2) for 
beneficiaries who are no longer within 12 months of their Medicare coverage effective date. 
Subsequent AWVs cannot be billed within 12 months of the initial AWV. Medicare will pay 
for one initial AWV per lifetime and one subsequent AWV per year thereafter.19 
CPT Code Type of Visit 
G0402 Initial Preventive Physician Examination (IPPE) or 
“Welcome to Medicare” physical 
G0438 Initial Annual Wellness Visit  
G0439 Subsequent Annual Wellness Visit  
 
Table 7-7. Medicare annual wellness visit billing codes 
 
CHRONIC CARE MANAGEMENT 
Chronic conditions such as diabetes and heart failure are devastating life-long diseases, and 
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primary care services help to contribute to better health and quality of life for patients living 
with chronic disease. Effective January 2015, Medicare began paying for Chronic Care 
Management (CCM), recognizing the value primary care brings to health care.20 CCM aims 
to utilize non-face-to-face interactions to decrease the risk of hospital readmission and 
prevent exacerbations by educating patients on their conditions, their medications, and 
providing access to care. Eligible CCM patients must have two or more chronic conditions 
which place the patient at significant risk of death, acute hospitalization, or functional 
decline.21 CCM chronic conditions include, but are not limited to, diabetes, heart failure, 
Alzheimer’s disease, asthma, cancer, COPD, depression, and osteoporosis.21 CCM has several 
required elements such as recording patient demographics, a written, patient-centered, care 
plan to be documented and given to the patient, providing 24/7 access to care, and managed 
care services.21 CMS requires the billing practitioner to conduct a comprehensive evaluation 
& management visit, AWV, or IPPE visit prior to billing for CCM services.21 Additionally, 
healthcare providers are required to inform patients of their CCM eligibility and obtain a 
written consent form before furnishing services.21 The practitioner must also explain to the 
patient how to revoke CCM services and that only one practitioner may bill for CCM services 
per month.21 A CCM visit provides payment for at least 20 minutes of a health care 
professionals’ time per month of non-face-to-face care.  
Billing for CCM is conducted on a per month basis and codes may only be submitted once per 
month per patient. This prevents multiple physician offices from conducting CCM visits on 
the same patient in the same month. CCM billing is not eligible to be billed in the same period 
as TCM services, hospice supervision services, or certain end-stage renal disease services.17 
Pharmacists may provide CCM services and bill “incident to” the billing physician or non-
physician practitioner and/or contribute to 20 minute/month time allotment, as long as they 
comply with all “incident to” physician billing requirements. CMS provided an exception 
under Medicare’s “incident to” rules to allow clinical staff (including pharmacists) to provide 
services under general supervision of a physician or non-physician provider. Therefore, not 
requiring the physician to be on the premises providing direct supervision.  CCM visits are 
billed using CPT code 99490. Although patient copayments or coinsurance applies to CCM 
visits; CCM provides a valuable service which may prevent patient costs for more expensive 
face-to-face visits in the future. 
Transitional care management, annual wellness visits, and chronic care management 
appointments are three unique services that are only eligible for reimbursement by Medicare 
Part B, unlike “incident to” services, which may be reimbursed by Medicaid, commercial third 
party payers, and self-insured employers. 
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DIABETES SELF-MANAGEMENT TRAINING 
Diabetes Self-Management Training (DSMT) is a service provided to patients with a new 
diabetes diagnosis or patients struggling to control their diabetes. Pharmacists must be a 
member of a recognized DSMT program by the American Association of Diabetes Educators, 
the American Diabetes Association, or Indian Health Services division of diabetes treatment 
and prevention in order to provide DSMT services.22 Because pharmacists are not a 
recognized Medicare provider, pharmacists may not bill for DSMT services; however, 
because pharmacies are a recognized Medicare entity, a pharmacist can bill under the 
pharmacy if it is a certified DSMT facility.  
DSMT services may also be billed in either a physician based or hospital based clinic. In order 
for a pharmacist to bill for DSMT services the pharmacist must have a written physician's 
order for DSMT services for the patients involved. During the first initial year, up to 10 hours 
of DSMT services can be billed per patient in 30 minute increments in either individual or 
group training.21 After the first year, up to 2 hours of DSMT services can be billed per patient 
in 30 minute increments in either individual or group training.22 Subsequent years begin 12 
months after the first DSMT visit. Individual visits are billed under CPT billing code G0108, 
group visits of 2-20 people are billed under CPT billing code G0109.22 Individual visits 
provide a higher reimbursement rate per person than group visits.22  
CLINICAL LABORATORY IMPROVEMENT ASSESSMENTS – WAIVED LABORATORY  
The Clinical Laboratory Improvement Amendments (CLIA) is the way CMS regulates 
laboratory testing performed on humans.23 CLIA ensures laboratories are performing tests 
correctly and providing accurate test results. CLIA covers blood tests such as electrolyte and 
cholesterol levels, in addition to home drug tests, pregnancy tests, and any other tests 
requiring bodily fluids. In order for a pharmacy to do point-of-care testing such as diabetes or 
cholesterol screening, they must apply for a CLIA certificate of waiver. The entity must use 
application form CMS-116 and pay a $150.00 application fee. If approved, the entity will 
receive a CMS Part B Provider Identification Number (PIN). Pharmacists submit claims to 
CMS by using the entities PIN on the CMS 1500 form and the proper CPT codes. Pharmacists 
are allowed to bill because the claim is for the laboratory services only, and not for cognitive 
services. There are numerous CPT billing codes for the variety of CLIA-waived laboratory 
assessments available. The pharmacy can bill CMS for the tests performed by their 
pharmacist, and the pharmacy will receive reimbursement.  
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SECTION 3 
QUALITY 
The manufacturing and aviation industries have long used quality improvement initiatives to 
remain competitive and manage public perception.1 Because cost has been the primary focus 
of healthcare reform, resources allocated for improvement were focused on medical and 
medication error reduction.  The focus on accountable care and patient-centered care has 
renewed and expanded the focus on healthcare quality. Outcomes, value, and patient 
satisfaction are emphasized and impact reimbursement to healthcare providers. 
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CHAPTER 8 
QUALITY MEASURES AND IMPROVEMENT 
Author: Carriann Smith, BS, PharmD 
 
Through the movement from fee-for-service to managed care (see Chapter 6), payers began 
to pay for performance rather than for quantity. This included paying for improving health 
outcomes while containing costs.  The movement to accountable care has created a similar 
initiative called value-based care. New value-based structures mean that healthcare entities 
must commit to delivery on many quality measures, which determine reimbursement. 
Therefore, there is a new financial incentive to focus on quality to control costs.   
The Institute of Medicine (IOM) defines quality as “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are 
consistent with current professional knowledge.”1 The 2001 Quality Chasm Report by IOM 
provided 6 dimensions of quality: Effective, safe, timely, patient-centered, equitable and 
efficient.2  
The first three dimensions, effective, safe, and timely, are the traditional items associated 
with quality healthcare interventions.  Effective refers to basing decisions on evidence and 
scientific knowledge which is discussed in Chapter 10. Safe refers to avoiding injury from 
care that is intended to help patients. Timely focuses on improving access and 
communication between healthcare providers to reduce delays in treatment. 
The other three dimensions, patient-centered, equitable, and efficient, are specific targets of 
health care reform.  Patient centered care refers to services that are respectful and responsive 
to individual patient preferences, needs and values and allowing those to guide treatment 
decisions.  Equitable care does not vary in quality because of personal characteristics 
including ethnicity and socioeconomic status. Equitable and patient centered care 
personalizes care to the patient not to the preference of the provider. Efficient care avoids 
waste to limit the additional cost and intrusion to patients but also to the system as a whole. 
Limiting unnecessary use protects funds and availability for other patients who need to 
access care. The challenge is to use evidence to determine what is necessary and unnecessary.   
QUALITY IMPROVEMENT 
Quality improvement (QI) is a formal method of analyzing and correcting errors. Quality 
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improvement is its own career path where individuals understand the different tools 
available and how to apply them to their setting.   Terminology associated with measuring 
quality includes quality assurance, quality control and quality assessments. Quality 
assurance is planning and ensuring compliance with set standards and requirements.  It may 
be thought of as the “office” component to quality reviewing reports, writing policies and 
procedures and reviews of processes. Quality control is the specific process for measuring 
products or services against the specific standard.  This may include sample testing to look 
for defects, customer service audits, etc.  It may also be thought of as a data collection aspect 
of quality to identify the current state of quality. Quality assessments are usually the specific 
standard or increment that is being evaluated.  These specific measures may be a stand alone 
clinical outcome or a tool that collects multiple measures.  Organizations that implement 
quality improvement initiatives may use the term Total Quality Management (TQM) which 
incorporate all of these items.3-5  
Agreement on a need to improve quality is easier than actually assessing quality and making 
improvement, this is especially challenging since patients, providers, administrators and 
payers may view quality differently.6,7 Several organizations referred to as quality 
improvement organizations (QIOs) utilize health quality experts, clinicians, and consumers 
to work together to establish quality measures and set standards.7 Some QIOs work directly 
with the Centers for Medicare and Medicaid Services (CMS).  There is also a federal agency 
that promotes evidence-based quality, the Agency for Healthcare Research and Quality 
(AHRQ).  These organizations develop quality measures, patient perspectives, and detailed 
outcomes measures. The Pharmacy Quality Alliance develops and recommends specific 
pharmacy based performance measures. These may be used to impact reimbursement in 
value based payment models. 
As mentioned above, quality tools and process exist to collect quality information within an 
organization and local, state and federal organizations exist to set standards and specific 
measures of quality.  The results of this effort may be reported and utilized in one of three 
ways: accreditation purposes, report cards, and consumer ratings.7   
Accreditation refers to acknowledgement by an authoritative group providing a certification 
of competency or credibility to an individual, institution or other healthcare entity.  The 
accreditation, used by payers, consumers, or employers, confirms certain standards.  For 
example, the Joint Commission is the standard accrediting body for hospitals, long-term care 
facilities, and other medical practices.5,7  
Report cards provide details on the results of specific quality measures often referred to as 
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key indicators.  The National Committee for Quality Assurance (NCQA) provides report 
cards for physicians and health care insurance plans.  One example of data provided by NCQA 
is the Health Care Effectiveness Data and Information Set (HEDIS). This data set is used by 
a majority of health insurance plans to measure performance. Other examples of 
organizations that report on quality initiatives include the Pharmacy Quality Alliance (PQA) 
and Medicare Health Outcomes Survey (HOS).5,7 
Many organizations now provide patients an opportunity to provide direct feedback via 
online or phone based surveys.  The data may be published or used internally for quality 
improvement.  A cycle of surveys followed by improvements and resurveys is often referred 
to as continuous quality improvement (CQI) or total quality management (TQM). CQI or 
TQM may utilize critical pathway processes to develop specific procedures to improve care 
and improve efficiency in a specific location.  They define key steps that are necessary quality 
checks. For example, a patient is admitted to the hospital for a severe skin infection.  A critical 
pathway may include ordering from a list of specific antibiotics, timing of cultures, timing of 
wound care, etc.7 
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CHAPTER 9 
INTRODUCTION TO STATISTICS AND 
RESEARCH DESIGN 
Author: Chad Knoderer, PharmD, FPPAG 
 
There will be interactions that pharmacists have with other providers that will require the 
pharmacist to be able to definitively and confidently support their position or perspective 
with evidence, or published medical literature.  Along with the ability to utilize drug 
information databases and effectively searching medical literature, pharmacists must also be 
able to understand and discuss research and research findings.  Collectively these skills 
enable the pharmacist to practice evidence-based medicine. 
Not all research is the same.  Understanding the different types of research will help the 
pharmacist when advocating for the patient.  Generally, the type of research that pharmacists 
will use will be clinical research, or research that is examining questions related to clinical 
practice, outcomes, or both.1 This is different from laboratory research, or basic research, 
which may be experimental or exploratory in nature.  Basic research is conducted in a 
controlled laboratory setting and does not involve human subjects.  Clinical research focuses 
on applications to patient care and uses a systematic process to answer clinical questions.2 
The goal of clinical research is to draw inference from the study sample to a larger population.  
A population would include every person with the specific disease or illness being studied and 
it’s not realistic or feasible to include everyone in a study, so instead a sample is used.  A 
sample is a group of subjects in the study that represent the population. 
Generally clinical research will either directly involve human subjects by having humans 
participate in the study or use data from human subjects.  In the latter, the data already exists, 
but humans aren’t actively enrolled in the study.  Instead human subjects’ data is used in the 
research.  To highlight this difference, Fuller and colleagues implemented a chronic 
obstructive pulmonary disease (COPD) clinic in a community pharmacy setting and designed 
a study to determine if pharmacists can accurately perform spirometry screenings.3  Some 
rationale behind the study was that if pharmacists could accurately perform the screening, 
then they could improve their education of the patient about COPD risk factors and 
potentially increase patient participating in smoking cessation programs.  A total of 175 
patients were enrolled and completed a spirometry session.3  In contrast, Chen and colleagues 
conducted a study to determine the effectiveness of a pharmacist-managed telephone 
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tobacco cessation clinic in a Veterans Affairs (VA) health system.4  This study looked at data 
from patients who had participated in the clinic, and the data was obtained through the health 
system’s electronic medical records.  Both of these studies are examples of clinical research 
that aimed to answer a clinical question about smoking/tobacco cessation.  A difference was 
that the study by Fuller actively included patients whereas the study by Chen looked at 
patient data, but didn’t actually enroll a single human.     
RESEARCH DESIGN 
The way a study is designed is based on the question the study sets out to answer.  Some 
questions can’t be answered with certain study designs.  Pharmacists will use information 
from studies during their interactions with other providers, and a good starting place in using 
the information is to determine what research question was being asked.  The research 
question is developed by researchers by starting with a broad idea or problem, and this might 
be something observed in everyday practice.  This larger idea or problem is then narrowed 
down into a smaller and specific question.  Sometimes several specific research questions 
might come from one larger idea, and this would result in multiple studies.  Once the 
researchers have finalized their research question, they will rephrase the question and write 
it into the study as the study objective.  As pharmacists read over a study’s objective, they can 
consider what the original question might have been and if the study was designed 
appropriately to answer the question.    
The studies by Fuller and Chen offer a look at different study designs and studies with 
different perspectives.  There are two perspectives a study might take.  A prospective study 
progresses forward in time and a retrospective study looks at data or information or events 
from the past. Fuller and colleagues started at one point in time and progressively enrolled 
patients and followed those patients into the future.  Chen and colleagues looked back in time 
at a specific time period and collected data that was obtained during that time period.  There 
are strengths and limitations of each perspective.  Retrospective studies might be easier to 
conduct and cost less, but are limited by confounding factors.  Prospective studies provide the 
research with more control, which will be discussed later in the chapter, but are potentially 
limited by the cost or time they take. Another limitation of prospective studies is patient 
enrollment, especially for studies looking at less commonly encountered conditions.  It’s 
important for pharmacists to understand these differences when discussing clinical research 
with providers.  
Other aspects of research design will be discussed throughout this chapter.  Aspects such as 
control types refer to what type of control, if any, is used in the study.  Some studies may not 
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include a control group, whereas other designs might include a placebo, historical, crossover 
(where the subject serves as their own control), or active (e.g. standard of care) control.5 
Studies should be designed to increase both internal and external validity.  Validity relates to 
how well a test is measuring what is intended to be measured.6 Internal validity, then, is how 
well the study was designed to minimize errors within the study.  Systematic and random 
error can impact internal validity.2 Systematic errors include bias and confounding and 
random errors include chance.2 Chance is what it sounds like and is the likelihood that a 
finding is due to random error.  Statistical tests are used to quantify or determine the level of 
chance.2,5 Bias occurs when there is a systemic error in subject selection or the 
measurement/collection of observations that leads to a false conclusion of association.2 
Confounding is commonly heard when thinking about variables.  For example, a study might 
be looking to determine if a variable is a risk factor for an outcome variable.  Confounding 
variables are those that are associated with the predictor variable, but are also themselves 
predictors of the outcome independent of the variable being studied.  But, the confounding 
variable is not part of the relationship between the study variable and outcome of interest.7 
Pharmacists evaluate internal validity of studies by reading through the methods and 
analyses and determine if they were appropriate to answer the research question.  Evaluation 
of the results, to determine if they are accurate based on the methods, and reading through the 
conclusions to make sure conclusions are supported by the data are additional ways for 
pharmacists to assess internal validity. 
External validity is slightly different and refers to how the study is applied to a wider 
population.  External validity can be thought of as related to generalizability.2 The ability to 
apply the findings from the study and make inference to a wider population is generalizability 
and this is an area that is sometimes difficult to navigate in interactions with practitioners.  
Issues of how easily findings from a study can be applied to a cohort within a certain practice 
arise commonly and these are instances where pharmacists can be pivotal in these 
conversations.  Ultimately, however, if there were errors leading to a decrease of internal 
validity, then there will be decreased external validity.  Without internal validity, there can be 
no external validity.  Some methods to improve both internal and external validity include 
reducing confounding variables, improve subject selection, blinding, using a control group, 
and using objective data and validated measurement techniques. 
Design Types 
In addition to the study perspective, there are different types of study design types that could 
be used to answer the research question.  Broad types include observational and 
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interventional studies, which are commonly referred to as clinical trials.  As the name 
indicates, there is no intervention in an observational study, rather events or patients are 
observed either prospectively or retrospectively.  Descriptive studies describe findings from 
observational studies.  Although statistics are commonly used to describe the findings, there 
won’t be any statistical comparisons of patient groups.  Analytical studies make use of 
statistical tests or analysis to determine presence of any association among variables and to 
make inference.  There are several different designs within observational studies.  A cohort 
study, makes observations of a group over time.  These can be retrospective or prospective 
and can be descriptive or analytical. Cohort studies can evaluate independent variables (or 
risk factors) for development of diseases or conditions.  This design is related to exposure.  
The Framingham Heart Study is a well-known and classic example of a prospective cohort 
study. Investigators prospectively followed over 5000 residents of Framingham, 
Massachusetts in order to get a better understanding of risk factors for cardiovascular 
disease.8 Nearly 70 years and hundreds of subsequent studies later, information obtained 
from the original Framingham cohort has shaped the way practitioners approach patient 
care.  A recent publication by Bolesta and Kong describes a retrospective and analytical 
cohort study to determine the impact of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (also known as statins) on post-operative atrial fibrillation.9     
Case-control studies are different from cohort studies in that there will be 2 distinct groups 
of subjects, but the design first finds cases of subjects with the outcome of interest (the 
condition or disease) and compares those subjects with a control group of subjects to 
determine exposure to an independent variable (risk factor).  These are retrospective and the 
design starts with the disease or condition of interest.  For example, a 2013 study by Barletta 
and colleagues is a case-control study aimed at determining any associations between proton-
pump inhibitor usage and Clostridium difficile infection (CDI).10 With this design the 
investigators first identified patients who had a hospital-acquired CDI.  This made up the case 
group.  The investigators then identified patients within the same time period who did not 
have CDI and used those patients to form the control group.    
Cross-sectional studies collect data or make observations at a single point in time.  Surveys 
are a common type of cross-sectional studies.  Surveys will be distributed and the collected 
responses will reflect data from the respondent at a single time point.  These study designs 
can be efficient and relatively cheap to conduct.  The designs can be used for different target 
recipients (ie. patients or practitioners), but they are limited by the observations being at one 
point in time.  Significant consideration must be made to the development of the survey 
questions and the types of response scales used in order to get the most accurate and unbiased 
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information from the target sample. The biggest limitation is participation, in that subjects 
may not participate. Survey response rate is important to consider when reviewing these 
types of studies. Owenby and colleagues distributed surveys to VA pharmacy clinical 
coordinators to characterize pharmacy services within VA emergency departments.11 In 
contrast, Li and colleagues surveyed patients with recent medical visits to assess factors 
related to their search of online health information.12 Both of these examples are cross-
sectional studies, but with different target recipients.   
Clinical trials are interventional studies that are designed to evaluate the efficacy and/or 
safety of an intervention.  Parallel designs, where subjects receive only the study intervention 
or the control throughout the study, are common.  Crossover designs, where subjects serve as 
their own controls may also be used.  Randomized controlled trials (RCTs) are the gold 
standard of clinical trials because of the degree of experimental control utilized in the study.  
These are also going to be the most expensive to conduct. To pay for RCTs, researchers may 
seek federal or organizational grants to pay for the study.  In other situations, and 
pharmaceutical or medical device company may pay to conduct the study.   
To better understand RCTs, it’s important to understand all of the aspects that go into one.  
Randomization is one key component of RCTs, and this is done at the beginning of the study 
to make the study groups similar.  The goal of randomization is to make any observed 
differences in the study group due solely to chance.  The group differences ultimately are 
balanced through randomization.  One way to think of randomization is to think of flipping a 
coin.  If a study has 2 study groups (also sometimes referred to as arms), a treatment and 
control, then a researcher might flip a coin to randomize assignment.  Subjects with heads on 
the coin flip could be assigned to the treatment group and those with tails on the coin flip 
could be assigned to the control group.  There are many more sophisticated randomization 
methods, but at the core randomization is intended to assure that subjects have an equal 
chance of being assigned to each study group, and baseline confounding variables are 
eliminated.  Blinding is a technique used to hide group assignments.  The intent is to reduce 
or eliminate information bias from the participant or observer/researcher.  Blinding can be 
single or double.  Single is where only one side is blinded (subject or researcher) and double is 
where both subject and researcher are unaware of the group assignment.  It can be difficult to 
blind some interventions.  For example, it might be difficult in a study comparing liquid 
clindamycin and amoxicillin because liquid clindamycin is well known for having a bad taste 
and amoxicillin is more palatable.  
Understanding RCT and being able to discuss RCT findings with practitioners also requires 
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knowledge of the analysis technique utilized in the study.  There are two general types, 
intention to treat (ITT) and per protocol (PP).  Either may be used and the methods section of 
the article should state which was utilized.  With the ITT analysis, outcomes are compared 
based on subjects’ assignments and no data is eliminated.  If subjects drop out of the study or 
are lost to follow-up their data is still included, but the outcome is characterized as no 
outcomes.  This provides a conservative estimate of efficacy difference between groups, but a 
more liberal estimate of toxicity differences.  Per protocol is different in that it compares 
outcomes based on subjects who followed the study protocol and eliminates data of subjects 
who did not complete study.  This provides higher degree of efficacy difference between 
groups for efficacy outcomes, but lower degree of difference for toxicity outcomes.  For 
example, a study comparing drug A and drug B is evaluating which drug has better treatment 
success.  If 20 patients are included in each study group, outcomes will be compared.  Let’s say 
for drug A, 15 subjects have success, 4 have failure, and 1 drops out.  For drug B, 15 subjects 
have success, 1 has failure, and 4 drop out.  Success rates for drug A and drug B would be equal 
with the ITT technique (ie. both at 75%), but would be 79% (15 of 19 completing protocol) vs. 
94% (15 of 16 completing protocol), respectively, with the PP technique.  The opposite would 
be true if a toxicity were an outcome of interest.  There are studies that will perform analyses 
based on both the ITT and per protocol to evaluate if there were different findings based on 
analysis strategy. 
There are different types of RCT. Table 9-1 highlights some differences between superiority, 
equivalence, and non-inferiority designs.13 When interacting with practitioners about 
equivalence or non-inferiority studies, it should be noted that a fundamental concept in these 
studies is that they are based off of a superiority RCT that has been previously conducted.  It 
would be important, then, to read through the original superiority RCT before discussing the 
merits of the non-inferiority or equivalence study.  A couple of terms will continually be noted 
for both equivalence and non-inferiority studies.  The delta (Δ) notes the least relevant 
difference and should be considered a marker of clinical significance or importance.  This will 
be established by researchers and should generally be based on existing literature.  The non-
inferiority margin is the pre-determined maximum difference between “intervention” and 
“control”, and is another term for delta.  The delta and non-inferiority margin will be utilized 
for interpreting study results.  
STATISTICAL ANALYSIS 
Even the term statistical analysis has a tendency to bring out a variety of uncomfortable 
responses from practitioners, but a common response is one of confusion and hesitancy. 
113 
 
 
Type Method Goal 
Superiority 
Compares investigational 
treatment to control (ie. placebo, 
standard of care) 
Show that investigational 
treatment is superior to control or 
standard treatment 
Equivalence Show that the treatments differ 
by an amount that is NOT 
clinically important (ie. difference 
between – Δ and + Δ) 
Non-inferiority Show that investigational 
treatment is NOT clinically inferior 
to control (ie. can be worse, but 
no worse than – Δ) 
Table 9-1. Randomized controlled trial typesa 
a = Table modified from reference #47, Δ = delta 
 
Many practitioners find statistics intimidating, almost like a foreign language.  Regardless of 
the response, the reality is that a basic understanding of how to apply statistical analysis 
techniques is needed if pharmacists are to have meaningful interactions with practitioners 
and optimize patient care.  The majority of pharmacists working in patient care roles won’t 
be doing statistical analysis, just like they won’t be doing research.  As was highlighted 
previously, a good understanding of research design and all of the elements that go into doing 
research will allow pharmacists to be smarter consumers leading to more effective 
interactions with other practitioners and more optimal patient advocacy. This is the case for 
statistical analysis as well. 
The statistical analysis section of a published study may seem like a good area to pass over 
quickly.  Perhaps some authors may not even spend much time writing this section.  Spending 
some time evaluating the statistical analysis section of a published study may allow the reader 
to discover that researchers used inappropriate statistical methods or potentially manipulate 
the findings.  Understanding statistics can help a reader connect the dots in a published study.  
That stated, statistical analysis is another piece of the overall research design.  It is connected 
with the research design, and ultimately the research question.  For example, the goal of 
clinical research is to draw inference from a study sample to a larger population, but the 
validity of that inference is dependent upon the appropriate design being married with the 
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appropriate statistical analysis.  If one of the two is not appropriate, then the study’s validity 
may be called into question.  If the validity is questionable, then the study findings may not be 
appropriate to utilize to drive patient care decisions.  All of this is complicated.  Knowing 
where to start and the process to use to apply knowledge of statistical analysis to patient care 
situations is crucial in overcoming the intimidating barrier that can sometimes arise from 
statistics. 
Data Types and Scales 
The type of statistics that are used depends on the type of data that is collected, and there are 
different types of data and data scales for discussion.  Remember that some practitioners will 
use the term variables or parameters or even outcomes, but all of these terms are also terms 
for data, and data can be considered either categorical or continuous.  Categorical are 
qualitative and can be placed into categories or buckets. Examples of categorical data include 
hair color or grade level.  Continuous data are quantitative and can take any range of 
possibilities.  Examples of continuous data include age, weight, or blood pressure.  Data are 
further considered on scales, and for the purposes of the medical literature there are 4 data 
scales (Table 9-2). 
 
Scale Characteristic Statistics Example 
Categorical or Discrete 
Nominal Unordered 
categories 
Counts, frequencies, 
percentages 
Gender, diagnosis 
Ordinal Ordered categories Above + medians Likert scales, pain 
scales 
Continuous 
Interval Arbitrary zero Above + means, 
standard deviations 
Temperature (C, F) 
Ratio Absolute zero Weight, age 
 
Table 9-2.  Data scales 
 
 
The nominal data scale is the most basic data scale.  Data falling onto this scale can be 
classified into two or more categories that are mutually exclusive from one another and are 
exhaustive.  The categories are unordered and have no relation to each other.  Dichotomous 
data are data that can be placed into one of two categories like alive or dead, pregnant or non-
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pregnant.  Dichotomous data is a specific type of nominal data. The ordinal scale includes 
ordered categories with some rank and relation to another.  Data derived from surveys using 
Likert-scale questions (ie. strongly agree, agree, disagree, strongly disagree) or measurement 
scales such as pain rating scales are examples of ordinal data.  While ordinal data may be 
reported as a number (ie. pain score of 7 or Likert score of 4) the number corresponds to a 
category, and there is no consistent degree of difference between each category (ie. 3 is not 3 
times greater than 1).  Continuous variables can take on an infinite number of possibilities.  
With continuous data there is both an order to the values and a consistent degree of difference 
between each value.  Continuous data can be placed on either the interval or ratio scale with 
the difference being that ratio data has real zero (ie. heart rate) compared to an arbitrary zero 
(ie. temperature on fahrenheit scale) of for interval data.14 Any continuous data could be 
turned into either nominal or ordinal categorical data, but the opposite is not true.  
Categorical cannot be converted to continuous data.14     
Descriptive Statistics 
Statistics should be considered as two broad categories, descriptive and inferential.  As the 
name implies, descriptive statistics describes study observations.  These are very useful to 
research consumers because descriptive statistics allow the reader an understanding of the 
subjects that were included in the study.  Data within these data scales can take on a number 
of possible values, making it important to understand data distribution.  The binomial and 
Poisson distributions are examples of distributions of categorical data.15 The normal 
distribution is a distribution of continuous data.  With this, data are equally distributed 
around the mean and the values of the mean, median, and mode are all equal.  The next 
paragraph describes mean, median, and mode.  The curve of a normal distribution takes on a 
bell appearance, and it’s often referred to as a bell-shaped curve.  Figure 10-1 illustrates a 
normal distribution curve of age that came from a dataset containing 229 patient 
observations and in addition to the shape of the curve, the distribution can provide a lot of 
useful information to providers.  Some examples of these will follow. 
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Figure 9-1.  Normal distribution curve 
 
 
Measures of central tendency and measures of variability are types of descriptive statistics.  
Measures of central tendency include mean, median, and mode and describe the main 
observations of the dataset while measures of variability are used to describe the amount of 
uncertainty in the dataset.  The mean is the average of the values in the dataset and can be 
calculated for continuous data.  The mean is highly affected by outliers making it suboptimal 
to describe data that aren’t normally distributed.  Because there is inconsistent degree of 
difference between ordinal categories, the mean is not useful to describe ordinal data.  The 
median is the middle measurement (ie. 50th percentile) in a dataset and can be used for ordinal 
data or continuous data that aren’t normally distributed.  There are an equal number of values 
above and below the median making it resistant to the influence of outlying variables.  The 
mode is the value occurring most often in a dataset.  The standard deviation (SD) is a measure 
of variability commonly used with the mean because it represents deviation from the 
dataset’s mean.  The SD is the square root of variance which is derived from sum of squares.  
The mean of a dataset is subtracted from each data observation, and all of those deviations are 
added together to make the sum of squares.  Neither the variance nor sum of squares are used 
commonly in the medical literature, but the SD is and knowing its origins helps make sense of 
what information the SD provides practitioners.  Because the mean is used in the calculation 
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of the SD, this variability measure is most appropriate for normal or near normally 
distributed data.  Using the SD, a reader can apply the empirical rule for additional 
information about the dataset.  The empirical rule states that for normally distributed data, 
68% of observations will fall between 1 SD of the mean, 95% of observations will fall between 
2 SD, and 99% of observations will fall between 3 SD.  Figure 9-2 provides an illustration.  
Applying this rule to the mean and SD within Figure 10-1 and learn that 68% of the patients 
had ages of 18.5 – 21.5 years, 95% were 17.1 – 23 years, and 99% were 15.5 – 24.5 years.  This 
type of application of descriptive statistics is particularly useful as a provider and when 
discussing with other providers because it allows for some generalization.  Using data from a 
study where 95% of the patients were 17.1 – 23 years old wouldn’t be useful or appropriate for 
providers who predominantly care for elderly patients.  
 
Figure 9-2. Normal distribution curve with 68, 95 rule 
 
 
The standard error of the mean (SEM) may be commonly confused with or used in place of 
SD.  However, the SEM quantifies certainty in the estimate of the true population mean where 
the SD is providing an estimate of variability around a sample mean.  The two are not 
interchangeable, but the SEM will always be smaller leading some researchers to report it 
because of the feeling that less variability is better.  A reader can always determine the SD 
from the SEM by taking the SD divided by the square root of the number of observations: 
118 
 
(𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆𝑆𝑆 ÷ √𝑛𝑛).  
Using the data from Figure 10-1, the SEM would be calculated as: 1.499 ÷  √229 = 0.098  
which is obviously smaller than the reported SD of 1.499.  This equation can be used to 
determine the SD when the SEM is inappropriately reported.  Standard errors are used in the 
calculation of confidence intervals (CI) which estimate a range of values that is likely to 
contain a population value a certain percentage of time.  These are commonly reported in the 
literature as 95% confidence intervals.  Confidence intervals will be further explained later in 
the chapter. The interquartile range (IQR) represents data between the 25th and 75th 
percentiles and contains the middle 50% of observations.  This measure of variability is 
commonly reported as 2 numbers with the highest representing the 75th percentile and lowest 
representing the 25th percentile.  The IQR is particularly useful for non-normally distributed 
continuous data, along with the median, or for ordinal data.  Other types of descriptive 
statistics include frequencies and percentages or visual data displays such as histograms, 
scatter plots, and box plots (Figures 9-3 - 9-5). 
 
 
Figure 9-3. Histogram 
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Figure 9-4. Scatterplot 
 
 
Figure 9-5. Box plot 
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Inferential Statistics, Hypothesis Testing, and Decision Errors 
Inferential statistics are used to make a generalization about a population from the results of 
a study and practitioners will use study finding to make decisions on how to manage the 
patients in their care.  The foundation of inferential statistics is with hypothesis testing, and 
statistical tests are used in hypothesis testing.  Not all studies will be testing hypotheses, so 
not every study will include inferential statistics, but all studies that are reporting findings 
will include some element of descriptive statistics.  With hypothesis testing, statistical tests 
are used to test the null hypothesis (H0) which states that there is no difference between 
predictor and outcome variables.  In other words, if a study were comparing two interventions 
(Intervention A and Intervention B) the H0 would state that Intervention A = Intervention B.  
The alternate hypothesis (H1) would then state that Intervention A ≠ Intervention B.  The H1 
cannot be directly tested, so it is accepted by default in instances where the H0 is rejected.  The 
H0 is rejected based on the results of a statistical test. In general, for studies which 
pharmacists will be reading and using, hypothesis testing is two-sided.  In other words, the 
researcher is interested in a difference in either direction. It might be important if 
Intervention A is better than or worse than Intervention B. Occasionally, inferential statistics 
will be used for one-sided hypothesis testing. In a one-sided hypothesis, a direction of 
difference is stated and tested. For example, the H0 might be written as Intervention A ≥ 
Intervention B with the H1 written as Intervention A < Intervention B.  
For statistical testing, researchers determine which statistical test should be used because 
there are different tests for different types of data or the number of groups being compared. 
Once the researchers decide on the statistical test, the level of significance (also referred to 
as alpha or α) is selected.  This is generally set at 0.05 and it essentially means there is a 5% 
probability of incorrectly rejecting the null hypothesis (ie. making a Type 1 error).  Once the 
alpha is set, a critical value will be determined based on what statistical test will be used.  The 
critical value corresponds to the pre-set α.  A common place where statistical testing becomes 
confusing for providers is what it all means.  The p-value is the probability of making an 
observation as extreme or more extreme than the observed if the H0 were true.17 The 
statistical test is then done and the test statistic is compared to the critical value and a p-value 
is calculated.  P-values less than the preset alpha are considered to be statistically significant, 
the H0 is rejected, and by default the H1 is accepted.      
A recent study by Hammond and colleagues sought to compare the incidence of acute kidney 
injury (AKI) in patients who were receiving vancomycin plus either piperacillin/tazobactam 
or cefepime.18 In this example, the H0 would be AKI with PT = AKI with cefepime.  This study 
121 
 
had two groups (PT vs. cefepime) and the primary variable being compared was AKI which 
was a nominal variable.  Patients either had AKI or didn’t making this a categorical and 
nominal variable.  Because the researchers were comparing a nominal variable between two 
groups, the chi-square test was most appropriate.  More on this test will follow.  The 
researchers state that the pre-determined α = 0.05, which meant that the corresponding 
critical value of the chi-square test = 3.84.  In general, textbooks of statistical analysis will 
include supplementary tables containing critical values for statistical tests, so this 
information is easy to obtain.  With a critical value of 3.84, any test statistic greater than 3.84 
would correspond to a p-value of < 0.05 (Figure 9-6).  Hammond and colleagues reported that 
there was no difference in AKI between the PT (32.7%) and cefepime (28.8%) patients and 
that the p-value = 0.761.  The actual test statistic was not reported, and it typically is not in 
medical literature, but a reader can assume from the reported p-value of 0.761 that the test 
statistic resulting from the chi-square test was less than the critical value of 3.84. With this 
example, because the test value was less than the critical value, the researchers could not 
show a difference in AKI between the drug regimens and would ultimately conclude that 
there is no AKI difference between patients receiving PT and those receiving cefepime.  
Figure 9-6. Chi-square critical value and p-value 
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With inferential statistics, there is always a chance of error and the two types of error that can 
be encountered are Type 1 (false-positive) and Type 2 (false-negative).  These errors are due 
to chance variability or bias and the likelihood of encountering them may decrease with 
increasing sample sizes. With a type 1 error the researcher rejects an H0 that is actually true.19 
The probability of making a type 1 error is signified by pre-set alpha (α) and the p-value that 
is determined from the test provides a more precise probability of making a type 1 error.  A 
type 2 error occurs when a researcher fails to reject an H0 that is actually not true.18 Beta (β) 
is the probability of making a type 2 error and this typically ranges from 0.1 – 0.2.  There are 
several ways to think about decision errors so that they make more sense.  One way to 
consider is related to that of a jury decision.20 An innocent person did not commit a crime and 
a guilty person did commit a crime.  If a jury convicts the criminal and acquits the innocent, 
then the correct decision was made.  But, if the jury convicts the innocent person, a type 1 
error has been made because the jury has concluded that there is an association when in 
reality there is not.  Likewise, if a jury acquits the criminal they have made a type 2 error by 
concluding that there is no association when there actually is one.20  The popular belief of 
those who followed or were familiar with the O.J. Simpson murder trial was that Simpson did 
commit the murders although the jury acquitted him (ie. making a type 2 error).21 Contrast 
that with the case of Mark Schand who spent 27 years in prison after a  jury wrongfully 
convicted him of committing murder (ie. making a type 1 error).22  In medicine, type 1 errors 
may result in drugs or treatment being introduced to market or practice when they are truly 
no different than standard treatments.  Concerning are the potential downfalls of the new 
treatments which likely are more expensive than standard care, but also may have more side 
effects.   
Power is a term that is used quite a bit by practitioners who might say that a particular study 
was underpowered or that a study had adequate power.  Power is the probability of correctly 
rejecting the H0.  This might also be considered as the probability to detect a difference when 
the difference exists.  The equation for power is: 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 = 1 −  𝛽𝛽  
and it’s dependent upon several things.  The predefined α, sample size, estimated size of 
difference between outcomes (ie. the difference that researchers are trying to detect), 
outcome variability, and the statistical test can all influence power. Sample size and power 
are connected in that while sample size can influence power, power is also considered when 
determine the required sample size. Hammond and colleagues determined that 122 patients 
were needed to detect an approximate 20% difference in AKI between PT and cefepime.18 
123 
 
Researchers established the α at 0.05 and β at 0.2 for a power of 80%.  The sample size was 
based on AKI estimates of 36.5% in the PT groups vs. 15% in the cefepime group.  While 
beyond the scope of this text, there are resources that would allow the reader to compute the 
actual power of this particular study.  
With inferential statistics, there is always a degree of uncertainty and p-values will tell one 
aspect of the story, which is about statistical significance.  But, the p-values themselves don’t 
provide information about the clinical impact or size of any difference, if present.  Confidence 
intervals are useful to determine the size of the potential difference because confidence 
intervals give a range of possible estimates including the observed value.  All values within the 
CI are statistically possible.  For examples, authors report no difference in mean ± SD 
vancomycin dosing (mg/kg/day) in pediatric patients with (47.5 ± 14.6) and without AKI [41.2 
± 16.6) with a p-value = 0.102.23 This finding is not statistically significant, so the researchers 
fail to reject the H0 that the dose in those with AKI = dose in those without AKI. But, is this 
finding clinically meaningful? Some practitioners might say yes, leading to the suggestion 
that dose is an important consideration with AKI, while other practitioners may disagree.  
The actual difference between the doses was -6.3 mg/kg/day, but if the 95% CI of the 
difference would have been included, it would have been -13.8 to 1.25.  Remembering that the 
CI is the range of values that could contain the true population value, one could interpret this 
95% CI by saying there is a 95% certainty that the true dosing difference lies between -13.8 
and 1.25 mg/kg/day.  This perspective provides more clinical importance to the finding.  Some 
practitioners might agree that a dosing difference of nearly -14 mg/kg/day is clinically 
important for this drug, but they may also to say that a difference of 1.25 mg/kg/day is not 
important at all.  It should be noted that within this 95% CI is 0, meaning that the true dosing 
difference could be also zero.  This is how CIs can also be used to test hypotheses.  If the H0 is 
that the dose in those with AKI = dose in those without AKI, or there is 0 difference in dose, 
then the 95% CI tells a reader that the H0 should not be rejected because 0 is contained within 
the CI.  A more simplified approach to determining statistical significance from reading a 95% 
CI is this. If estimating a difference between continuous (ie. means) or categorical variables 
(ie. percentage or proportions), CIs containing zero (0) are NOT statistically significant (ie. 
the p-value > 0.05), and the H0 should not be rejected.  If estimating an odds ratio (OR), relative 
risk (RR), or hazard ratio, CIs containing one (1) are NOT statistically significant, (ie. p-value 
> 0.05), and the H0 should not be rejected. 
Common Statistical Tests 
Statistical tests are widely reported in both pharmacy and medical literature.24,25 Common 
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statistical tests can be divided into parametric and non-parametric categories.  Assumptions 
for parametric tests are that the data is continuous with a normal or near-normal distribution, 
data is randomly obtained, the observations are independent of one another, and the 
variances between groups are equal.  Parametric tests include t-tests and analysis of variance 
(ANOVA) and are considered more powerful than non-parametric tests.  The t-test compares 
means between no more than 2 groups.  These will be used to test an H0 that a mean in one 
group is the same as the mean dose in another group, similar to the previous example of mean 
vancomycin dose and AKI.  There are different types of t-tests.  A one-sample compares the 
mean in a study group to that of a known population.  Independent samples t-tests (also called 
Student t-tests) compare means of two unrelated groups (ie. Group 1 vs. Group 2), where 
paired t-tests compare the means of dependent observations (ie. measurement 1 vs. 
measurement 2 in one group). A paired t-test would be commonly used in a before-after type 
of study design. Analysis of variance compares means of 3 or more groups. The ANOVA is 
more powerful than a t-test when there are 3 or more groups because the alpha is held 
constant. There are a different types of ANOVA: one-way (ie. mean in Group 1 vs. Group 2 vs. 
Group 3), two-way (ie. comparing two factors in Group 1 vs. Group 2 vs. Group 3), and 
repeated measures (ie. one group but comparing the mean of Measurement 1 vs. 
Measurement 2 vs. Measurement 3).  With ANOVA, the test result will correspond to a p-
value that tells the researcher or reader if a significant difference exists, but the test doesn’t 
signify where the difference exists.  If an ANOVA yields a significant p-value, researchers 
must perform further tests, called post-hoc tests, to determine precisely where the difference 
lies. Pearson correlation is a parametric procedure used to examine the direction and 
strength of relationship between 2 normally distributed continuous variables. The Pearson 
correlation coefficient (r) ranges from -1 to +1 with values closer to 1 representing a stronger 
relationship between the variables. Positive numbers indicate direct or positive relationships 
with negative numbers representing inverse or negative relationships. In general r values of 
< 0.3 are considered weak, 0.3 – 0.5 are moderate, and > 0.5 are considered strong 
relationships.26 The coefficient of determination (r2) is the percentage of variance in the 
dependent variable that is explained by the other.26 Lee and colleagues evaluated the 
relationship of serum creatinine concentrations on antifactor Xa concentrations and found 
an r = -0.262.27 This can be interpreted as a weak negative relationship. The r2 value = 0.0688 
which means that 7% of the variance in antifactor Xa concentrations can be explained by 
serum creatinine concentrations.   
Non-parametric tests are used when the assumptions of parametric tests are violated. Several 
analogies can be made to parametric tests. The Wilcoxan rank sum and Mann-Whitney U are 
analogous to the independent samples t-tests and are used for two independent samples of 
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non-normally distributed continuous data or ordinal data.  The Wilcoxan signed rank test is 
analogous to the paired samples t-test and would be used for data types above from related 
samples. The Kruskal-Wallis test can be considered analogous to ANOVA, and would be used 
for non-normally distributed continuous data or ordinal data from 3 or more groups. For 
nominal data, Chi-square analysis can be used to compare proportions between 2 or more 
independent groups. An assumption of the Chi-square analysis is that of sufficiently large 
expected frequencies, so when this is violated (eg. when any cell has less than 5 expected 
frequencies) the Fisher exact test is more appropriate. The McNemar test can be used to 
compare proportions in paired samples. Lastly, Spearman correlation is analogous to Pearson 
correlation and is used for continuous variables that aren’t normally distributed or for 
nominal and ordinal data. Range of values from the Spearman rho (rs), which is the output 
from a Spearman correlation, are negative 1 to positive 1 and interpretation is similar as 
Pearson. Table 9-3 describes common statistical tests and their appropriate uses. 
Regression determines how one variable predicts another variable, but it shouldn’t be 
considered as establishing a cause-effect relationship. Simple regression is a relationship 
between a single dependent and independent variable; multiple regression is a single 
dependent with multiple independent variables. There are 2 types of regression. Linear 
regression is used when dependent variable is continuous and normally distributed, and the 
independent variable is continuous (simple regression) or either continuous or categorical 
(multiple regression). The output from linear regression is the coefficient of determination 
(r2) which explains how clearly the model describes the relationship and beta (β) which 
describes the change in the dependent variable caused by a 1-unit change in the independent 
variable. Logistic regression differs in that the dependent variable is categorical while the 
independent variables could be continuous or categorical. The result of logistic regression is 
an odds ratio that can be interpreted as previous described.  
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CHAPTER 10 
EVIDENCE-BASED MEDICINE 
Author: Joe Jordan, PharmD, BCPS 
 
Evidence-based medicine (EBM) has been defined as the “conscientious, explicit, and 
judicious use of current best evidence in making decisions about the care of individual 
patients”.1 In recent history, the EBM movement has been credited to a group of clinicians 
working on new approaches to teaching medical professionals over 25 years ago.2 While 
medical professionals have always relied on clinical experience when making decisions, the 
original impetus of EBM was to intentionally incorporate appraisal of the best available 
evidence to resolve practice issues. However, clinical expertise should not be ignored as it is 
integral to balancing the patient’s clinical circumstances, relevant research evidence, and the 
patient’s preferences or values when making decisions.3-4 Clinicians are now expected to not 
only consult the best available evidence, but also be able to make their own independent 
appraisal and application of the evidence.5  A process or step-wise EBM approach commonly 
cited in literature is described below and depicted in Figure 10-1, which can be used for 
resolving patient issues or practice challenges. 
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Figure 10-1. Evidence-based medicine cycle 
 
 
ASSESS 
The EBM process starts with an assessment of a patient or practice situation.  Assessment is 
a skill that many first acquire in the classroom or in training programs, and then further 
develop with experience.  Assessing an individual patient or practice situation will likely lead 
to issues that need to be resolved and resultant questions that need to be answered.  These 
questions that arise are often referred to as knowledge gaps.  It is possible that many 
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knowledge gaps may arise in a single encounter or situation necessitating a prioritization 
approach to addressing and resolving them. Knowledge gaps will vary among practitioners 
based on their level of clinical experience and familiarity with the current best available 
evidence.5 Before proceeding, it is important to have a good idea of the clinical status and 
circumstances of the patient and their preferences or values with respect to their health 
goals.6-8 Without this crucial step, clinicians may not achieve optimal outcomes for their 
patients.  During this phase, clinicians may need to research background questions, to answer 
any resounding knowledge gaps, before they pursue specific questions.  If a practitioner is 
unfamiliar with a given disease, intervention, or outcome, it is important to understand these 
elements before pursuing specific patient questions involving these variables.  For example, 
before answering the question, “does tranexamic acid increase the risk of venous 
thromboemboembolism (VTE) in patients with atrial fibrillation who are undergoing knee 
replacement?” one may need to review background information on how tranexamic acid 
works, common risk factors for VTE in general, and VTE complication rates in the orthopedic 
setting.  Common sources of information clinicians use to answer background questions are 
tertiary sources such as review articles or textbooks. 
ASK 
The next step is to frame the knowledge gap into a structured question.  Structured questions 
are one way of finding answers using keywords that will hopefully best address the situation.5  
Many databases used to search for literature utilize structured search terms that can 
accommodate this strategy.   
Patient specific questions usually require the practitioner to refer back to original studies or 
primary literature. On occasion, pre-appraised sources of information such as guidelines or 
systematic reviews may have addressed the specific question, but more commonly clinicians 
have to extrapolate information from studies with similar but not identical characteristics of 
their clinical situation.3,5,9  While different types of specific questions may arise in the course 
of clinical work (e.g. diagnosis, prognosis, therapy, prevention), a suggested general acronym 
practitioners can remember when structuring questions is PICO.  PICO stands for 
population, intervention, comparator, and outcome.3  In order to be efficient at evaluating a 
body of literature that is expanding at exponential rates, asking a focused question using a 
structured template such as PICO, can assist in yielding relevant studies.  In the example used 
previously, the population would be patients with atrial fibrillation who are undergoing knee 
replacement, the intervention would be tranexamic acid, the comparison is inferred to be not 
using tranexamic acid, and the outcome is venous thromboembolism.  Occasionally, our 
questions may not yield any literature hits and then we need to expand some element of our 
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PICO framework.  In this case, one might expand the population to patients undergoing joint 
replacement and leave out atrial fibrillation under the auspices that this still may help answer 
whether tranexamic acid increases risk of VTE, irrespective of atrial fibrillation. 
ACQUIRE 
While possessing the requisite skills to assess patients and discern what questions need to be 
addressed, the process of acquiring information takes time that many practitioners do not 
have.3,5,8,10  One popular approach is to consider the usefulness of information as an equation, 
with relevance and validity in the numerator and work in the denominator.11-12 The relevance 
of an information source refers to whether the outcome described is of value to your patient, 
whether the interventions or practices described are feasible, and if the interventions  would 
lead to a change in practice.  The validity refers to the trustworthiness of a given article, and 
the work refers to the time, money, and effort it takes to obtain an answer to a clinical 
question.  While relying on authority or experience may require little work on the clinician’s 
part, this equation reminds the clinician that information which is not relevant or valid is 
useless, no matter how much effort is required.  This approach also encourages clinicians to 
focus on finding relevant evidence first and then apply principles for assessing validity rather 
than vice versa.   
Acquiring evidence can be an intimidating task because information appears to be increasing 
at exponential rates.10 It is difficult to stay up to date with medical information so one must 
find ways to efficiently make use of the available evidence. While many types of information 
are available to practitioners today, this doesn’t mean all resources are useful.  Knowing types 
of resources and how they differ from each other, their strengths and weaknesses, and how to 
use them is an important attribute for efficient practice.12 Studies on information seeking 
behavior in literature note that this step is often not pursued when questions arise in practice 
and when it is pursued, clinicians spend little time on this before either quitting the search or 
going with what they were able to find.5 
Strategies to ensure one is getting the best available evidence commonly vary from asking 
colleagues for their expert opinion, reviewing clinical practice guidelines, searching for 
systematic reviews and/or meta-analyses on existing literature, to searching databases such 
as PubMed for original research studies.13  While practice guidelines or systematic reviews 
may appear useful since they have already appraised the validity of information sources, the 
clinician needs to be aware these can rapidly be out of date, based on the number of trials that 
get published every day.  Likewise, relying on experts or clinical experience to answer 
questions may be perceived as an efficient way to acquire evidence, but a danger with this 
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approach is that it assumes that practitioners are up to date with current literature and that 
he or she is not biased by their own personal experiences.  Similar to this, using general search 
engines on the web can be misleading in that they provide ‘hits’ but they may not provide 
information specific to your inquiry.   
A traditional model in EBM is the hierarchical approach of categorizing types of resources as 
seen in Figure 10-2.3 This approach implies there are some resources with more validity and 
relevance than others.  Study designs are ranked based upon the likelihood of providing 
causality estimates.  Randomized controlled trials are commonly listed at the top of these 
models since the design allows the researcher control over various factors.  Opinions are 
commonly listed at the bottom of the pyramid because there is not a readily available way of 
testing this information for validity.   
 
 
 
Figure 10-2. Hierarchy of study designs 
 
 
Another way sources of evidence are described is based on efficiency (i.e. time required for 
practitioner to find answer) as seen in Figure 10-3.2,5  In this case, resources that are pre-
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to do this) as less useful.  However, these models do not adequately address every type of 
question or resource that could arise so practitioners ultimately need to be familiar with 
multiple types of resources and how to appraise them.   
 
Figure 10-3. Hierarchy of resources based on efficiency 
 
 
APPRAISE 
After acquisition of evidence, the clinician must be able to appraise the information for 
validity, or trustworthiness.  Depending on the type of original question asked (e.g. diagnostic, 
prognostic, therapy, etiology), some primary sources of literature are better suited than 
others. While some sources of information have been pre-appraised (e.g. guidelines, 
systematic reviews), it is important to determine the process of validation and be able to 
confirm or agree with the information independently.14-17 Otherwise this is analogous to 
relying on authority or experts again.  While prospective controlled studies by design are more 
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suited to answering questions of causality, this does not automatically mean observational 
study designs are weaker as all studies can have methodologic flaws impacting their validity.17  
Several tools are available for evaluating research evidence for validity.  The EQUATOR 
network (www.equator-network.org) provides reporting guidelines for a variety of study 
designs in order to enhance the quality and transparency of the published article. The Centre 
for Evidence Based Medicine (www.cebm.net/critical-appraisal) at the University of Oxford 
provides appraisal tools to help clinicians determine reliability, importance, and applicability 
of articles. While these tools can offer a checklist approach to evaluating studies, it is 
important to remember that the appraisal process is just to determine whether given results 
are plausible, not whether they should be used in your patient or practice setting.  A common 
criticism of EBM is that it implies there is a stepwise appraisal approach (i.e. cookbook 
approach) to treating every practice issue.  This objection is related to the loss of perception 
of autonomy in decision making and is an untoward application of EBM with respect to 
standardizing care and insisting on one way of doing things.  However, this is not the intent of 
EBM and it actually acknowledges the role of experience and intuition and the fact there are 
differences in skill, is what explains variations in results at times.1-4   
APPLY 
After the evidence has been acquired and appraised, it must be applied back to the individual 
issue, be it a patient or practice situation.  This process of application should not be based 
solely on the conclusions of studies written by study investigators or the opinions of experts.  
A danger with relying on those with vested interest in a given intervention, could be 
misappropriating what is of value both to patients and clinicians.  For example, drug and 
medical device companies could set research agendas to define what are relevant disease 
characteristics, what test and treatments to compare (thus of value) and what outcomes will 
be valuable.3  Additionally, with a lot of drug therapies available that have marginal, if any, 
differences in outcome, it is important to be able to answer what is the best course of action 
for this patient, in these circumstances, and at this time in their illness or condition?8,18 
External evidence can inform but not replace individual expertise.  This is what ultimately is 
drawn upon to balance research evidence plus clinical status, and decides what applies to 
whom and if it should be used in a decision.  There may be tradeoffs that affect a given decision 
and some recommendations may be stronger or weaker based upon these factors such as cost, 
risks, and benefits. An online resource that can be used to develop recommendations based 
on these factors is http://www.gradeworkinggroup.org.16 While costs are often not 
necessarily the focus of EBM, certainly effective care is important, and ineffective care  would 
be seen as waste from a cost standpoint.  Effectiveness depends on not only whether 
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something can work but also on the accuracy of diagnosing a condition, compliance with 
protocols, patient adherence, and coverage.  Just because something can work doesn’t mean 
it will be used in the right people, at the right time, if patients will take it right, or whether 
people can afford it.18 Often, an overlooked area in the EBM process is an ideal way to present 
information to patients so that they can make an informed decision.  Keeping in mind that the 
original reason to apply EBM is resolve patient issues or questions, the way this information 
is communicated to patients plays a large role in achieving optimal outcomes. 
ASSESS 
We end where we started.  That is, after applying the research evidence to the clinical 
situation and taking into account the patient preferences and values, we should seek out 
whether issues have resolved or whether new issues have presented.  This is why this process 
is sometimes referred to as a cycle. 
SUMMARY 
Evidence is essential, but not sufficient, for practitioners wanting to use EBM.  The best 
available evidence, clinical context, and patient preferences integrated with clinical 
experience are what make up the hallmark of decision making.7  Without clinical experience, 
practice is at risk of becoming dictated by checklists on appraisal of evidence, which may be 
inapplicable to or inappropriate for an individual patient.  Without the best evidence, practice 
is at risk of becoming rapidly out of date, to the detriment of patients.1 It is this individual 
expertise that can effectively integrate experience and evidence within context, decides 
whether external evidence should be applied at all, and if so, how it should be integrated.1 
Efficient EBM practice requires formulating focused questions (PICO), matching questions 
to most appropriate resources, assessing confidence in estimates, and understanding how to 
apply results to clinical decision making.  In addition, given the acknowledgment of time 
constraints, we need to ensure that management strategies are consistent with patient values 
and preferences.  
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CHAPTER 11 
RISK EVALUATION AND MITIGATION 
STRATEGIES (REMS) 
Author: Annette McFarland, PharmD 
 
The Center for Drug Evaluation and Research (CDER) and the Center for Biologic Evaluation 
and Research (CBER) are the departments within the Food and Drug Administration (FDA) 
responsible for evaluating drugs (or biologics in the case of CBER) to make sure they are not 
only effective but safe for human use. Every prescription and over-the-counter medication is 
evaluated by CDER or CBER prior to market.1 There are drugs that, although they have 
substantial therapeutic benefits, carry significant risks. To ensure that the benefits outweigh 
the risks, the FDA may require manufacturers to go beyond product labeling and implement 
special restricted access programs.  
Risk management programs have been around since the early 1990s. One of the first 
medications to have prescribing and dispensing restrictions is clozapine (Clozaril®).2 This 
antipsychotic significantly increases a patient’s risk for agranulocytosis, so patients must 
obtain weekly blood counts to receive the drug. Physicians must monitor and submit lab 
results to the manufacturer’s restricted access program in order to receive prescribing 
authority. The amount of clozapine dispensed is limited to the number of days until the next 
lab draw. Patients, physicians, and pharmacies must be registered with clozapine’s “no blood, 
no drug” program to ensure compliance.2 
Historically, such risk management programs were called Risk Minimization Action Plans 
(RiskMAPs). The Prescription Drug User Fee Act (PDUFA III) of 2002 allowed the FDA to 
suggest RiskMAP programs for drugs that might not otherwise be allowed on the market 
because of significant safety concerns. RiskMAPs were tools “…designed to meet specific 
goals and objectives in minimizing known risks of a product while preserving its benefits.”3 
Examples of these tools include targeted education, reminder systems, and performance-
linked access systems (eg. clozapine’s “no blood, no drug” program). Although effective, there 
were limitations to the program. RiskMAPs were voluntary and the FDA could only 
recommend a risk minimization program. They had no authority to require a manufacturer to 
comply, nor could they require postmarking studies, labeling changes, or other safety 
communications. The FDA Amendments Act of 2007 expanded the FDA’s authority 
regarding drug safety. A section of the legislation now allows the FDA to require 
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postmarketing studies and to mandate Risk Evaluation and Mitigation Strategies (REMS) for 
drugs that have the potential to cause serious patient harm.2,4  
WHAT ARE REMS? 
REMS are strategies designed to mitigate a known or potentially serious risk associated with 
a drug or biologic product.5 When determining whether or not a REMS is needed, the FDA 
takes into consideration the number of patients who would potentially use the drug, the 
seriousness of the disease or condition it’s intended to treat, the duration of treatment, and of 
course, the expected benefit compared to the severity of its adverse effects.4 The FDA can 
base its decision on results from clinical trials, adverse drug event reports, or post-marketing 
studies.  
REMS can be implemented at any stage of the product lifecycle. It can be included as part of a 
license application for a new drug or new indication, or the FDA can require the 
implementation of a REMS for drugs already on the market if new safety information 
becomes available.6 This is why post-market surveillance is so important. The number of 
people who participate in pre-market, Phase 3 clinical trials can be small compared to the 
larger population who ultimately uses the drug. Therefore, continually assessing the efficacy 
and safety of drugs post-market is necessary to identify any potential safety concerns not 
known at the time of a drug’s approval process. 
The FDA can mandate a REMS for drugs they feel need additional safety measures beyond 
that of standard professional labeling. These safety measures are unique to each drug or 
therapeutic class. Therefore, no two REMS are exactly alike. The following are potential 
elements of a REMS:6 
● Medication guide 
● Communication plan 
● Elements to assure safe use (ETASU) 
● Implementation system 
Once a REMS is approved, it is enforceable. The FDA has the authority to hold the 
manufacturer accountable for not complying. If the manufacturer fails to implement a REMS, 
they can be fined. The FDA can also restrict its use by preventing the sale of the drug and/or 
consider it misbranded.4 
REMS REQUIREMENTS 
A REMS can contain any one element or a combination of elements listed above. The specific 
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components of a REMS can vary based on several factors, including the severity of the drug’s 
potential adverse effects and the population likely to use it.6  
Medication Guides 
A medication guide is a handout written in patient-friendly language by the manufacturer 
highlighting important safety or efficacy information about a drug product. These are not the 
same as Consumer Medication Information sheet (CMIs) which provide general information 
about all aspects of a prescription drug. Unlike CMIs, which are written by organizations or 
the private sector without review by the FDA, medication guides are written specifically for a 
drug product by its drug manufacturer. Since each medication guide is approved by the FDA, 
they are not interchangeable. Substitution of one manufacturer’s medication guide for 
another is discouraged, even though the content for a generic drug may be similar to that of its 
brand name equivalent. 
Medication guides may be related to safety, addressing potentially serious risks patients 
should be aware of prior to taking the drug or they can be about efficacy, where patient 
adherence to directions for use is important to a drug’s effectiveness. The FDA determines 
whether or not a medication guide is required. Although close to 300 drug products have 
medication guides, only a small portion are part of a REMS.  Typically, medication guides that 
are part of a REMS include an Element to Assure Safe Use (ETASU), which often have more 
stringent requirements. 
If required, medication guides must be dispensed with every new prescription and with each 
refill. They do not, however, have to be given to patients in an inpatient setting (eg. hospital, 
nursing home) since the medication is being administered by a healthcare professional. The 
only exception is if the patient requests one or if the medication guide is part of a REMS that 
requires distribution to inpatients. In other settings where medications are dispensed to a 
healthcare professional for administration to a patient, medication guides are only required 
when the patient is receiving the medication for the first time or if the medication guide has 
been updated with new information. Examples of such settings include dialysis centers, 
physician offices, chemotherapy infusion clinics, home health care, etc.7 
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Setting 
Patient or 
Patient’s 
Agent 
Requests 
Medication 
Guide 
Medication 
Guide 
Provided 
Each Time 
Drug 
Dispensed 
Medication 
Guide 
Provided at 
Time of First 
Dispensing 
Medication 
Guide 
Provided 
when 
Medication 
Guide 
Materially 
Changed 
Drug is 
Subject to an 
ETASU REMS 
that includes 
Specific 
Requirements 
for Providing 
and Reviewing 
a Medication 
Guide 
Inpatient 
Must provide 
medication 
guide 
FDA intends 
to exercise 
enforcement 
discretion; 
Medication 
guide need 
not be 
provided 
FDA intends 
to exercise 
enforcement 
discretion; 
Medication 
guide need 
not be 
provided 
FDA intends 
to exercise 
enforcement 
discretion; 
Medication 
guide need 
not be 
provided 
Must provide 
medication 
guide as 
specified in 
REMS 
Outpatient 
when drug 
dispensed to 
healthcare 
professional 
for 
administration 
to patient  
(e.g., clinic, infusion 
center, emergency 
department, 
outpatient surgery) 
Must provide 
medication 
guide 
FDA intends 
to exercise 
enforcement 
discretion; 
Medication 
guide need 
not be 
provided 
Must provide 
medication 
guide 
Must 
provide 
medication 
guide 
Must provide 
medication 
guide as 
specified in 
REMS 
Outpatient 
when drug 
dispensed 
directly to 
caregiver 
(e.g., retail 
pharmacy, 
hospital 
ambulatory 
pharmacy, 
patient samples 
Must provide 
medication 
guide 
Must provide 
medication 
guide 
Must provide 
medication 
guide 
Must 
provide 
medication 
guide 
Must provide 
medication 
guide as 
specified in 
REMS 
Table 11-1. Medication guide enforcement discretion policy7 
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Communication Plan 
While a medication guide educates patients, a communication plan is a REMS element that 
informs healthcare professionals about the safe and effective use of a drug product. 
Manufacturers use communication plans to inform health care providers about the risks of a 
drug. They are also used to educate them about REMS elements, such as the use of periodic 
laboratory tests for medical monitoring, and encourage implementation. Communication 
plans typically involve sending “Dear Healthcare Professional” letters.  These are sent 
directly to the health care provider, disseminated through professional organizations, or 
distributed to specific practice settings. Communication Plans may also include training 
materials or presentations. Health care providers are then supposed to use the information to 
promote appropriate use of the drug and reinforce patient compliance.  
The antidiabetic agent liraglutide (Saxenda®) is an example of a medication with a 
Communication Plan.5 This REMS is required so that healthcare professionals are aware of 
liraglutide’s increased risk of thyroid carcinoma and acute pancreatitis.8 The manufacturer’s 
Communication Plan for this drug includes a Dear Healthcare Professional letter, web-based 
information, and dissemination of a letter to professional organizations.  
Elements to Assure Safe Use 
The most complicated and extensive component of a REMS is the Element to Assure Safe Use 
(ETASU). As defined by the FDA, they are “strictly controlled systems or requirements put 
into place to enforce the appropriate use of a drug.”6 Drugs with ETASUs can be considered 
potentially harmful if not used appropriately. Therefore, this REMS element allows patients 
to have access to drugs known to have serious risk that would otherwise not be available.  
Every ETASU is different. Medications with an ETASU may require that prescribers have 
specific training, experience, or be certified before being able to prescribe that drug.9 Other 
ETASUs may require special laboratory monitoring and/or enrollment of patients in a drug 
registry. Still other ETASU may only allow the medication to be dispensed by a specialty 
pharmacy or dispensed to patients in certain healthcare settings, such as a hospital. 
One example of a medication with an ETASU is Aveed® (testosterone undecanoate).5 This 
injectable product is used to treat adult males with low testosterone levels. The REMS 
requires that it be administered by a trained healthcare professional in a doctor’s office, clinic, 
or hospital with on-site access to equipment because of its significant safety risks. Aveed® has 
the potential to cause anaphylaxis as well as pulmonary oil microembolism (POME), which is 
a serious lung condition that occurs when tiny droplets of castor oil contained in Aveed® 
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travel to the lungs.10 Since anyone can experience these adverse reactions with any treatment, 
the ETASU requires that patients stay in the healthcare setting at least 30 minutes after 
receiving the injection for observation. Additionally, the REMS requires that both the 
prescriber and healthcare setting complete the REMS certification with an assessment of 
knowledge before being able to prescribe or administer the drug. The education program 
includes training on the proper administration of Aveed®, information on patient counseling, 
and understanding of how to manage POME and anaphylaxis.11 Patients must also be aware 
of the potential side effects and agree to receive the drug, despite its significant risks. 
Implementation System  
All ETASU include an Implementation Plan. This REMS element tells the FDA how the 
manufacturer plans to monitor patients, practitioners, and healthcare settings to ensure they 
are being compliant with the ETASU. It is also a way for the manufacturer to evaluate their 
REMS program and make improvements, if necessary.  
For example, the Implementation System for Aveed® spells out exactly how the manufacturer 
will “…maintain, monitor, and evaluate” the REMS to ensure it’s meeting the program’s goals. 
It includes items such as maintaining a database of all certified healthcare providers, 
maintaining an informational call center and website, as well as completing an audit of 
certified healthcare settings.  It also includes a timetable for when the manufacturer will 
submit assessments of the REMS to the FDA.12   
Timetable for Submission of Assessments  
Assessments are also technically considered a REMS element. They are used to evaluate the 
effectiveness of a particular REMS. For example, healthcare professionals can be surveyed 
regarding their understanding of the safe use of a drug. Prescriber compliance with REMS 
certifications is another assessment tool. Data can also be collected on patient use of a 
particular drug. Depending on the results, REMS can be modified if the assessment shows 
changes are needed. REMS can even be eliminated if it has been shown that the REMS was 
successful at meetings its goals.6 
SHARED SYSTEM REMS 
As of July 2017, there are 70 approved REMS.5 With so many REMS and each one unique to a 
particular drug’s manufacturer, it has been very cumbersome for healthcare professionals to 
comply, especially for drugs with an ETASU. It is time consuming for a physician to make sure 
he/she has completed the required training before writing a prescription or for a pharmacist 
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to verify a patient’s labs in a registry before dispensing a medication, for example. To 
minimize the workload and burden on healthcare systems, the FDA has been moving towards 
the development of standardized REMS. For some identical or closely related drugs (ie. drugs 
within the same therapeutic class), the FDA has mandated drug companies to develop a 
single, shared system REMS. Once such example is isotretinoin’s iPLEDGE program.13  
Isotretinoin is a drug used for the treatment of severe acne. Studies have shown a 15-20 week 
course of therapy to be effective at improving nodular acne. However, isotretinoin is 
teratogenic and serious birth defects, spontaneous abortion, and premature births have been 
reported.14 Therefore, the REMS for isotretinoin informs prescribers, pharmacists, and 
patients about the drug’s serious safety risks and safe-use conditions with the goal of 
preventing fetal exposure to isotretinoin. In the past, every manufacturer of isotretinoin, 
brand and generic, had their own REMS each with different ETASU. This made prescribing 
and dispensing isotretinoin extremely challenging and frustrating. To consolidate and 
simplify the process, the FDA requested that all the manufacturers of isotretinoin products 
work together to create one standardized REMS. This single, shared system REMS, called 
iPLEDGE, includes a medication guide, ETASU, and implementation plan.14  
Prescribers, pharmacies, patients, and wholesalers must all be registered with the iPLEDGE 
program.14 It is a computer-based program that tracks and verifies the critical elements of the 
program. Prior to receiving the medication, females must commit to 2 simultaneous forms of 
birth control. They must also complete Patient Monthly Comprehension Questions and a 
pregnancy test before each prescription.15 Physicians then enter the results of the pregnancy 
test and the patient’s forms of contraception into iPLEDGE. The pharmacist must obtain 
verification from iPLEDGE before given authorization to dispense isotretinoin to the patient. 
Since patients are required to meet these same criteria every month, refills are not allowed 
and only a 30 day supply can be dispensed.15 
REMS FOR OPIOID PRODUCTS 
There are several other single, shared system REMS including a number of class-wide 
programs for opioid agents. Not only were these designed to streamline the REMS process, 
but the opioid REMS are part of a larger, federal initiative aimed at reducing prescription drug 
abuse, misuse, and overdose.  Extended-release and long-acting (ER/LA) opioid products 
were identified as a subset of opioids at high risk of abuse and misuse, while simultaneously 
having a high volume of use. The misuse and abuse of this potent class of drugs led to a 
significant health crisis of addiction, overdose, and death. According to the CDC, 40 people 
die every day from prescription painkiller abuse. As a result, a class-wide REMS was 
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introduced for all ER/LA opioid products and their generic equivalents.16  
The purpose of the ER/LA Opioid Analgesics REMS is to reduce risks while maintaining 
patient access.17 This potent class of drugs is intended to manage chronic pain and serious 
medical conditions, so it’s important that these products continue to be available for patients 
with these conditions. Unfortunately, they often lead to improper use and then abuse. One in 
20 individuals age 12 and older admit to taking prescription opioids for non-medical use.18 It 
is thought that prescribers are contributing to this abuse and misuse epidemic, as the number 
of painkillers prescribed over the past 15 years has quadrupled.19 As a result, prescriber 
education and patient awareness are the main components of the ER/LA Opioid REMS. 
Currently, prescribers are not required to complete the training associated with ER/LA 
Opioid REMS; however, it is “strongly encouraged”.20 In addition to educating prescribers on 
proper pain management and patient selection, the REMS education program includes 
patient counseling tips. Patients should be aware of opioids’ addiction potential, informed on 
the proper disposal of expired or unused medications, and the need to lock them away when 
not being used.21 
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CHAPTER 12 
HOUSEHOLD DISPOSAL OF PRESCRIPTION 
DRUGS 
Author: Annette McFarland, PharmD 
 
The amount of unused, unwanted, and expired medications is a growing problem that is 
significantly impacting our healthcare system. Not only is it costly, but the health and safety 
of patients and our environment is being affected. One recent study found that approximately 
2 out of 3 prescription medications per household were unused.1 The most common reason 
cited by study participants was discontinuing use because of improvement in their medical 
condition and/or symptoms. Other reasons included side effects, expiration, felt it wasn’t 
helping, felt they no longer needed to take it, or forgot to take it. Noncompliance is a major 
contributing factor to the volume of unused/unwanted medications and it is costing the 
United States about $100 billion per year in extra medical costs.2 According to a 2010 bulletin 
published by the World Health Organization, only about half of the population takes their 
medications correctly. Additionally, more than half of prescriptions are prescribed, 
dispensed, or sold inappropriately, further contributing to household possession of excess 
medications.3  
Medications left unused in the home pose potential safety concerns.  For example, if an 
elderly patient has multiple medication bottles in their medicine cabinet they are at a greater 
risk for inadvertently taking the wrong drug or duplicating therapy.4,5 Accidental ingestion is 
also a concern.5 There have been over 30 reports received by the FDA of accidental exposure 
to fentanyl patches, a potent opioid analgesic. Most of these involved small children less than 
2 years old that resulted in hospitalization or death.6 Drug overdose is another safety concern; 
it’s the leading cause of death by injury according to the CDC.7 Having excess medications 
laying around the home also leads to diversion.5 When a national survey asked nonmedical 
users of opioids where they obtained their drugs, more than 50% said a family member or 
friend gave it to them, over 10% bought them from family or friends, and about 5% just took 
them.4 Therefore, properly disposing of unused, expired, and unwanted medications is 
important to help minimize the risk of accidental exposure, intentional misuse, or diversion.   
Studies have found that consumers don’t always know how to dispose of medications 
properly, nor do they remember receiving education on proper storage and disposal.1,8 The 
majority either throw them away in the trash or use the toilet or sink for disposal.7 Such 
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practices have been questioned in terms of their safety and appropriateness.9 Disposing of 
medications via sink or toilet has a negative impact on rivers, streams, and supplies of 
drinking water. A US Geological Survey that studied water in Minnesota found organic 
contaminants in 90% of the samples tested, most of which were prescription and 
nonprescription medications.10 Although not at therapeutic levels, active therapeutic 
ingredients in water could be dangerous not only to humans but to wildlife as well.11 Disposing 
of unwanted medications in the trash has its own set of concerns. Throwing away 
prescription bottles with personal, patient information on the label can lead to identity theft. 
It can also be a source of accidental exposure by children and animals or contribute to drug 
diversion. 
Various organizations have developed programs or guidelines on the proper disposal of 
medications, including the Office of National Drug Control Policy in conjunction with the 
Food and Drug Administration (FDA). These federal guidelines suggest:12 
● taking advantage of pharmaceutical take-back programs in the community 
● using appropriate safeguards when throwing away medications in the trash 
● flushing drugs down the toilet or drain ONLY if advised by the FDA and/or instructed 
by printed material accompanying the medication  
 
COLLECTION PROGRAMS 
Drug take-back programs are the preferred method for disposing medications.4,5,12 These 
programs allow consumers to bring their unwanted and expired medications to a central 
location for proper disposal. Collection events are designed to ensure that unused, expired, or 
unwanted medications are collected anonymously and destroyed in a way that is safe, legal, 
and environmentally sound. 
There are various types of take-back programs available, ranging from small, one-day events 
to on-going collection sites. City, county, and state sponsored take-back programs are 
available. One such event is the National Prescription Take-Back Event hosted by the Drug 
Enforcement Administration (DEA) twice a year, once in the spring and again in the fall.13 
These events have been extremely successful. In April of 2017, the DEA, along with more than 
4,000 state and local law enforcement partners, held its 13th Take-Back event which collected 
over 900,000 pounds of unwanted medications across 50 states.14 The DEA’s take-back 
events began in 2010 with the passing of the Secure and Responsible Drug Disposal Act which 
was intended to help address the growing prescription drug abuse epidemic. According to a 
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recent National Survey on Drug Use and Health, 6.5 million Americans abuse prescription 
drugs.15 As mentioned previously, the majority of abused drugs are obtained from family and 
friends. Therefore, it’s extremely important to get rid of unwanted, unused medications. In 
the past, however, only law enforcement officials were allowed to take-back and inventory 
controlled substances at collection events. This act gave the DEA authority to expand ways in 
which the general public can dispose of medications, including controlled substance 
prescriptions, safely and conveniently. 
In October of 2014, the DEA’s revisions to the Controlled Substance Act were implemented. 
The Disposal of Controlled Substances Rule now allows authorized collectors to accept 
unwanted, unused, or expired prescription medications, including controlled substances, by 
providing collection receptacles and/or mail-back programs.16 Medications can only be 
placed in the receptacles or mailed by ultimate users which is defined as “a person who has 
lawfully obtained, and who possesses, a controlled substance for his own use or for the use of 
a member of his household.”17 Pharmacy staff are not allowed to do it on their behalf. So who 
is considered an authorized collector? Facilities, such as retail pharmacies, hospitals and 
clinics with on-site pharmacies, narcotic treatment programs, long-term care facilities with 
pharmacies, manufacturers and distributors can volunteer to become an authorized collector 
simply by modifying their DEA registration. Many law enforcement or police stations are 
authorized collection sites as well. 
Facilities that choose to have collection receptacles must follow certain requirements. 
Receptacles must:16 
● have tamper-evident, waterproof, tear-resistant inner liners 
● be securely fastened to a permanent structure so that it cannot be removed 
● be placed in a location that is not only be accessible to the public but where employees 
are present 
Pharmacies that choose to offer mail-back programs can sell or provide at no cost prepaid, 
pre-addressed mail-back packages. Packages must:16 
● be nondescript, water- and spill-proof, tamper-evident, tear-resistant, and sealable 
● include a unique identifier that can be tracked 
● sent to authorized collectors that destroy medications on-site  
Information about take-back programs in your area can be obtained by contacting local waste 
management agencies. Online resources, such as Dispose My Meds, DEA’s Office of 
Diversion Control, US Environmental Protection Agency, and Recycle Indiana – Unwanted 
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Medicine, are also helpful for locating pharmacies and authorized collection sites with 
options for safe disposal of unwanted, unused, and expired medications.  
HOUSEHOLD DISPOSAL 
In the event that a take-back program or authorized collector is not available, most 
medications can be disposed of in the household trash. Several agencies, including the FDA, 
DEA, and EPA recommend the following steps for properly disposing of unwanted, expired, 
and unused medications:5,18 
1. Take drugs out of their original containers. 
2. Mix the medications with a substance that is unpalatable and undesirable, such as dirt, 
kitty litter, or used coffee grounds. 
3. Place the mixture into a disposable container, such as a sealable bag. 
4. Throw the sealed container away in the household trash. 
5. Remove, cover with permanent marker, or scratch out all personal information on the 
prescription label of the empty pill bottles and medicine packages to make it 
unreadable before placing them in the trash. 
 
FLUSHING 
Not all medications should be thrown away in the trash if a take-back event or collection 
receptacle is not available. The FDA recommends disposing of certain medications by 
flushing them down the toilet or sink. There is a small list of medications that are considered 
life-threatening if taken by someone other than the person for whom it’s intended.17,18 These 
drugs are mostly high-potency opioid analgesics and other controlled substances that are not 
only dangerous if accidentally ingested by a child or pet, but are more likely to be associated 
with drug diversion and misuse. Examples include fentanyl, morphine, and oxycodone. The 
most complete and up-to-date list of medications recommended for disposal by flushing can 
be found on the FDA’s webpage on Disposal of Unused Medication.18 
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VALUE 
 
In the perspective of access, cost and quality, value is the balance of quality with cost.  In other 
words, value equals quality divided by cost. Access is assumed to remain constant for this 
determination because without continued access there can be no value.  Value can be 
increased either by increasing the quality or decreasing the cost. In order to determine value 
we must be able to measure quality.   
As discussed in Section 3, health outcomes are one way to measure quality for healthcare 
providers.  Patient satisfaction, time off work and quality of life may be different ways 
patients measure quality. Since quality can change by perspective, value changes as well.   For 
example, a treatment for cancer may continue to decrease the size of a tumor but the quality 
of life provided during that treatment may not be worth it to the patient.  In the first part of 
this example, value as measured by the oncologist is determined by the decrease in tumor size 
divided by the cost of the medication and any health care provider fees.  In the second part of 
this example, value to the patient is quality of life is divided by the cost of the medication and 
any health care provider fees. There may come a point at which the patient feels the value 
assessed by the health care provider, decreased size of tumor, is less than the value to them in 
terms of quality of life.   
Different pharmacoeconomic evaluation methods are used to measure quality and value for 
patients and health care providers. Through provisions of the Affordable Care Act, the 
Centers for Medicare and Medicaid Services (CMS) developed a payment option for acute 
care hospitals that bill CMS for services provided to Medicare patients. This is called hospital 
value-based purchasing.1-3 
Value-based purchasing rewards hospitals based on the quality of care they provide to 
patients, how closely recommended guidelines are followed and the extent patients are 
satisfied with their hospital experiences.1 Previously hospitals were paid by Original 
Medicare on a fee for service basis as explained in Section 1, Chapter 1.  This means they were 
paid for the quantity of services they provided (paid for each service provided).  The 
movement away from quantity and towards value pays hospitals on the quality of the care 
they provide and the value they provide to patients. There are many criteria in which quality 
and value are measured which is beyond the scope of this chapter. Hospitals can chose to 
participate in these new payment models.  If they do each hospital receives a score on these 
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different measures. The results are compared to other hospitals and provided publically.  Data 
on hospitals participating in this model is provided on the CMS website.4 The score is also 
used for each hospital by comparing yearly performance to a baseline score for that specific 
hospital. This allows hospitals to demonstrate improvement.  
The incentive for participating in the value-based program is initially financial. At the start 
of this initiative CMS reduced the payments to hospitals for the care they provided to 
Medicare patients. The score is then used to redistribute the money back to those hospitals 
with the highest score.  Therefore, the hospitals that do well receive more payment for 
services than those who do not score well. An added benefit for those hospitals that don’t just 
score well but who make a noticeable improvement from a patient perspective is that those 
patients may refer other patients to that facility. Increasing the revenue for that hospital. 
Since different patients and communities may view improvement differently, health systems 
may need to consider the communities they serve. Physician practices have a similar program 
to the acute care hospital value-based purchasing program.  This program, currently referred 
to as the Quality Payment Program (QPP), provides incentives for physicians and clinics to 
be rewarded for quality and value to patients.5  
While healthcare providers have always been focused on caring for individual patients, value 
based changes have the potential to change how care is delivered to all the patient served in a 
specific office or hospital.  One example of value is electronic prescribing.  Electronic 
prescribing allows pharmacists to receive prescriptions quicker and often more legibly than 
before. This improves health outcomes.  Patients receive value because the prescription can 
be sent to the pharmacy before the patient leaves the clinic and the prescription is more likely 
to be ready when they get to the pharmacy. Despite the work involved in purchasing and 
learning new computer software, the subsequent value associated with this change has 
changed how pharmacy services are provided. Looking back at our earlier example, if all 
practitioners changed how they viewed value for cancer therapies it might change how we 
approach cancer therapy especially in end of life decisions. Therefore, value based changes 
made by multiple offices or hospitals can lead to changes for an entire population of people.  
POPULATION HEALTH 
The education of healthcare providers is focused on preparing providers to serve the needs of 
individual patients.  However, sometimes the needs of one patient may be applied to multiple 
patients within an institution or practice. If this need impacts the community as a whole, a 
public health concern might arise.  This is especially important if the condition impacts 
others either because it can be easily transmitted to others or it uses significant financial 
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resources.  The connection between public health and healthcare delivery is hundreds of 
years old.6   Initially, focused on communicable diseases, public health means so much more 
today and is sometimes referred to as population health.  However, population health usually 
relates to large efforts by an institution such as a health systems or health care payer whereas 
public health is more general.  As mentioned above, as quality and value are improved for 
patients, facilities, and communities, the impact continue to expand to new populations. 
These initiatives and innovations can impact a single state or in the case of the value-based 
program the entire United States population.  
While the value-based program is one example of a population-based initiative, many 
different population-based local, state, and federal initiatives are taking place. The use of 
healthcare information technology is one source of information for population health 
initiatives.  This includes patient care electronic medical records, insurance based electronic 
claims transmissions, and pharmaceutical and device company data collection. The analysis 
and use of these large databases of information are often referred to as data analytics. For 
example, data collected primarily from health insurance claims allows payers for health care 
to determine how best to spend their money.  
Expanding the view of healthcare beyond the patient-provider relationship, expands our 
discussion of value.  Payers must consider value for the health care they purchase.  Medicare 
was the payer in the value-based program mentioned earlier but state Medicaid programs and 
private insurance companies are also interested in establishing payment based on value.  As 
more payers seek value, healthcare providers will need to continue to justify value in their 
daily operations.  This perspective can be applied to pharmacy practice as well.   
Brian is a 55 year old patient with multiple sclerosis. Because of his condition, he requires a 
high cost injectable medication that has side effects.  Brian gets this medication from 
specialty pharmacy X.  His medication is paid for by insurance company Y.  The medication is 
made by pharmaceutical manufacturer Z.  Because of the high cost of the medication, the 
value of paying for this medication has to be determined by insurance company Y.  If the 
medication keeps Brian, and others like him, from incurring other medical expenses, there is 
likely a value for insurance company Y to pay for Brian’s medication, as long as the cost does 
not outweigh the benefit. The insurance company however does have to consider that the 
more medications it covers, even if they all add value to their patients. This means it will add 
cost to the plan which will likely result in increased premiums or co-insurance rates for all 
patients being served by that insurance company. All the patients served by that insurance 
company would be the “population” served by their insurance company.  
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Pharmaceutical manufacturer Z has to be able to demonstrate that value, determined by the 
payer, to justify the price they place on their medication.  This could change the strategy of 
pharmaceutical manufacturer Z; not only do they need to show that their medication is 
effective but they need to show that the medication produces appropriate value. Assuming 
that manufacturer Z is able to demonstrate value to insurance company Y, then the patient 
will be able to order the medication from the specialty pharmacy X.   
When Brian begins treatment and obtains the medication from the specialty pharmacy, 
specialty pharmacy X must demonstrate that they are providing Brian the medication in a 
timely manner, without interruption, and that they are supporting Brian through his 
treatment, such as answering questions and addressing side effects.  The reason that the 
specialty pharmacy needs to demonstrate this is because the payer and the manufacturer 
have a role in determining which specialty pharmacy will supply the medication to the 
patient.  If the specialty pharmacy wants to maintain that business, they need to demonstrate 
their value to the payer and manufacturer.  
If the patient is not adherent or successful on the medication due to preventable causes, such 
as delay in receiving treatment or misjudging a potential side effect, the money that has 
already been spent on that medication was wasted.  This wasted money reduces the amount 
of money available to be spent on other patients in the population of that insurance company. 
In the case of wasted dollars, money for no value.   
ADVOCACY, PUBLIC POLICY, POPULATION HEALTH AND VALUE 
Every day that pharmacists care for patients, they advocate for their success.  This may 
include discussing a medication change with the prescriber based on a new study, negotiating 
coverage with the insurance carrier based on patient experience, or providing advice on 
proper medication disposal.   The development of policies for a practice site may include 
establishing guidelines for antibiotic use or setting prescribing guidelines for a new 
formulary agent.  When, these policies extend beyond individual advocacy they serve as 
advocacy of the site population.  When multiple advocates seek for higher level population 
changes, such in the form of laws or regulations, this is referred to as public policy.  
Public policy development involves the creation of laws and regulations as well as identifying 
the necessary budgets and resources necessary to make them a reality.7 For example, Section 
1: Chapter 3 discusses the growth in ambulatory care, the need for provider status and the 
importance of billing for services.   Different legislation and regulation is needed at the federal 
and state level to support provider status to allow pharmacist to be recognized as health care 
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providers who can bill for their services.  Without the approval of federal funds to support 
payment to pharmacists, which is based on the demonstrated value of pharmacists, the 
proposed legislation would not be implemented.  
The process of public policy development can be divided into three phases: 1) formulation, 
which involves deciding what to focus on, 2) implementation, which involves executing the 
policies, and 3) modification, which involves reviewing current policies and identifying areas 
for improvement.8 At each stage different special interest groups may demonstrate a voice. 
For healthcare policy, these may include employers, payers, providers, consumers, etc.   
Public policy efforts initiated by volunteers or members of an association that are advocating 
for themselves is often called grassroots efforts.  Public policy efforts initiated by paid 
individuals is called lobbying and these “lobbyists” register with the government entity they 
serve.  For example, state and national pharmacy associations are involved in many kinds of 
advocacy and policy development.  The participation of their members is considered 
grassroots but they may also hire paid lobbyists to assist with the cause. 
The target of public policy may be legislators or one of many government agencies that make 
decisions on health policy.  Locally, this may include the state department of health, board of 
pharmacy, department of insurance, etc. At the federal level, regulatory agencies include the 
Department of Health and Human Services (DHHS), Centers for Medicare and Medicaid 
Services (CMS), Food and Drug Administration (FDA), National Institutes of Health (NIH), 
Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and 
Quality (AHRQ), etc.  In addition to government agencies, several non-government (private) 
groups are influential in setting health care policy. These include the Institute of Medicine 
(IOM), The Joint Commission (JTC) and the American Medical Association (AMA).7   
Policy decisions are often supported by data collected by individuals who do health services 
research. These researchers examine the influence that pharmacists and other health care 
providers have on patients and the health care system.  This is a robust field in the current 
environment of frequent health care reform.8   
CONCLUSION 
The authors of this text expect that many changes will continue to happen with healthcare 
reform in the United States over the next several years.  While the authors cannot predict 
these changes, the fundamentals of health care reform presented in this book are likely to 
remain: the focus on access, cost, and quality. And specifically, the renewed focus of value will 
continue to evolve the health of patients and populations.  
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